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ABSTRACT 
Marcoita T. Gilbert.  CHANGES IN ZEBRA FINCH CENTRAL NERVOUS SYSTEM 
MORPHOLOGY ASSOCIATED WITH DEVELOPMENTAL CANNABINOID 
EXPOSURE. (Under the supervision of Dr. Ken Soderstrom) Interdisciplinary Doctoral 
Program in Biological Sciences, Brody School of Medicine, East Carolina University, 
October 2012. 
 
Adolescent CNS development is a highly organized, coordinated process that is both 
genetically and environmentally influenced, and is characterized by a period of dynamic, 
activity-dependent changes in synaptic connectivity.  Growing evidence suggests that 
adolescent cannabis use is a risk factor for the development of persistent alterations in 
brain function.  Taeniopygia guttata, the zebra finch, was used as a model of 
cannabinoid-altered vocal learning.  We explored effects of cannabinoid-altered 
signaling during normal late-postnatal CNS development, as well as lasting 
morphological changes following exogenous cannabinoid exposure.  In these studies, 
the cannabinoid agonist WIN 55,212-2 was administered to developing male zebra 
finches during sensorimotor song learning and dendritic spine densities measured 
following Golgi-Cox impregnation.  Within HVC, a region necessary for songbird vocal 
production, and Area X, a striatal region essential for song learning, dendritic spines 
were inappropriately elevated by an average of 25% following developmental 
cannabinoid treatment.  Treatments of adults that had already learned song were not 
associated with spine density changes.  Cannabinoid-altered song and neuronal 
morphology were correlated with changes in levels of proteins related to cell signaling 
and morphology, including axonal Nf-200 and dendritic MAP2.  After sensorimotor 
 
 
developmental cannabinoid treatment, anti-Nf-200 and -MAP2 antibodies were used to 
immunohistochemically confirm Golgi-Cox staining results.  In the same brain areas 
where dendritic spines were elevated following CB agonist treatment, Nf-200 and MAP2 
immunoreactivity (ir) were also elevated.  To investigate mechanisms of cannabinoid-
induced changes in neuronal morphology, we measured expression of the cytoskeletal 
protein Arc in NCM.  A single exposure to novel song increased the postsynaptic 
densities of Arc protein.  Two exposures to song were sufficient to produce habituation 
of this response. Habituation was prevented by pretreatment with WIN.  These findings 
suggest there is a persistent, developmentally-restricted condition during 
periadolescence, and that cannabinoid agonism interferes with sensory integration and 
encoding necessary for accurate formation of memories. 
  
 
 
CHANGES IN ZEBRA FINCH CENTRAL NERVOUS SYSTEM MORPHOLOGY 
ASSOCIATED WITH DEVELOPMENTAL CANNABINOID EXPOSURE 
 
 
 
 
A Dissertation 
Presented To 
The Faculty Associated with the Interdisciplinary Doctoral Program in Biological 
Sciences 
The Brody School of Medicine at East Carolina University 
 
 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in Interdisciplinary Biological Sciences 
 
 
 
By 
Marcoita Terreen Gilbert 
October 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Marcoita Terreen Gilbert, 2012 
  
 
 
CHANGES IN ZEBRA FINCH CENTRAL NERVOUS SYSTEM MORPHOLOGY  
FOLLOWING DEVELOPMENTAL CANNABINOID EXPOSURE 
 
 
 
by 
Marcoita Terreen Gilbert 
APPROVED BY: 
 
 
DIRECTOR OF DISSERTATION:___________________________________________ 
Ken Soderstrom, Ph.D. 
COMMITTEE MEMBER:__________________________________________________ 
Rukiyah Van Dross-Anderson, Ph.D. 
COMMITTEE MEMBER:__________________________________________________ 
Kori L. Brewer, Ph.D. 
COMMITTEE MEMBER:__________________________________________________ 
Mona M. McConnaughey, Ph.D. 
COMMITTEE MEMBER:__________________________________________________ 
Brian A. McMillen, Ph. D. 
DIRECTOR OF IDPBS:___________________________________________________ 
Terry L. West, Ph.D. 
DEAN OF THE GRADUATE SCHOOL:______________________________________ 
Paul J. Gemperline, Ph.D. 
  
 
 
ACKNOWLEDGEMENTS 
Psalms 25. 
Isaiah 54:17. 
  
 
 
TABLE OF CONTENTS 
LIST OF TABLES ............................................................................................................xi 
LIST OF FIGURES ......................................................................................................... xii 
LIST OF ABBREVIATIONS ......................................................................................... xviii 
CHAPTER 1: INTRODUCTION ....................................................................................... 1 
The History of Cannabis Usage ................................................................................... 1 
Trends in Marijuana Consumption: Before 1800....................................................... 1 
Trends in Marijuana Consumption: 19th Century Pioneers ....................................... 2 
Trends in Marijuana Consumption: The 20th Century and Beyond ........................... 3 
Adolescents and Cannabis Use ................................................................................... 6 
What Are Cannabinoids? ........................................................................................... 12 
Phytocannabinoids ................................................................................................. 13 
Endocannabinoids .................................................................................................. 16 
Synthetically-Derived Cannabinoids ....................................................................... 22 
Cannabinoid Receptors ............................................................................................. 25 
Structure ................................................................................................................. 26 
Signaling ................................................................................................................. 27 
Distribution .............................................................................................................. 31 
Pharmacodynamic Properties of Cannabinoid Agonism ......................................... 35 
The Neurobiology of Cognition ................................................................................... 39 
 
 
Dendritic Spines ...................................................................................................... 39 
How Does the Brain Learn and Memorize Information? ......................................... 41 
The Endocannabinoid System in Developing Individuals: How is This System 
Influenced by Cannabinoid Abuse? ........................................................................... 48 
Postnatal Development of the Endocannabinoid System ....................................... 48 
Persistent Behavioral and Neurphysiological Effects Following Adolescent 
Cannabinoid Exposure ........................................................................................... 49 
Songbird Models Provide Powerful Models for Studying Cannabinoid-Altered CNS 
Learning and Development ........................................................................................ 50 
The Zebra Finch ..................................................................................................... 52 
Preliminary Observations ........................................................................................... 60 
The Purpose of this Study .......................................................................................... 65 
CHAPTER 2: LATE-POSTNATAL CANNABINOID EXPOSURE PERSISTENTLY 
ELEVATES DENDRITIC SPINE DENSITIES IN AREA X AND HVC SONG REGIONS 
OF ZEBRA FINCH TELENCEPHALON ........................................................................ 67 
ABSTRACT: ............................................................................................................... 67 
INTRODUCTION ....................................................................................................... 68 
MATERIALS AND METHODS ................................................................................... 69 
Materials ................................................................................................................. 69 
Animals ................................................................................................................... 69 
Treatments ............................................................................................................. 70 
 
 
Golgi-Cox Treatments ............................................................................................. 70 
Light Microscopy ..................................................................................................... 71 
Measurement of Dendritic Spine Densities ............................................................. 72 
Measurement of Cell Body Major Diameters. ......................................................... 72 
Statistical Analyses. ................................................................................................ 73 
RESULTS .................................................................................................................. 73 
Dendritic Spine Densities. ....................................................................................... 73 
Cell Body Diameters ............................................................................................... 74 
DISCUSSION ............................................................................................................. 74 
CHAPTER 3: CANNABINOID TREATMENT DURING ADOLESCENT DEVELOPMENT 
PERSISTENTLY ALTERS AXONAL PHOSPHORYLATED NF-200 AND DENDRITIC 
MAP2 EXPRESSION IN BRAIN REGIONS IMPORTANT FOR VOCAL LEARNING ... 92 
ABSTRACT: ............................................................................................................... 92 
INTRODUCTION ....................................................................................................... 93 
MATERIALS AND METHODS ................................................................................... 94 
Materials ................................................................................................................. 94 
Animals ................................................................................................................... 95 
Treatments ............................................................................................................. 95 
Western Blotting ..................................................................................................... 96 
Immunohistochemistry ............................................................................................ 97 
 
 
Optical Density Measurements ............................................................................... 98 
Statistical Methods .................................................................................................. 99 
RESULTS ................................................................................................................ 100 
Western Blotting ................................................................................................... 100 
Phosphorylated Nf-200 Optical Densities ............................................................. 100 
MAP2 Optical Densities ........................................................................................ 104 
DISCUSSION ........................................................................................................... 108 
CHAPTER 4: CANNABINOID DISRUPTION OF NOVEL SONG-STIMULATED 
ARC/ARG 3.1 EXPRESSION IN ZEBRA FINCH AUDITORY TELENCEPHALON: 
NEURAL CORRELATES OF AUDITORY STIMULATION AND RECOGNITION ....... 147 
ABSTRACT: ............................................................................................................. 147 
INTRODUCTION ..................................................................................................... 148 
MATERIALS AND METHODS ................................................................................. 153 
Materials ............................................................................................................... 153 
Animals ................................................................................................................. 153 
Acute/Chronic Treatments .................................................................................... 154 
Western Blotting ................................................................................................... 155 
Immunohistochemistry .......................................................................................... 158 
Golgi-Cox Impregnation ........................................................................................ 159 
Optical Density Measurements ............................................................................. 160 
 
 
Measurement of Dendritic Spine Densities ........................................................... 160 
RESULTS ................................................................................................................ 161 
Anti-Arc Antibody Selectivity ................................................................................. 161 
Cannabinoid Inhibition of Novel Song-Stimulated Arc Expression ........................ 162 
WIN Prevents Habituation of Arc Expression Following Repeated Auditory 
Stimulation ............................................................................................................ 164 
WIN Disrupts Auditory Perception-Induced Increased Dendritic Spine Densities 
within NCM ........................................................................................................... 165 
DISCUSSION ........................................................................................................... 166 
Conclusion ............................................................................................................ 169 
CHAPTER 5: GENERAL CONCLUSIONS .................................................................. 185 
INTRODUCTION ..................................................................................................... 185 
CANNABINOID-ALTERED VOCAL DEVELOPMENT CORRELATES WITH 
INNAPROPRIATE DENDRITIC SPINE INCREASES .............................................. 187 
VOCAL DEVELOPMENT-ALTERING CANNABINOID EXPOSURE PERSISTENTLY 
CHANGES EXPRESSION PATTERNS AND DENSITIES OF AXONAL AND 
DENDRITIC PROTEINS IN ZEBRA FINCH SONG REGIONS ................................ 190 
CANNABINOID AGONISM ALTERS CNS DEVELOPMENT BY INTERFERING WITH 
STRUCTURALLY-RELATED IMMEDIATE EARLY GENE EXPRESSION .............. 192 
Appendix A: Animal Use Approval Letter .................................................................... 234 
Appendix B: PC12 experiments .................................................................................. 236 
 
 
APPENDIX C: Caspase-3 Experiments ...................................................................... 253 
APPENDIX D: Notch1 Experiments ............................................................................ 261 
APPENDIX E: General Materials and Methods ........................................................... 275 
In-Silico Cloning ....................................................................................................... 275 
Gene-Specific Primer Design ................................................................................... 275 
Traditional RACE Cloning ........................................................................................ 276 
Total RNA Isolation ............................................................................................... 276 
First Strand cDNA Synthesis ................................................................................ 278 
PCR Amplification of DNA .................................................................................... 280 
TA cloning of Taq-Amplified PCR Products ............................................................. 283 
TOPO Cloning Reaction ....................................................................................... 283 
Transforming Chemically-Competent DH5-α E. coli Cells .................................... 283 
Isolation of Plasmid DNA from Bacterial Cultures ................................................. 284 
Restriction Digestion of DNA ................................................................................ 286 
Dephosphorylation of Linearized Plasmid ............................................................. 287 
Phenol/Chloroform Extraction of DNA .................................................................. 287 
DNA Purification from Agarose Gels ..................................................................... 289 
Ligation of Target DNA Inserts into Linearized Vectors ........................................ 289 
DNA Sequencing of Results ................................................................................. 290 
Receptor Protein Analysis ........................................................................................ 290 
 
 
Cell Culture ........................................................................................................... 290 
Preparing Cell Culture Media ................................................................................ 292 
Preparing for Subculturing Cells ........................................................................... 293 
Cryogenic Preservation of Cell Lines .................................................................... 295 
Transfection of Plasmid DNA into Cultured Cells .................................................. 296 
Pseudoviral Particle Production ............................................................................ 298 
HIV-Based Lentiviral Infections ............................................................................. 298 
Immunocytofluorescence ......................................................................................... 298 
Receptor Protein Analysis ........................................................................................ 299 
Preparation of P2 Membranes .............................................................................. 299 
 
  
 
 
LIST OF TABLES 
Table 1.1.  The physiological effects of cannabinoids.   
 
 
LIST OF FIGURES 
Figure 1.1. The relationships between crude Cannabis products and pure cannabinoids. 
Figure 1.2. Percent of individuals using an illicit drug in the past month (2010). 
Figure 1.3. The biosynthesis and inactivation of endocannabinoids. 
Figure 1.4. The rat CB1 receptor in two-dimensional representation. 
Figure 1.5. Schematic illustration of signal transduction mechanisms stimulated by CB1 
receptor in a presynaptic nerve terminal. 
Figure 1.6. Stabilization of dendritic spines. 
Figure 1.7. Sonogram depicting zebra finch vocal development. 
Figure 1.8. Auditory and vocal pathways of the songbird brain within the context of the 
new consensus view of avian brain organization.   
Figure 1.9. Images (12.5X) of immunohistochemical staining of zebra finch brain with 
anti-zebra finch CB1 receptor antibody. 
Figure 1.10. Representative adult song patterns produced by a sibling pair treated with 
either Vehicle or WIN 55,212-2. 
Figure 2.1. Representative image of Golgi-Cox impregnated spiny dendrites used for 
analysis within HVC of birds developmentally treated from 50 - 75 days of age with WIN, 
or vehicle.  
 
 
Figure 2.2. Effect of developmental treatments from 50 – 75 days on song region spine 
densities at adulthood (n = 8).   
Figure 2.3. Effect of treatments given to adults for 25 days on song region spine 
densities (n = 8).   
Figure 2.4. Effect of developmental treatments from 50 – 75 days on song region 
average cell diameter at adulthood (n = 8).   
Figure 2.5. Effect of treatments given to adults for 25 days on song region average cell 
diameter at adulthood (n = 8). 
Figure 3.1. Photomicrographs of Nf-200 staining within caudal song regions of adult 
male zebra finch telencephalon following postnatal developmental treatment with either 
vehicle or WIN (1 mg/kg) using DAB immunohistochemistry.   
Figure 3.2. DAB-immunohistochemical staining of Nf-200 protein within rostral song 
regions lMAN and Area X of adult male zebra finch telencephalon following 
developmental vehicle treatment or treatment with WIN (1 mg/kg).   
Figure 3.3.  Representative low and high-power micrographs of Nf-200 staining of adult 
male zebra finch midbrain thalamic regions Ov and DLM using DAB 
immunohistochemistry. 
Figure 3.4.  Representative images of DAB-immunohistochemical staining of Nf-200 
protein within the cerebellum of adult male zebra finches developmentally treated with 
either vehicle or WIN.  
 
 
Figure 3.5. Photomicrographs of Nf-200 staining within caudal song regions of adult 
male zebra finch telencephalon following 25 days of treatment with either vehicle or 
WIN (1 mg/kg), using DAB immunohistochemistry. 
Figure 3.6. DAB-immunohistochemical staining of Nf-200 protein within rostral song 
regions lMAN and Area X of adult male zebra finch telencephalon following 25 
consecutive days of vehicle treatment or treatment with WIN (1 mg/kg). 
Figure 3.7. Representative low and high-power micrographs of Nf-200 staining of adult 
male zebra finch midbrain thalamic regions Ov and DLM using DAB 
immunohistochemistry.  Animals were subjected to either 25 consecutive treatments 
with vehicle or WIN (1 mg/kg) after song learning had occurred. 
Figure 3.8. Representative images of DAB-immunohistochemical staining of Nf-200 
protein within the cerebellum of adult male zebra finches treated with either vehicle or 
WIN (1 mg/kg) after song learning. 
Figure 3.9. Photomicrographs of dendritically associated MAP2 staining within caudal 
song regions of adult male zebra finch telencephalon following developmental treatment 
with either vehicle or WIN (1 mg/kg) using DAB immunohistochemistry.   
Figure 3.10. DAB-immunohistochemical staining of MAP2 protein within rostral song 
regions lMAN and Area X of adult male zebra finch telencephalon following 
developmental vehicle treatment  or treatment with WIN (1 mg/kg).   
 
 
Figure 3.11.  Representative low and high-power micrographs of MAP2 staining of adult 
male zebra finch midbrain thalamic regions Ov and DLM, using DAB 
immunohistochemistry.   
Figure 3.12.  Representative images of DAB-immunohistochemical staining of MAP2 
protein within the cerebellum of adult male zebra finches developmentally treated with 
either vehicle or WIN (1 mg/kg). 
Figure 3.13. Photomicrographs of MAP2 staining within caudal song regions of adult 
male zebra finch telencephalon following 25 days of treatment with either vehicle or 
WIN (1 mg/kg), using DAB immunohistochemistry.   
Figure 3.14. DAB-immunohistochemical staining of MAP2 protein within rostral song 
regions lMAN and Area X of adult male zebra finch telencephalon following 25 
consecutive days of vehicle treatment or treatment with WIN (1 mg/kg).   
Figure 3.15. Representative low and high-power micrographs of MAP2 staining of adult 
male zebra finch midbrain thalamic regions Ov and DLM using DAB 
immunohistochemistry. 
Figure 3.16. Representative images of DAB-immunohistochemical staining of MAP2 
protein within the cerebellum of adult male zebra finches treated with either vehicle or 
WIN (1 mg/kg) after song learning. 
Figure 4.1. Simplified schematic representation of the avian auditory brain regions 
studied. 
 
 
Figure 4.2. (A) Representative Western blot of the soluble fraction of protein isolated 
from male NCM brain homogenates. 
Figure 4.3. Double immunofluorescence labeling of Arc protein with dendritically-
associated MAP2 (630,1000X), visualized via confocal laser scanning microscopy.  
Figure 4.4. Immunohistochemical staining of NCM and Field L2 with Arc antibody. 
Figure 4.5. Optical densities and immunohistochemical staining of Arc expression within 
Ov in unstimulated controls, after acute novel song exposure, and after pretreatment 
with WIN. 
Figure 4.6. Habituation to novel song-induced Arc expression occurs in vehicle treated 
group as evidenced by a return to baseline levels. WIN exposure disrupts habituation 
however, the effect is reversed with the antagonist SR141716A. 
Figure 4.7. Representative high power image of an NCM spiny neuron used for 
analysis. Bar = 30 μm. 
Figure 5.1. Diagrammatic models illustrating potential mechanisms responsible for 
cannabinoid mitigation of neuronal morphological change. 
Figure AB1.  Results of PC12 radioligand binding experiments, using zebra finch 
membranes as a control. 
Figure AB2. A) Immunofluorescent confocal image of PC12 cells heterologously 
expressing CB1 receptor. 
 
 
Figure AD1. Electrophoretic analysis of PCR products generated in an effort to clone 
ZFN1. 
  
 
 
LIST OF ABBREVIATIONS 
(PC)-AEA o-phosphorylcholine 
3H Tritium 
Amp Ampicillin 
AMPA  2-amino-3-(3-hydroxy-5-
methyl-isoxazol-4-
yl)propanoic acid 
Area X Proper name 
BLAST Basic Local Alignment 
Search Tool 
 
Bmax Maximum saturation 
BSA Bovine Serum Albumin 
Bsd Blasticidin 
CB Cannabinoid 
cDNA Complimentary DNA 
CHO Chinese Hamster Ovary 
CI Confidence interval 
Ci Curie 
 
 
CIAP Calf Intestinal Alkaline 
Phosphatase 
 
CMV Cytomegalovirus 
CNS Central nervous system 
COX-2 Cyclooxygenase-2 
CYP450 Cytochrome P450 
DEPC Diethylpyrocarbonate 
DLM Dorsolateral nucleus of  
medial hypothalamus 
 
DMEM Dulbecco’s Modified Eagle 
Medium 
 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTP Deoxyribonucleotide 
Triphosphate 
 
E. Coli Escherichia coli 
EcoRI E. coli restriction enzyme 1 
 
 
EDTA Ethylenediaminetetraacetic 
Acid 
 
EtOH Ethanol 
F12-K F12 Kaighns 
FAAH Fatty acid amide hydrolase 
FBS Fetal bovine serum 
FITC Fluorescein Isothiocyanate 
GABA γ-aminobutyric acid 
GF/C Glass Microfiber Filter type 
C 
GPCR G-protein coupled receptor 
GPR55 G-protein coupled receptor 
55 
HEK Human epithileal kidney 
HI Heat-inactivated 
HindIII Haemophilus influenza 
deoxyribonuclease III 
 
HIV Human Immunodeficiency 
Virus 
 
 
 
HSP70 Heat-shock protein 70 
HVC Proper name 
IM Intramuscular 
Kd Dissociation constant 
kDa Kilodalton 
LB broth Luria-Bertani Broth 
lMAN Lateral magnocellular 
nucleus of the anterior 
neostriatum 
 
LOX lipoxygenase 
MAG-L Monoacylglycerol lipase 
MgCl2 Magnesium chloride 
NaOAc Sodium acetate 
NAPE N-acyl 
phosphatydilethanolamine 
NMDA N-methyl-D-aspartic acid 
OEA N-oleoyl ethanolamine 
 
 
ORF Open reading frame 
Ov Nucleus Ovoidalis 
P/S  Penicilin-Streptomycin 
Solution, 100X 
PC12 Pheochromocytoma line 12 
PCR Polymerase chain reaction 
PGH2 Prostoglandin H2 
PGP P-glycoprotein 
PLD Phospholipase D 
PLL, PDL Poly-L-Lysine, Poly-D-
Lysine 
PND Postnatal day 
QS Quantity Sufficient 
RA Robust nucleus of the 
Arcopallium 
 
RACE Rapid Amplification of cDNA 
Ends 
 
RNA Ribonucleic acid 
 
 
RNase  Ribonuclease 
RPM Revolutions per minute 
RPMI Roswell Park Memorial 
Institute 
 
S.O.C medium Super Optimal broth with 
Catabolite repression 
medium 
 
TAG Triacylglicerol 
Taq Thermus aquaticus 
Tris hydoxymethylaminomethane 
TRPV1 Transient receptor potential 
vanilloid 1 
Vd Volume of distribution 
VEH Vehicle 
Vent Deep-vent polymerase 
WIN WIN 55,212-2 
X-Gal 5-bromo-4-chloro-indolyl-β-
D-galactopyranoside 
Δ9-THC Δ9-Tetrahydrocannabinol 
CHAPTER 1: INTRODUCTION 
The History of Cannabis Usage 
Trends in Marijuana Consumption: Before 1800 
Cannabis Indica, Cannabis Sativa, Cannabis Americanus, Indian hemp and 
marihuana are names that all refer to the same plant: marijuana.  While its sharp rise in 
popularity and usage has occurred over the past couple of decades, marijuana has 
been known since antiquity, and used as a medicinal and recreational agent since 
ancient times.  Some of the first recorded medicinal uses of marijuana occurred around 
3000 B.C., with the Chinese emperor Shen Nung prescribing Cannabis tea and seedling 
preparations for the treatment of malaria, rheumatism, gout, female reproductive issues, 
intestinal constipation, and even poor memory (Russo, 2007).  As a result, these 
practices were recorded in the world’s oldest pharmacopeia, the Pen T’s-aoChing, 
which was compiled in the first century of this era (Lambert, 2001; Zuardi, 2006).  At the 
turn of the first millennium (A.D. 110 – 207), preparations of marijuana compounds 
mixed with wine were frequently used as an anesthetic during surgical operations (Li, 
1973).  Evidence suggests that in ancient India, marijuana was widely used as a 
medicine and as an agent for achieving euphoria as well.  It is speculated that within 
this society, the medical and recreational use of marijuana began around 1000 B.C. 
(Touw, 1981).  In many regions, cannabis usage maintained a close association with 
religious rituals, which often assigned sacred virtues to the plant.  For example, the 
Atharvaveda, a sacred text of Hinduism, mentions cannabis as one of five sacred plants 
used as a “source of happiness, donator of joy, and bringer of freedom” (Mikuriya, 
1969).  In Assyria (1000 B.C) and Persia (650 B.C), many also knew about the 
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psychoactive effects of marijuana, and the plant was burned as a medicinal incense for 
analgesia, and used as a hypnotic tranquilizer  (Mikuriya, 1969).  However, in the 12th 
and 13th centuries, ancient Arabs documented very cruel but unsuccessful attempts 
made by the local authorities to suppress recreational consumption (Walton, 1938).  For 
a more thorough review of this topic, please refer to (Fernberger, 1939).   
Trends in Marijuana Consumption: 19th Century Pioneers 
Before the 19th century, marijuana use was often described in both the literature 
and pharmacopeia as being a physical and mental health benefit; however, in the 
decades following, religious and medical views towards excessive consumption began 
to change.  Investigation into the properties of marijuana began in this era, following a 
major trend in pharmacological research at the time that centered on the isolation of 
natural active compounds (Kogan and Mechoulam, 2007).  In the 19th century, interest 
in use of cannabis as a therapeutic agent was intensified by the works of William 
Brooke O’Shaughnessy, a British pharmacologist working as a Professor of medicinal 
chemistry and Material Medica in Calcutta, India.  He brought a large supply of cannabis 
over to England, and provided samples to physicians in the form of Squire’s Extract, a 
concentrated alcoholic extract of Indian hemp.  After testing several cannabis 
preparations on animals, he decided the compounds were safe, and beneficial for 
human medicinal use.   As a result, in his published 1839 account of his experiments, 
he describes several successful attempts to treat general pain symptoms, rheumatism, 
and even muscular spasms resulting from rabies (Zuardi, 2006).  In this publication, he 
perceptively alludes to the fact that “In the popular medicine of [other] nations, we find it 
extensively employed for a multitude of affections.  But in Western Europe, its use either 
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as a stimulant or as a remedy is unequally unknown” (original documents reproduced by 
(Mikuriya, 1973).  In 19th century France, however, cannabis was used with a very 
different purpose: as a psychoactive agent.  Dissatisfied with the inability to locate a 
physiological cause for mental illnesses, early French psychiatrists such as Jacques 
Joseph Moreau eventually began to focus on gross and molecular brain function.   As 
an assistant physician at the Charenton Asylum near Paris, one of his duties was to 
accompany patients to the Far East, in the then eclectic practice of “therapeutic travel”.  
During these trips, he both observed and participated in hashish usage, and was able to 
experience effects first-hand.  Upon returning to France, he proceeded to experiment 
with a slew of cannabis preparations on himself and his students, and published his 
findings in Du Hachisch et de l’Alienation Mentale: Etudies Psychologiques, (which was 
later translated in to English as Hashish and Mental Illness) known to be one of the 
most complete descriptions of the acute effects of cannabis ever written (Moreau, 1973; 
Nahas, 1984).  In these writings, he proposed an organic basis of insanity; he theorized 
that since cannabis elicited some of the same psychoactive effects as what were 
observed in patients with mental illnesses, then psychopathy most likely stemmed from 
a persistent disruption of brain function that led to imbalance.  As a result of his work, 
Moreau revolutionized Western European medicine by being one of the first to employ 
herbal pharmacology in the systematic treatment of mental illnesses (Abel, 2005).   
Trends in Marijuana Consumption: The 20th Century and Beyond 
As the years progressed into the early 20th century, interest in using marijuana as 
a medicine and euphoric agent began to decline, and, usage in the clinical setting 
rapidly came to a halt. Consequently, when cannabis was dropped from the British and 
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American Pharmacopeia in 1932 and 1941, respectively, its original illegalization was 
barely challenged (Kalant, 2001).  This lack of enthusiasm occurred for many reasons, 
namely because the shelf-life of the plant was very short and unpredictable.  In addition, 
caregivers faced the predicament that since cannabis was a natural raw product, 
different samples of the many species of cannabis varied widely in both efficacy and 
potency.  Due to the fact that these synthesized preparations (used in the form of 
tinctures or extracts whose power was dependent on origin, age, and method of 
preparation) almost always contained different proportions of flower, stem, plant and 
seed, it was virtually impossible to achieve medicinal/psychoactive effects that were 
replicable (Kalant, 1971).  Furthermore, the introduction of the hypodermic needle, and 
faster acting, more water-soluble drugs (such as opioids) became more readily 
available, and replaced cannabis as an analgesic (Mikuriya, 1969).  Narcotics such as 
chloral hydrate, paraldehyde, various barbiturates and synthetic drugs replaced 
cannabis as a sedative (Bennett, 1974; Zuardi, 2006).  However, interest in marijuana 
piqued again in the 1930’s, when scientific experiments were conducted in which 
isolated crude cannabinoid compounds (which contained cannabidiol and various 
tetrahydrocannabinoids) were shown to be solely responsible for the psychoactive 
effects experienced.  Accordingly, this body of work is at the nexus of modern-day 
recreational cannabinoid use (Adams et al., 1941; Pertwee, 2006a).  
In several ways, the insufficient amount of concrete knowledge available 
regarding cannabinoid effects on neurophysiology is the consequence of two main 
issues: 1) our inability to understand and isolate pure cannabinoid compounds until the 
mid-20th century, and 2) the long and complicated legal history of marijuana usage in 
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this country.  In the early 1900’s, an explosion of marijuana consumption occurred for 
hedonistic purposes in the United States.  During this time, usage was mostly restricted 
to minorities, Mexican immigrant rural workers, musicians/artists, and individuals of a 
low socioeconomic status.  The use of cannabis continued to spread in the United 
States in these populations, mostly in the southern and southwestern states until the 
late 1920’s (Mikuriya, 1969).  However, laws were passed in 27 states between 1915 
and 1937 to discourage use (Musto, 1972).  Many speculate these actions were largely 
based on hysteria engendered by law enforcement officials and other alarmist groups at 
the time, (many felt great hostility toward the individual populations that used it, and 
others feared that cannabis would be used as a substitute for other narcotics banned by 
the 1914 Harrison Tax Act) and medical ignorance (little was known about active 
constituents, and many believed that other addictive substances would lead to cannabis 
addiction), and as such, the events during this time period have resulted in a slow 
progression in the field of cannabinoid research (Grotenhermen, 2007; Hollister, 1969; 
Kaplan, 1969; Mikuriya, 1969; Mikuriya, 1973).  As a finale to the growing state 
legislation trends, the Marijuana Tax Act of 1937 was passed in an effort to regulate 
marijuana.  
Despite restrictive legislation, the use of marijuana among individuals, especially 
adolescents for recreational purposes has quickly spread throughout the U.S. over the 
past couple of decades. As stated previously, crude cannabis compounds were indeed 
isolated in the 1930’s and 1940’s, however the chemical structure of Δ9-THC has only 
been known since 1964 (Gaoni and Mechoulam, 1964), and thus neither purification of 
natural compounds, nor production of synthetic compounds was possible (Figure 1.1). 
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In this country, the historical percentage of adolescents reported to have used cannabis 
at least once went from 5% in 1967, to 44%, 49%, 68%, and 64% in 1971, 1975, 1980, 
and 1982 respectively (Kandel, 1984; Lipton et al., 1979; Zuardi, 2006).  This startling 
trend that still continues today, which has severely magnified its societal importance, 
has heightened the need to understand the chemical composition of drugs within this 
class, and the physiological and psychoactive effects conferred upon the central 
nervous system.  
Adolescents and Cannabis Use 
Illicit drug consumption among adolescents is steadily increasing, and reportedly, 
usage occurs the most frequently among individuals in their teens and early twenties 
than at any other age (Figure 1.2). This increase is mostly due to the rising popularity of 
marijuana and new synthetically derived cannabis-like substances.  Monitoring the 
Future is an ongoing study that obtains data from 50,000 8th, 10th, and 12th graders 
regarding illicit drug, alcohol and tobacco use. This research is conducted yearly by a 
series of National Institute on Drug Abuse (NIDA, a division of the National Institute of 
Health)-funded investigators. The following statistics are reported from this source. In 
addition, more details and supplemental information on this subject can be found at 
(available 1 October 2012) http://www.monitoringthefuture.org/, and 
http://www.drugabuse.gov/drugs-abuse/marijuana. In 2010, more than 29 million 
Americans (11.5%) aged 12 or older reported abusing marijuana within the past year; 
this is an enormous increase over rates reported each year from 2002-2008. 
Apparently, a consistent decline in marijuana use began in the mid-1990's and 
continued into the early 2000s, but since then, this downward trend has completely 
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Figure 1.1. The relationships between crude cannabis products and pure cannabinoids. 
Cpds = compounds; THC = Tetrahydrocannabinol [Adapted from (Kalant, 2001)].  
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reversed itself. These results show a significant rise among older adolescents, (both 
10th and 12th graders) in daily, current, and past-year marijuana use. In 2011, 7.2% of 
8th graders, 17.6% of 10th graders, and 22.6% of 12th graders were reported to have 
used marijuana in the past month, compared to 5.7%, 14.2%, and 18.8% respectively, 
in 2007. Daily use in 12th graders also increased: 6.6% used marijuana at least once a 
day, compared to only 5% in the previous decade. This year (2012), 12.5% of 8th 
graders, 28.8% of 10th graders, and 36.4% of 12th graders reported past-year marijuana 
use (Figure 1.2). 
Even though there were no significant increases between 2010 and 2011, it 
appears that using marijuana continues to far exceed cigarette use in adolescents—a 
quite surprising trend. In 2011, 22.6% (almost 1 in 4) of high school seniors were 
reported to have used marijuana in the past month compared with 18.7% who smoked 
cigarettes. In addition, for the first time, the 2012 study captured the use of synthetic 
marijuana among teenage groups, as these drugs have seen a spike in popularity over 
the past year. The results are startling: 11.4% (that is almost 1 in 9) of high school 12th 
graders reported using these agents in the past year (Johnston, 2012).  
Why is this drug class so popular among adolescents and young adults? 
Superficially, these trends seem somewhat inexplicable, however upon closer 
inspection; the reasoning behind this is pretty straightforward.  Historically speaking, as 
the perception of risks associated with using a particular drug goes down, the use of 
that drug goes up. The inverse of this statement is true as well: As perception of risks 
goes up, usage goes down. Adolescents are likely having less of an issue with 
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Figure 1.2.Drug use is highest among people in their late teens and twenties. In 2010, 
23.1 percent of 18- to 20-year-olds reported using an illicit drug in the past month. 
[taken with permission from drugabuse.gov/drugs-abuse/marijuana]  
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marijuana use, and therefore a perception that the drug is less dangerous. This attitude 
likely reflects recent discussions and legislation involving cannabis use for medical 
reasons. Furthermore, many believe that because most cannabis products are naturally 
derived, they pose less of a health risk than those agents that are not produced in 
nature. In addition, users report that they have a greater availability of cannabis 
products, based on use among their friends within their social group (Ausems et al., 
2003; Brown, 2005; Marroyo Gordo et al., 2012). Finally, cannabis is more attractive to 
teenagers because compared to other illicit substances; the legal ramifications of 
possession are less harsh. 
What Are Cannabinoids? 
Cannabinoids are traditionally known as a diverse class of structurally-related 
chemical constituents of cannabis that bind to the cannabinoid receptor. The system 
that these compounds belongs to is one of the most evolutionarily conserved in nature, 
and subsequently, an enormous variety of these agents exist within both plants and 
animals (Chang et al., 1993; Elphick, 2002; Elphick and Egertova, 2001a). In the last 
few years, a cohort of “non-cannabinoid” plant constituents have been shown to bind to 
and functionally activate cannabinoid receptors (Gertsch et al., 2010), however these 
results will not be reviewed in this text. Cannabinoids are traditionally divided into three 
main groups: these include phytocannabinoids (cannabinoids derived from plant 
sources), endocannabinoids (endogenously produced cannabinoids), and synthetically-
derived cannabinoids.   
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Phytocannabinoids 
According to Gertsch et al. phytocannabinoids are defined as those plant-derived 
natural products capable of either directly interacting with cannabinoid receptors, 
sharing chemical similarity with cannabinoids, or both.  Phytocannabinoids have been 
identified in a large number of plant species, namely the well-characterized Cannabis 
sativa, Cannabis indica, Echinacea purpurea, Echinacea pallida, Echinacea 
angustifolia, and others (ElSohly, 2006; Woelkart et al., 2008). As a general rule, most 
phytocannabinoids are 21-carbon compounds, but are known to vary in the number of 
carbons in the side chain attached to the aromatic ring. So far over 85 different types of 
cannabinoids have been isolated from cannabis plants, and 25 identified in Echinacea 
plants. These phytocannabinoids are divided into nine distinct subclasses. One of these 
subclasses, Δ9-THC- type (also referred to as THC in this text), is the principal 
psychoactive constituent of marijuana, and is thus one of the more well-known 
phytocannabinoids of this group  (ElSohly, 2006; Hemphill et al., 1980; Iversen, 2003; 
Turner et al., 1973). 
Δ9-THC 
The pharmacokinetics of THC involve different absorption rates through various 
routes of administration, and from different drug formulations (e.g. tablet vs. cigarette). 
As an aromatic terpenoid, THC has a very low solubility in aqueous solutions but is 
soluble in organic preparations, especially lipids and alcohols. Smoking is the principal 
route of THC administration, due to the fact that inhalation delivers the drug rapidly from 
the lungs to the brain, resulting in almost immediate CNS drug exposure. Recent 
studies have demonstrated that intravenous injection of THC results in only slightly 
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higher peak concentrations than what is achieved after smoking (Ohlsson et al., 1980).  
The bioavailability of THC following smoking varies widely (2% - 56%); due to 
differences in smoking methods, plasma concentrations vary from subject to subject. 
There have been fewer studies conducted on the oral absorption of THC compared to 
smoking; however this route is generally preferred for therapeutic applications, as most 
experts believe the advantages of THC inhalation are offset by the harmful effects of 
cannabis smoke. Accordingly, Marinol® (dronabinol) preparations are usually 
administered orally or rectally.  Orally, THC is readily absorbed, due to its high 
alcohol/water P (partition coefficient, 9 X 106 (Harder and Rietbrock, 1997)) however 
absorption is slower than other routes when ingested, resulting in low, more delayed 
peak concentrations (bioavailability of ~20 %, (Grotenhermen, 2003; Law et al., 1984). 
Although THC is typically not abused through intravenous injection, pharmacologists 
often employ this technique in the lab. A study was conducted in which 0, 2.5 and 5 mg 
of THC was administered to healthy individuals with a history of cannabis use in the 
past. (Assuming these individuals weighed 70 kg, concentrations were 0, 0.35, and 0.7 
mg/kg, respectively). After 10 minutes, plasma [THC] = 82 ± 87.4 and 119.2 ± 166.5 
ng/ml for 0.35 and 0.7 mg/kg THC, respectively (D'Souza et al., 2004). THC is 
distributed rapidly into tissues after administration.  Due to its high lipophilicity, THC is 
distributed and retained in fatty tissue as opposed to less-fatty tissue in a 64:1 ratio after 
about a month’s exposure (Kreuz and Axelrod, 1973). In addition, THC is taken up by 
other organs that are highly perfused such as the liver, brain, heart, and lung. This 
substance is also known to rapidly distribute into the placenta and breast milk, and is 
greatest within these areas in early pregnancy (Atkinson et al., 1988; Perez-Reyes and 
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Wall, 1982). Surprisingly, even though THC is 95% – 99% protein bound in the blood 
(mostly to lipoproteins),  Vd of THC is quite large, 101 L/kg (Huestis, 2007).  Metabolism 
of THC has been known to occasionally occur in the intestines, however for the most 
part, it undergoes hepatic biotransformation. Phase I reactions include allylic and 
aliphatic hydroxylations at C (9) by CYP 450, leading to the metabolite 11-OH-THC, 
originally thought to be the true psychoactive constituent of cannabis, and oxidation of 
alcohols, β-oxidation, and degradation of the pentyl side-chain.  Phase II reactions 
involving THC include glucuronidation, and sometimes sulfation (Huestis, 2007; Iribarne 
et al., 1996; Lemberger et al., 1970).  Lastly, it has been demonstrated that within five 
days, almost all of THC is excreted out of the body as a hydroxylated metabolite.  THC 
is mostly eliminated in the feces (65% of a total dose), followed by the urine (20%). 
Most of the glucuronic acid-conjugated metabolites are excreted through the urine, as 
the Phase II glucuronidation step increases their solubility in water. 11-OH-THC is 
primarily eliminated in the feces (Wall et al., 1983; Williams and Moffat, 1980).  
Other Phytocannabinoids 
THC is known as the most potent psychoactive phytocannabinoid from Cannabis 
sativa, but there are several other structurally related cannabinoids that interact with 
cannabinoid receptors.  Cannabigerols (CBG), were the very first cannabinoids 
identified, cannabichromenes (CBC), are non-psychoactive C5 cannabinoid analogs, 
cannabidiols (CBD), are psychoactive agents which constitute the most abundant 
cannabinoid found in hemp, representing about 40% of its extracts, Δ8-THC- type, exist 
as the more thermodynamically stable, 20% less active artifacts of Δ9-THC, and 
cannabicyclols (CBL), are heat-generated artifacts of CBC. Other subclasses include 
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cannabielsoins (CBE), which are byproducts formed from CBD, and cannabinols (CBN), 
mildly psychoactive substances synthesized by degradation (oxidation) of Δ8- or Δ9-
THC, and of which concentrations in cannabis vary widely with age and storage 
conditions. Lastly, there are cannabitroils (CBT), which have no known pharmacological 
characteristics at this time (ElSohly, 2006; Hemphill et al., 1980; Turner et al., 1973). 
Endocannabinoids 
After researchers determined that the human body actually possessed receptors 
that selectively bind cannabinoids, they soon realized that the presence of these 
receptors could only be explained by the presence of endogenous ligands that were key 
to its use. Hence, they soon discovered that mammalian tissues were able to both 
synthesize endogenous agonists, and release them retroactively onto various receptors 
(Devane et al., 1992; Mechoulam et al., 1995; Sugiura et al., 1995).  Endogenous 
cannabinoids, or “Endocannabinoids”, are the terms for these polyunsaturated fatty 
acids which are synthesized and released in response to rises in intracellular calcium 
(Basavarajappa, 2007; Maccarrone and Finazzi-Agro, 2002). Endocannabinoids are 
derivatives of arachidonic acid and conjugated with ethanolamine or glycerol, which 
closely resemble other lipid-based neuromodulators (eicosanoids, such as leukotirenes 
and prostaglandins, (Rodriguez de Fonseca et al., 2005). Produced on demand from 
components of the phospholipid bilayer, these lipid messengers rapidly influence 
cellular dynamics in response to both the subtlest and most robust changes in 
physiology.  Endocannabinoids play neuromodulatory roles in a number of physiological 
processes, but most notably, these lipids appear to be critically involved in the 
maintenance of homeostasis and physiological stress recovery (Pagotto et al., 2006).  It 
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is important to note that endocannabinoids are extremely labile and undergo almost 
instant cellular hydrolysis after production (Murphy et al., 2012), thus much of the 
information gathered about these substances has been obtained from enzyme inhibitor 
studies.  At the present time, five endocannabinoids have been isolated and 
characterized, and all five have been found in the brain, plasma, and peripheral tissues.  
AEA 
In 1992, the amide of arachadonic acid and ethanolamine was identified in 
porcine brain, and named anandamide (AEA, or arachidonylethanolamide, (Devane et 
al., 1992)).  Although the chemical structure of AEA is different from other cannabinoids 
(namely THC), it has been shown to possess very similar pharmacological properties 
(Romero et al., 1995; Smith et al., 1994). AEA is widely distributed throughout the brain, 
with levels varying by a factor of 4-6 within different regions, with the lowest amounts in 
the cerebellum and cortex, and the highest levels in the striatum and brainstem 
(Basavarajappa, 2007).  It has become  increasingly clear that the relative abundance of 
AEA in the brain does not correlate with the distribution of cannabinoid receptors, and 
therefore may serve a purpose within the CNS apart from the cannabinoid system 
(Basavarajappa, 2007). Unlike classic peptide and transmitter ligands, AEA is not stored 
in intracellular compartments or vesicles, but is synthesized almost instantaneously, and 
released from neurons immediately afterwards. AEA is formed by cleavage of its 
phospholipid precursor NAPE, by the action of PLD (phospholipase D). To review the 
synthesis of AEA, please refer to Figure 1.3. Once AEA is formed, it can either exert 
effects on the same cell from which it was produced, or diffuse backwards through the 
extracellular fluid to reach targets with the help of lipocalins and/or albumin (Piomelli, 
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2003). Generally speaking, two mechanisms are present within our organ systems that 
aid to eliminate AEA signal; uptake and enzymatic degradation. Uptake of AEA is 
accomplished by the actions of the following intracellular transport proteins: fatty acid 
binding protein 5/7, HSP 70, albumin, and FAAH-like AEA transporter protein (Fowler, 
2012). The most common method of AEA degradation within the cell is via hydrolysis by 
FAAH, but alternative processes do exist. In addition to being hydrolyzed, AEA is readily 
metabolized by COX-2, LOX, and CYP450, and in the absence of FAAH, is converted to 
(PC)-AEA in the CNS (Basavarajappa, 2007). 
2-AG 
Soon after the discovery of AEA, scientists isolated a second arachidonic acid 
derivative that functions as an endocannabinoid, 2-arachidonoylglycerol (2-AG, 
(Mechoulam et al., 1995). In contrast to being a product of membrane phospholipid 
cleavage like AEA, 2-AG, a monoacylglycerol, is a metabolic intermediate in lipid 
metabolism. In the brain, the distribution of the two endocannabinoids is similar, 
however the concentration of 2-AG is 200 fold higher than AEA, and is therefore 
considered the most abundant endocannabinoid.  Even so, researchers have yet to 
determine the full role of this messenger in the body. Not only is information regarding 
tissue levels of 2-AG sparse, but there are no correlations between regional 2-AG 
concentrations and cannabinoid receptor distributions in the brain (Sugiura et al., 2002).  
The biosynthesis of 2-AG is very different from AEA; since 2-AG is a monoglyceride, its 
formation is based on the metabotropic receptor-dependent activation of PLC, which 
mediates the breakdown of triacylglycerols.  PLC-mediated hydrolysis of TAG in turn  
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Figure 1.3. The biosynthesis and inactivation of endocannabinoids. Endocannabinoids 
are membrane-derived local neuromodulators that are synthesized on demand. They 
can, in principle, be released from pre-and postsynaptic nerve terminals [taken with 
permission from (Di Marzo et al., 1998)].  
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produces DAG, which is converted into 2-AG by the enzyme DAGL-α (Siguria et al. 
1995). Thus, unlike the previously discussed endocannabinoid, 2-AG is heavily 
dependent on postsynaptic Ca2+ release. For a review of 2-AG biosynthesis, please 
refer to Figure 1.3. Similar to AEA, once synthesized, 2-AG is immediately released 
from the cell plasmalemma, targets receptors, and is metabolized (Rodriguez de 
Fonseca et al., 2005). 2-AG signal is tightly regulated in tissues by rapid elimination. 
Like AEA, this includes transport into cells, and hydrolysis by enzymatic systems. 2-AG 
is eliminated by the AEA membrane transporter (known to be widely distributed 
throughout the brain) in an energy-dependent fashion (Beltramo et al., 1997).  In certain 
cases, 2-AG is metabolized by enzymatic oxygenation (COX-2) into PGH2 glycerol 
esters (Basavarajappa, 2007).  It has been demonstrated that fatty acid amide 
hydrolase (FAAH) can also inactivate 2-AG (this enzyme is widely distributed 
throughout the body, but concentrated in the brain), however the main enzyme 
responsible for its degradation is monoacylglycerol lipase (MAGL), located in the 
presynaptic terminal (Dinh et al., 2002). 
Other endocannabnoids 
Since the discovery of these compounds, three other endocannabinoids have 
been identified. The third type of endocannabinoid, an ether derivative of 2-AG (2-
arachidonylglycerol ether, or noladin ether), was isolated from porcine CNS, and 
displays pharmacological properties similar to that of AEA. The fourth endocannabinoid, 
virodhamine (OEA), is an arachidonic acid and ethanolamine joined by an ester link, 
instead of an amide linkage like AEA. This molecule is mostly found peripheral of the 
central nervous system. N-arachidonoyl-dopamine (NADA), which also binds to TRPV1 
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vannilloid receptors, has just been recently identified as an endocannabinoid; 
researchers are currently working to investigate its pharmacological properties 
(Basavarajappa, 2007).  
Synthetically-Derived Cannabinoids 
The history of the development of synthetic Δ9-THC, and other synthetic 
cannabinoid analogs can provide some insight into why cannabinoid-based illicit drugs 
are emerging as the most popular drugs of choice these days. Once the structure and 
function of phytocannabinoids became more clear in the mid- 20th century, laboratory 
synthesis of cannabinoid derivatives were produced and tested in a variety of 
applications (Gaoni and Mechoulam, 1964; Reggio, 2008).  From a historical 
perspective, these agents were mainly produced to be used either in medications such 
as Dronabinol, Sativex, Nabilone, and Rimonabant, or to be used in experiments that 
determined relationships between the structure and function (activity) of cannabinoid 
compounds. Subsequently, this class of cannabinoids made their appearance into 
mainstream medicine. Unfortunately, for almost every beneficial use identified, these 
synthetic substances exerted many more undesirable physiological and behavioral side 
effects, which greatly limited their therapeutic use (Carroll et al., 2012).  
Synthetic Cannabinoid Agonist: WIN55,212-2 
In the present day, most of the newer synthesized cannabinoids are not related 
to phytocannabinoids, or based on the structure of endocannabinoids.  Members of the 
aminoalkylindole group of cannabinoid agonists have structures that differ greatly from 
those of classical cannabinoids. The best known, and most widely utilized member of 
this group is: R-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
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benxozazin-6-yl]-1-napthalenylmethanone mesylate, or WIN55,212-2 (which is usually 
shortened even further: WIN).  The pharmacokinetics of WIN resemble the kinetics of 
THC in rodents (Agurell et al., 1986), but besides this information, there has been very 
little research on the metabolism of WIN and other analogs, either in vitro or in vivo.  
However, because of the vast structural difference between WIN and other 
cannabinoids, many predict that WIN undergoes biotransformations that differ from 
classical cannabinoid metabolic patterns, and still possess functional metabolites that 
contribute its  efficacy (Zhang et al., 2002). WIN produces physiological effects similar 
to that of THC, but offers a great advantage in larger scale experimental studies, as it is 
much more potent, more soluble in aqueous solutions, and is easier to obtain in a 
laboratory setting (Pertwee, 2006a). WIN is unscheduled in many countries, including 
the United States, as it has not yet been approved for human consumption. For this 
reason, the addictive potential of WIN is currently unknown.  
Synthetic Cannabinoid Antagonist: SR141716a 
One other major advance made by those in the field of cannabinoid research was 
the development of selective cannabinoid receptor antagonists.  These ligands are 
useful in experiments that examine the necessity of cannabinoid function, as they block 
agonist-induced activation of cannabinoid receptors in a competitive manner, yet lack 
the capability to activate cannabinoid receptors when administered alone. That having 
been said, a plethora of evidence exists that within some cannabinoid receptor-
containing tissues and systems, these substances are able to induce physiological 
responses in the opposite direction of those elicited by an agonist (“inverse cannabinoid 
agonism”, reviewed in later sections); this reflects an ability of these compounds to 
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decrease the spontaneous coupling of cannabinoid receptors to their effector 
mechanisms that sometimes occur in the absence of exogenously added, or 
endogenously released agonists (Pertwee, 2006a; Pertwee et al., 2010). The 
diarylpyrazole SR141716a (Rimonabant, or SR), along with its structural derivatives 
AM251 and AM281 are some of the most commonly used cannabinoid antagonists in 
the laboratory setting. With the exception of SR for a brief period of time, these agents 
have not been approved for human consumption. The pharmacokinetics of SR were 
described as dose-proportional up to 20 mg in humans. Rimonabant is not a P-
glycoprotein (PGP)  substrate, inhibitor, or inducer, however it does cross the BBB and 
is psychoactive, nevertheless, its absolute bioavailability in humans is not currently 
known. Since SR is an water soluble compound, Vd is proportional to body weight, with 
more obese organisms having a higher distribution volume, and taking a much longer 
time to reach a steady state. In vitro, SR’s protein binding in plasma is very similar to 
that of phytocannabinoids, approximately 99%. SR is hepatically metabolized by 
CYP3A, and its metabolites do not contribute to its pharmacodynamic effects. 
Approximately 90% of SR is excreted in the feces as unchanged drug (Samat et al., 
2008).   
Designer Cannabinoid Drugs 
Throughout the drug discovery process, research labs, pharmaceutical 
companies, and other institutions publish data in manuscripts, books and patents, most 
of which is freely accessible by the public. As stated before, this information is used to 
understand the nature of drug abuse, develop the therapeutic potential of cannabinoids, 
and to investigate related mechanisms of action. Unfortunately, many times this 
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information is used by “sketchball chemists” for lack of a better term, to copy what has 
been produced in the medical community to manufacture an endless variety of analog 
designer drugs.  This class of cannabinoid drugs has proven to be very dangerous; 
most have not been approved for human consumption or use. Furthermore, many of 
these compounds are so new that researchers and other professionals rarely get an 
opportunity to fully examine these drugs in mechanistic or functional studies in order to 
characterize pharmacokinetics and side effects. Because of a lack of legal controls and 
adequate detection methods (mass spectometry, immunoassays, etc.,) the number of 
derivatives has rapidly multiplied (Carroll et al., 2012). The synthetic cannabinoid 
agonists HU-210 and JWH-018 are examples of THC analogs that have very slight 
modifications, yet are significantly more potent (1999). 
Cannabinoid Receptors 
In the early to mid-1980’s, studies conducted in Allyn Howlett’s laboratory 
elucidated the existence of cannabinoid receptors by demonstrating that 1) psychotropic 
cannabinoids have the ability to inhibit adenylyl cyclase by acting through Gi proteins, 
and that 2) unlabeled cannabinoid possessed the ability to displace [3H]-CP55940, from 
a receptor site, an effect that was coupled with the Gi-inhibition of adenylyl cyclase, and 
the production of cannabimimetic behavioral responses (Howlett, 2005; Johnson et al., 
1988; Pertwee, 2006a). This was confirmed in 1990, when the rat CB1 receptor was 
cloned (Matsuda et al., 1992).  Since the discovery of these receptors, much has 
become known about their structure and signal transduction, as well as their regulation, 
distribution, and roles within the body. To date, two absolute cannabinoid receptors 
exist: CB1, found predominantely at the terminals of CNS neurons, and CB2, found 
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predominately on immune cells. Within recent years, some have classified the 
lysophosphatidylinositol-sensitive receptor GPR55 as a putative cannabinoid receptor, 
however it presently remains a contentious issue (Ross, 2009). Since almost all of the 
behavioral effects of cannabinoids are mediated through the CB1 receptors, this 
receptor is discussed with more detail. For a review of the CB2 receptor system, refer to 
(Pertwee et al., 2010).  
Structure 
The coding sequence of cannabinoid receptor 1 (CNR1) is approximately 1.5KB, 
and in its translated form, has a molecular mass of approximately 60 kDa. As mentioned 
previously, the CB1 receptor is highly conserved in vertebrates, with most other 
vertebrates, sharing at least an 85% sequence homology to humans (Soderstrom and 
Johnson, 2001).  The CB1 receptor is a well-defined, but dynamic protein, as this 
receptor is subject to post-translational modifications that contribute to its 
pharmacological properties (especially receptor binding). These changes include 
nitrosylation, phosphorylation, and most commonly, glycosylation (Bosier et al., 2010).  
In addition, CB1 receptors can exist as homodimers, and have been shown to 
heterodimerize with other GPCRs, existing in such forms as A2ACB1, Orexin1CB1, and 
CB1D2 (Pertwee, 2006b).  Cannabinoid receptors are rhodopsin-like members of the 
super family of GPCRs, and as such, are classified as heptahelical receptors. Like other 
GPCRs in this class, they couple to guanine-nucleotide-binding proteins, possess an 
extracellular amino terminal, an intracellular carboxy terminal, and thread through the 
membrane seven times. These receptors are associated with the inhibitory proteins G i/O 
through the intracellular loops of the protein (Howlett, 2005). The results of structure-
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activity relationship studies have helped researchers identify a number of amino acid 
moieties that are key to CB1 receptor binding and function (Pertwee, 2006b; Pertwee et 
al., 2010; Razdan, 1986).  Within the third transmembrane region (TM3) of CB1, Lys192 
is an important residue for ligand binding. Not only is this residue homologous to other 
key amino acids essential for agonist binding in rhodopsin receptors, Lys192 is essential 
for binding of [3H]-CP55940 and subsequent intracellular signaling response as 
demonstrated by site-directed mutagenesis studies (Chen et al., 1998; Song and 
Bonner, 1996).  It was hypothesized that Lys192 serves as a hydrogen bond donor to a 
phenolic hydroxyl shown to be critical for agonist binding (Reggio, 1987). Similar to 
other GPCRs, the CB1 receptor interacts with G proteins on the cytoplasmic domain.  In 
pertussis toxin sensitivity studies, it was demonstrated that the juxtamembrane C-
terminal of CB1 is critical for recognizing and facilitating the activation Gi proteins, the 
actions of which are promoted by changes in its seventh transmembrane region. 
Additionally, the third intracellular loop (C3) is important for directing G protein signal 
transduction (Howlett, 2000). Just beside the C3 loop lays a Ser317 which is responsible 
for the cannabinoid agonist-regulation of ion channels (Garcia et al., 1998).  For an 
illustration of CB1 receptor structure, please see Figure 1.4. 
Signaling 
Under certain conditions with certain agonists, the CB1 receptor may couple to 
GS and Gq, but mainly signals through Gi/O. Subsequently, the consequences of the CB1 
receptor activation are mediated through three main signal transduction pathways: 1) 
the inhibition of adenylyl cyclase, 2) the modulation of various ion channels, and 3) the  
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Figure 1.4. The rat CB1 receptor in two-dimensional representation. Three extracellular 
(E1, E2, and E3) and intracellular (C1, C2, and C3) regions are represented. The most 
conserved residues within each helix is indicated by an arrow. The palmitoylation of a 
C-terminal cys residue is depicted as a membrane attachment locus. Amino acid 
residues mentioned in the text are depicted in bold type. Putative intrahelical 
interactions are denoted by lines drawn between amino acid residues proposed to be 
associated by hydrogen bonding interactions. [Taken with permission from (Howlett, 
2000)].  
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regulation of mitogen-activated protein kinase (MAPK) pathways (Demuth and 
Molleman, 2006).The inhibition of adenylyl cyclase was the first CB1 signaling pathway 
characterized (see Figure 1.5).  Since Allyn Howlett’s laboratory demonstrated that 
micomolar concentrations of THC blocked cAMP production in N18TG2 neuroblastoma 
cells (an effect reversed by pertussis toxin), the functional inhibition of the cAMP 
cascade was shown in a number of studies. CB1-mediated adenylyl cyclase inhibition 
can be observed both centrally and peripherally, as well as in cells overexpressing 
functional CB1 receptors (Howlett, 2005).  Specifically, cannabinoids have displayed an 
attenuation of cAMP production in CHO cells heterologously expressing CB1 receptors; 
an effect that can be reversed by both pertussis toxin and SR. (Matsuda et al., 1992).  
Many have repeatedly shown that brain regions that contain the highest concentrations 
of cannabinoid binding sites are the areas in which cannabinoids are the most effective 
in inhibiting adenylyl cyclase activity. Therefore, it is no surprise that WIN, AEA, and 
CP55940 were demonstrated to be potent inhibitors of cAMP in cerebellum, striatum, 
hippocampus, and cortex (Childers and Deadwyler, 1996). 
The modulation of Ca2+ and G-protein inwardly-rectifying potassium (GIRK) 
channels is thought to underlie the inhibition of neurotransmitter release from 
presynaptic nerve terminals. In this context, cAMP, serving as a second messenger to 
outward GIRK channels is inhibited, thereby prolonging the duration of the 
hyperpolarizing GIRK currents. Simultaneously, activation of CB1 receptors directly 
inhibits Ca2+ entry through L, N, and P/Q type inward Ca2+ channels, which are required 
for neurotransmitter vesicle fusion and exocytosis (Demuth and Molleman, 2006; Turu 
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and Hunyady, 2010). These mechanisms synergistically shorten the duration and 
strength of presynaptic action potentials. 
In general, stimulation of GPCRs leads to activation of MAPK pathways (Demuth 
and Molleman, 2006). Accordingly, CB1 signal transduction mechanisms involving 
MAPK have not been fully clarified. Some have proposed that CB1 stimulation indirectly 
regulates MAPK activity through its modulation of cAMP, and consequently PKA activity 
(Melck et al., 1999). This cannabinoid induced activation of MAPK expression has been 
linked to the mediation of immediate-early gene expression in a number of studies 
(Bouaboula et al., 1995; Patel et al., 1998). 
Characterizing the dynamics of cannabinoid receptor signaling is key to 
understanding the functional properties of cannabinoids. It is worthy to note that in 
recent years, many studies have demonstrated that cannabinoid receptors adopt 
multiple conformations and affinity states (Pertwee et al., 2010), which lead to a number 
of entirely different signaling cascades.  Each of these different conformations is subject 
to stabilization by a number of cannabinoids, leading to a situation where the 
transduction of a particular signal pathway is contingent upon the individual type of 
ligand bound.  In this situation, the signal transduction pathway elicited defines the 
agonistic/antagonistic properties of the ligand, as the same cannabinoid can act as an 
agonist in one pathway, and an antagonist in an entirely different pathway (Kenakin, 
2007).  
Distribution 
The development of high-affinity synthetic cannabinoid agonists (as discussed 
earlier) has allowed researchers to map CB1 receptor distribution throughout the CNS  
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Figure 1.5. Schematic illustration of signal transduction mechanisms stimulated by CB1 
receptor in a presynaptic nerve terminal. [Taken with permission from (Yamamoto and 
Takada, 2000) 
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and periphery (Reggio, 2008).  Much of what is currently known about receptor 
localization has been determined through in situ hybridization, quantitative 
autoradiography, and immunohistochemistry. The in situ hybridization studies spawned 
from the first cloning of CB1 demonstrated that receptor expression in neurons was 
dichotomized; for example, in the forebrain, hippocampus, and striatum, a very small 
number of specialized neurons express CB1 receptors on a large scale, while most 
other neurons express CB1 on a much smaller scale (Mackie, 2005).  Autoradiographic 
studies performed by Herkenham and colleagues (Herkenham et al., 1991; Herkenham 
et al., 1990) demonstrated that the brain regions that expressed CB1 were those same 
regions expected to be influenced by the psychoactive effects of THC (such as the 
hippocampus), and that receptor expression was low in areas that were responsible for 
effects that weren’t altered by cannabinoids (such as the medulla). These studies also 
provided researchers with an accurate quantitation of CB1 receptor expression levels, 
and interestingly, they determined that cannabinoid receptors are among the most 
abundant GPCRs in the body, and the most abundant GPCR in the brain.  The results 
of these receptor binding experiments in combination with in situ hybridization 
demonstrated that CB1 receptors are mostly localized to presynaptic axon terminals, 
and that very few are located on proximal axons, dendrites, or the cell body.  
Immnunohistochemistry experiments allow for very precise mapping of receptor 
expression, and demonstrate that CB1 receptors are densely expressed on CCK-
containing basket cells (a subset of GABAergic interneurons in the forebrain), and 
sparsely expressed on glutamatergic terminals (Bodor et al., 2005).  For a more detailed 
review of this subject, please refer to (Mackie, 2008). 
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CB1 receptors are expressed most densely in the CNS, and the receptor 
distribution pattern within the CNS correlates with the characteristic behavioral effects of 
CB1 agonists, such as their ability to produce anxiolysis, hypokinesia and catalepsy, and 
to induce various psychoactive effects (Abood, 2005; Grotenhermen, 2003).  CB1 
receptor expression was detected in the cortical regions besides the GABAergic 
interneurons of the hippocampus (neocortex, amygdale),  some subcortical regions 
(hypothalamus, basal ganglia, thalamus) , the granular layer of cerebellum, brainstem, 
and interneurons of the dorsal horn (Pagotto et al., 2006).  Although sparse, CB1 
receptors were also found in a number of peripheral tissues. Among these organs and 
tissues are endocrine glands, leukocytes, spleen, heart, and parts of the urinary, 
reproductive and GI tracts (Pertwee, 1997).  A series of recent studies reported receptor 
expression on adipocytes, liver, pancreas, and skeletal muscle. It has been 
hypothesized that these play a role in metabolism, however results are inconclusive 
(Cavuoto et al., 2007; Cota, 2007; Osei-Hyiaman et al., 2005).  
Pharmacodynamic Properties of Cannabinoid Agonism 
The main action of cannabinoid receptor activation is to decrease the probability 
of depolarization and neurotransmitter release from the presynaptic terminus and 
decrease transmitter reaching the postsynaptic neuronal membrane. In non-human 
primates, cannabinoid agonism decreases locomotor activity, and impairs learning and 
memory recall by governing mechanisms of long-term and short-term depression. In 
rodents, CB1 agonism is known to produce a tetrad of characteristic pharmacological 
effects. These include hypothermia, sedation, catalepsy, and antinociception (Martin et 
al., 1991).   In humans, activation of CB1 receptors leads to a number of physiological 
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effects, most of which are psychoactive. A number of cannabinoid drugs were tested in 
humans for subjective perceptions of “highness”, as well as more objective measures 
such as tachycardia; and compatible doses of SR were able to block both responses 
(Razdan, 1986).  In addition, activation of CB1 receptors inhibits gastrointestinal 
mobility, contributes to hemorrhagic cardiovascular hypertension, and increases 
lipogenesis in the liver (Osei-Hyiaman et al., 2005; Varga et al., 1998). A more detailed 
description of the central and peripheral consequences of cannabinoid agonism can be 
found in Table 1.1.  
Within a system, different cannabinoids activate the CB1 receptor to a different 
degree, and consequently, the magnitude of the behavioral and physiological effects 
conferred upon on the system vary as well.  Cannabinoids that are full CB1 agonists, 
such as HU-210, CP55940, and AM-2201, which possess relatively low Ki values for the 
CB1 receptor (0.06 nM, 0.5 nM, and 1 nM respectively), favor an active receptor 
conformation. In contrast, partial cannabinoid agonists like THC (Ki = 5 nM) favor both 
active and inactive receptor states. As a result, generally speaking, a dose of the full 
CB1 agonist will elicit more intense cannabimimetic responses than the same dose of 
partial agonist. For a list of relative cannabinoid Ki values for CB1, please refer to 
(Pertwee et al., 2010). There are exceptions to this rule however; occasionally, the 
difference between the efficacy of a full and partial agonist lies in the relationship 
between the percent of cannabinoid receptors occupied and the responses evoked.  
Consider the scenario where the same dose of HU-210 and THC was administered to a 
system: If CB1 receptors within that system are few, then the effects of THC would 
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expectedly be much less than that of HU-210. However, if the system or tissue densely 
expressed CB1 receptors, (like in the case of the hippocampus), the biological effects  
Table 1.1. Physiological effects of cannabinoids. These dose-dependent effects have 
been observed in clinical studies, in vivo, or in vitro. [Taken from (Grotenhermen, 2003) 
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would not be limited by the number of bound CB1 receptors, and thus maximal 
responses to CB1 receptor agonism by these two drugs could be exactly the same.  
 Thus, the effects of partial cannabinoid agonists like THC and 2-AG depend on the 
properties of each particular signaling system (e.g. the amount of proteins available in a 
signaling cascade). For a review of these topics, please refer to (Mackie, 2008; Pertwee 
et al., 2010; Turu and Hunyady, 2010).  
The Neurobiology of Cognition 
One of the central questions in the cannabinoid neurobiology field is how the 
cannabinoid system contributes to cognitive development and function under normal 
conditions, and how this architecture disintegrates in cannabinoid abuse. It is becoming 
increasingly clear that subjective clinical studies are no longer sufficient; the need to 
understand the physiological basis of cognition as it relates to cannabinoid signaling is 
urgent.  
Dendritic Spines  
The brain as a whole is a very complex structural and functional network that is 
dramatically modified by our sensory experiences during early postnatal life.  How do 
we process sensory information that eventually results in the formation of a memory? 
The bases of these modifications are various forms of synaptic plasticity that contribute 
to learning and memory acquisition (Clem et al., 2008).  The dendritic spine is a 
structure specialized for synaptic transmission, and the locus of long-term synaptic 
plasticity associated with the storage of information in the brain. These door knob-like 
protrusions are often thought of as a stable structural extension of the synapse.  These 
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entities process and retain sensory information by mechanistically undergoing long term 
and short term morphological changes. Receptor and protein turnover is rapid within the 
spine, which allows neurons to keep up with the fast flow of information through the 
brain on a minute-to-minute basis (Segal, 2005). Once information is processed through 
the neuron, spines are either formed de novo, or from an existing dendritic shaft. In the 
case of de novo synthesis, filipodia shoot out of the dendrite in search of a presynaptic 
axon complement, makes contact, and pulls it in close to the dendritic synapse, from 
which it later forms a spine. This mechanism is proposed to occur mostly during early 
postnatal development, as few filipodia are found in studies that examine mature 
neurons (Woolley and McEwen, 1993). Conversely, with the help of adhesion 
molecules, and proteins located in the postsynaptic density (PSD-95), existing dendritic 
shafts protrude out to nearby presynaptic terminals, and then collapse to become a 
short mature spine that is typically 1-2 µm long (Dailey and Smith, 1996; Harris and 
Kater, 1994). Rapid local spine morphing is essential to learning and memory formation, 
as it is proposed to be involved in the diffusion of molecules through the plasma 
membrane into the spine. In addition, a recent study showed that this mechanism aids 
in the rapid delivery of AMPA receptors into the postsynaptic density, a process that is 
accelerated during memory acquisition (Richards et al., 2004). Spine pruning, an active, 
ongoing process which requires the acute activation of NMDA receptors, occurs 
simultaneously with spine formation. When neurons are activated with extracellular 
glutamate, spines disappear rapidly, and reappear just as quickly in the same location 
when the stimulus is removed (Hasbani et al., 2001).  
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How Does the Brain Learn and Memorize Information? 
The interaction between dendritic spine densities and the ability to form new 
memories from sensory experiences has been a hot topic for decades. In the past, it 
has been proposed that dendritic spine densities and learning/memory formation are 
positively correlated, that is to say, that memory formation was thought to always result 
in an increase in dendritic spine densities (Airey et al., 2000; Moser, 1999). This theory 
presents a conundrum, however. If memory formation results in a higher spine density, 
then this suggests that when new memories are formed, they will either reside on 
independent spines of the same neuron, or on a totally different neuron altogether. If 
this is so, then our memory storage capacity would be limited to how many spines could 
fit on a neuron, or how many neurons could reside in our brain. This would also suggest 
that the number of neurons within the brain (around one billion) increases significantly 
with time, and that all synaptic connections are of the same strength, but research has 
repeatedly demonstrated that this is not true (Jones, 1994). Furthermore, what would be 
the purpose of simultaneous synaptic pruning during learning? This scenario is highly 
unlikely, as it is counterintuitive to the brain’s tendency to conserve energy and 
resources (e.g. sensory habituation, optical illusions). A more reasonable theory for the 
physiological basis of learning is that early on during the first years of development, 
neurons undergo synaptogenesis, a massive spontaneous overproduction of synapses 
between neurons. A main reason for this is because early postnatal sensory systems 
are not yet cross-modally differentiated (Kozorovitskiy et al., 2012).  In other words, as 
the efficiency of neural activity and amount of sensorimotor experience increases, some 
synaptic connections selectively strengthen and stabilize, while other, less used 
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connections are subsequently eliminated. This process known as selective stabilization 
(Figure 1.6) is the basis of much of the learning and memory acquisition that occurs 
within the brain (Allport, 1985; Changeux et al., 1973; Landmesser, 1998; Xu et al., 
2009). The most direct links between memory and spine densities have been shown in 
songbirds. For example, Wallhausser-Franke and colleagues report that in a CNS 
region essential for vocal learning, social, song-tutored zebra finches have dendritic 
spine densities 41% lower than that of learning-deprived animals (Wallhausser-Franke 
et al., 1995). For more examples of this well-documented phenomenon in songbirds, 
please refer to chapter 1.  
Long-Term Potentiation 
One of the main neuronal processes that is correlated with spine maintenance, 
and thought to underline learning and memory, is the modulation of synaptic 
transmission either in an upward or a downward direction. The synaptic plasticity and 
memory hypothesis states that “activity-dependent synaptic plasticity is induced at 
appropriate synapses during memory formation, and is both necessary and sufficient for 
the information storage underlying the type of memory mediated by the region in which 
plasticity is observed” (Martin et al., 2000).  Long-term potentiation (LTP) is a long-
lasting increase in the synaptic strength of an excitatory afferent following high-
frequency stimulation. This phenomenon can be induced either by strong stimulation of 
one solitary pathway to a synapse, or through the weaker, simultaneous stimulation of 
many pathways that converge upon a synapse (McNaughton, 2003).  The end result of 
this process is the enhancement of signal transmission between two neurons; synapses 
that have undergone LTP have much stronger chemical/electrical responses to stimuli  
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Figure 1.6. Stabilization of dendritic spines. (a) Synaptic activity, including adhesive 
contact between pre- and postsynaptic compartments and trophic signaling between the 
two compartments, enhances dendritic spine stability. (b) Synaptic support maintains 
the integrity of dendritic architecture over time. The loss of this support results in 
destabilization of dendritic spines followed by dendritic simplification.  
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than those that have not undergone LTP (Welberg, 2008). In general, most regions 
display Hebbian LTP (under the Hebb’s rule that “cells that fire together, wire together”, 
LTP ensues when both the presynaptic and postsynaptic membrane are depolarized at 
the same time, (Wigstrom and Gustafsson, 1986)) and is therefore the focus here. One 
of the main mediators of LTP is Ca2+, which is required in order for potentiation to occur 
(Kapur et al., 1998).  Most forms of LTP are glutamatergic, and involve the activation of 
the NMDA receptor.  Recent studies have shown that the NMDA receptor is involved in 
mediating LTP at synapses, however continued activation acts to suppress synaptic 
strengthening after prolonged stimulation, in a process called LTP occlusion (a 
physiological method in which the brain stabilizes memory encoding (Martin et al., 
2000). Additionally, these same studies demonstrated that the mGluR is also involved in 
LTP, as it can counteract the synaptic occlusion mediated by the NMDA receptor, and 
maintain synaptic plasticity (Clem et al., 2008). This mechanism underlies learning-
related neuroplasticity  in compulsive drug seeking and addiction (Bellone and Mameli, 
2012).  
Long-Term Depression 
If dendritic spine formation and maintenance can be correlated with LTP, then 
dendritic spine retraction is, perhaps, correlated with Long-term depression (LTD) 
and/or depotentiation (DP). LTD is a lasting decrease in synaptic strength resulting from 
prolonged, low frequency neurotransmission, and DP is an activity-dependent reversal 
(depression) of a long-term potentiated synapse. Like LTP, LTD is induced by an 
increase in the concentration of Ca2+ within the postsynaptic dendritic spine, but the 
sources of Ca2+ are very different. In LTP, Ca2+ influx is NMDA/mGluR receptor-
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dependent, whereas LTD requires mGluR activation paired with influx through L-type 
voltage-gated Ca2+ channels. Other differences lie in the synaptic environments: LTP is 
due to an increase in either transmitter release or to an increased postsynaptic 
response to glutamate, whereas LTD usually results from a long-lasting decrease in 
presynaptic neurotransmitter release, coupled with a decrease in postsynaptic receptor 
densities (Bolshakov and Siegelbaum, 1994). It is thought that LTD functionally 
dampens LTP in an effort to make constructive use of the enhancement of signal 
transmission resulting from LTP. This mechanism is necessary in order to prevent 
synapses from reaching a plateau in efficiency, which would retard sensory encoding of 
information (Purves, 2011). LTD can also be classified in regards to Hebb’s rule: 
Homeosynaptic LTD is restricted to individual synapses, and is activity dependent 
(requires simultaneous presynaptic and postsynaptic activation). However 
heterosynaptic LTD, in contrast, occurs at a synapse that is not potentiated; 
postsynaptic activity is driven by other afferents that converge upon the dendritic spine 
(Massey and Bashir, 2007).  
The cannabinoid system is heavily involved in both short and long-term synaptic 
plasticity, especially in LTD in many memory-related CNS regions, such as the 
amygdala, hippocampus, striatum, neocortex, and cerebellum (Izumi and Zorumski, 
2012; Massey and Bashir, 2007).  Most agree that the endocannabinoids AEA and 2-
AG act as retrograde messengers through activation of CB1 receptors, and modify 
neural circuits through two main mechanisms: 1) by long-term regulation of GABA 
release, and 2) Depolarization-induced suppression of excitation (DSE)/(inhibition, DSI). 
By regulating presynaptic GABA release, endocannabinoids profoundly impact circuit 
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processing by indirectly decreasing the inducibility of LTP (Azad et al., 2004; Carlson et 
al., 2002).  DSI and DSE are transient forms of neurotransmitter-mediated synaptic 
depression in which cannabinoid signaling causes a temporary reduction in inhibitory or 
excitatory input into the postsynaptic cell (Diana and Marty, 2004). Because the 
cannabinoid system is so widely distributed throughout the brain, this is the most 
common method by which LTD is induced (Diana and Marty, 2004). 
In general, learning and memory processing by LTP and LTD is network-specific. 
What gets encoded, and the way it gets encoded is heavily dependent on the 
region/type of network where the plasticity takes place, not just the mechanisms that 
happen at the synapse. For example, hippocampus and cortically-encoded memories 
are vastly different from those processed in the amygdala (Martin et al., 2000). 
Immediate Early Genes and Memory Acquisition 
Neurons can also display adaptability in response to sensorimotor perception of 
the external environment by coupling extracellular cues with changes in transcription 
and translation. Behavioral changes that lead to altered synaptic activity or changes in 
neurotransmitter levels can lead to rapid activation of immediate-early gene (IEG) 
expression despite not having any proteins yet translated. Neuronal IEGs function at the 
synapse to encode cytoskeletal proteins, transcription factors, proteins, and metabolic 
enzymes involved in signal transduction cascades (Lanahan and Worley, 1998). Most 
typically, they function as part of a network of constitutively expressed proteins, and 
their regulation provides a means of controlling neuronal function. IEGs such as Arc and 
Egr-1 are highly correlated with sensory-evoked neuronal activity, facilitate the 
maintenance of LTP and LTD (Guzowski et al., 2000) and are required for both 
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encoding and consolidation of sensory memories (Okuno, 2011). IEGs are activity 
regulated, and thus mark very recent changes in neuronal activity (Bramham et al., 
2010). 
The Endocannabinoid System in Developing Individuals: How is This System Influenced 
by Cannabinoid Abuse? 
Postnatal Development of the Endocannabinoid System 
The endocannabinoid system plays a number of vital roles in developing 
individuals, a number of which have been discussed above (see Endocannabinoids 
section). It is because of this that concern continually grows about adverse 
psychological and neurophysiological effects produced by these agents, which are 
significantly more pronounced among those who use cannabinoids at an early age, 
mainly during mid-adolescence  (Arseneault et al., 2004; Fernandez-Ruiz et al., 1999; 
Hall, 2006; Verdurand et al., 2011). Unfortunately, limited information is available 
regarding mechanisms underlying the role of the endocannabinoid system in late-
postnatal development. Several autoradiographic studies have examined the density of 
cannabinoid receptor binding sites in telencephalic regions from early postnatal 
development through adulthood, and show that CB1 receptors are steadily increased 
during a critical time window: the transition from early to late-postnatal development. 
Rodriguez and colleagues found a region-specific increase in CB1 receptor binding in 
rats, which rose starting from PND 10, and plateaued around an average PND of 35. 
This was followed by a decrease during the transition into adulthood (Rodriguez de 
Fonseca et al., 1993).  This pattern is very interesting, namely because it is the opposite 
of what is seen with patterns of most other neuroreceptor systems, which have usually 
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already tapered off during this time period (Verdurand et al., 2011). In humans, 
researchers demonstrated an increase in CB1 receptor density between childhood 
(average of 4 years of age) and adulthood (average of 37.5 years old) in the 
hippocampus, frontal cortex, and cerebellum (Mato et al., 2003).  Interestingly, studies 
have shown that mRNA expression can be detected within the CNS as early as PND 3, 
however these levels remain roughly the same throughout adulthood. One rationale for 
this discrepancy is that the transcriptional information for the CB1 receptor is 
consistently present at high levels within the cell, but the message remains mostly 
untranslated into receptor protein. The increase in CB1 receptor binding in 
autoradiographic studies might reflect the number of CB1 receptors that are functionally 
mature at that time in life (Schneider, 2008). In addition to the restricted increase in CB1 
receptors during postnatal development, research has shown that levels of AEA 
increase correlatively during this period (Wenger et al., 2002).  
Persistent Behavioral and Neurphysiological Effects Following Adolescent Cannabinoid 
Exposure  
The cannabinoid system is most active during the onset of late postnatal 
development, which makes adolescents particularly vulnerable to the negative 
neurophysiological effects of cannabinoids. Chronic treatment of animals with WIN 
leads to persistent alterations in adult learned behavior that differ significantly with 
comparable treatments with vehicle (Schneider and Koch, 2003; Soderstrom and 
Johnson, 2003). In humans, cannabinoid consumption produces lasting morphological 
changes in teenagers that are absent after identical exposures of adults (Ehrenreich et 
al., 1999). As cannabinoid signaling is involved in altering neural circuit modulation and 
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maturation, it can be expected that these changes will manifest in behavioral alterations. 
Behavioral abnormalities following cannabinoid exposure during adolescence, but not in 
adults, are known for several vertebrate species.  Deficits in learning (Cha et al., 2007) 
memory (Moore et al., 2010; Rubino et al., 2009b), and cognitive function, including 
increases in anxiety and depressive phenotypes (Rubino et al., 2009a), with correlates 
to results of human studies, have been documented (Dekker et al., 2010; Hanson et al., 
2010; Kristensen and Cadenhead, 2007; Solowij and Michie, 2007) (Realini et al., 2011) 
For a review, please see (Soderstrom and Gilbert, 2012).   
Songbird Models Provide Powerful Models for Studying Cannabinoid-Altered CNS 
Learning and Development 
Cannabinoid-altered cognition studies in humans are useful in rectrospectively 
underscoring the consequences of adolescent cannabis use on adult CNS function, and 
how this issue relates to human health and performance, but several limitations 
unfortunately exist.  Firstly, many studies fail to provide information about the manner in 
which cannabinoids were consumed early on, like whether this usage was persistent or 
occasional.  Furthermore, the type of cannabinoid used, abstinence patterns, and the 
route of administration vary widely in human studies. Lastly, the diminished ability to 
obtain anatomical/morphological information about the brains of human cannabinoid 
users in real time is a hindrance. Keeping in mind the limitations of each individual 
experimental system, animal models may offer many advantages, namely 
experimentation within a controlled environment.  
Songbirds present a useful model to study how abused substances influence 
CNS physiology and cognition, as well as natural behavioral and neuromolecular 
51 
 
mechanisms that underlie developmental learning, processing, and memorizing vocal 
communication systems. Vocal learning is an extremely rare ability: songbirds are one 
of the  few species of animals (besides bats, cetaceans, and humans)  who have 
evolved a natural capacity to acquire a concatenate system for communication, and 
offer a unique advantage over other learning models that often involve some type of 
reinforcement conditioning (Fee and Scharff, 2010). Songbird expert Richard Mooney 
points out that “one of the greatest similarities between human speech and birdsong is 
that both processes are under executive control of the telencephalon, as opposed to the 
brainstem-mediated control of vocalizations seen in most other vertebrates, including 
non-human primates” (Mooney, 2009a).  Similar to humans, the act of songbird auditory 
learning is a complex behavior that is essential for accomplishing such tasks as 
memorizing the correct song of an adult tutor during sensorimotor learning, mate 
recognition, and distinguishing between conspecific vocalizations and those of 
heterospecific threats. This includes the ability to detect and localize vocal signals, 
discrimination between target signal and noise, categorize and represent distinct 
functional units of vocal communication, such as calls, motifs and songs, as well as 
individual vocal recognition (for a review, see (Knudsen and Gentner, 2010)). Thus, the 
songbird model enables the characterization of specialized brain areas responsible for 
learning and memorizing information, explore relationships between neural circuitry and 
the production/function of sequential behaviors, identify genetic and protein targets that 
underlie learned communication such as FoxP2,egr-1, Arc, etc. (Fee and Scharff, 2010; 
Soderstrom and Luo, 2010).   
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The Zebra Finch 
Song Learning 
Young male zebra finches learn to sing (females do not sing) during a sensitive 
period that is critical for vocal learning (Figure 1.7). Experts usually divide this critical 
period into two distinct phases: sensory learning, and sensorimotor learning. Both of 
these periods depend heavily on auditory sensory experience. The sensory learning 
period generally takes place during the first couple of months of life, ranging from day 
20 to around day 65, significantly overlapping with sensorimotor learning (Mooney, 
1999). During sensory learning, young animals listen to one or more songs of their 
father, or another conspecific adult, which is referred to as tutor song. Soon after, these 
birds begin to memorize the spectral and temporal qualities of the tutor song template. 
Interestingly, zebra finches that have been experimentally deafened, or raised in 
auditory isolation sing much simpler (isolate) songs as adults than those that were 
tutored (Marler and Tamura, 1964). The termination of sensory learning is dependent 
upon both the age of the bird and the amount of tutor song exposure. Nottebohm and 
colleagues determined that zebra finches raised in auditory isolation until adulthood 
(>100 days) are able to learn a new tutor song, in spite of already having memorized an 
isolate song (Marler and Tamura, 1964). 
Before discussing the dynamics of zebra finch sensorimotor learning, it may prove 
helpful to evaluate a couple of key points regarding what is necessary of these young 
zebra finches in order to produce a high-fidelity copy of his father’s song: 
1. The ability to control the vocal/respiratory organs with great precision 
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Figure 1.7 Birdsongs consist of ordered, often highly stereotyped strings of sounds 
separated by brief silent intervals. Sound energy is plotted as a function of 
frequencyand time. Syllables are indicated by letters, and form a repeated ‘motif’. a, 
Adult zebra finch song. b, Song of a zebra finch, tutored by the bird in a, at an early 
stage of sensorimotor learning. c, Song of the same bird close to song ‘crystallization’. 
Note the similarities between this bird’s song and that of its tutor. d, Song of a zebra 
finch raised in acoustic isolation. Note the overall simplicity of this song, but its general 
similarity of structure to other zebra finch songs. [Taken with permission from Brainard 
and Doupe, 2002] 
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2. The ability to compare their vocalizations to that of the tutor song memory, using 
auditory feed-back in order to detect vocal errors 
3. When these mistakes are detected, the ability to (accurately) correct them by 
modifying produced song (adapted from (Mooney, 2009b)) 
During sensorimotor learning, young birds gradually match their own song to the 
memorized tutor song. This phase of learning is comprised of several stages. Subsong, 
which is the equivalency of babbling in babies, bears very little resemblance to that of 
the tutor song. As young zebra finches grow older, they begin to produce notes and 
syllables that are recognizable from the tutor’s song, but greatly vary in structure and 
syntax from one song to the next. This is referred to as plastic song. After many weeks 
of singing practice, the bird’s song undergoes crystallization changes that render songs 
that are extremely high in fidelity (but not always a 100 % copy, as birds are prone to 
making mistakes just like everything else in nature). Thus, the song produced during 
this period contains notes and sequence structures that vary greatly in the beginning, 
but gradually crystallizes with the onset of adulthood.   Auditory feedback is essential for 
evaluating differences between its song and the template, as juvenile zebra finches 
deafened after song tutoring subsequently develop low-stereotypy (a high variability in 
syllable production and order) songs (Mooney, 2009b). Thus, sensorimotor learning 
exhibits a great deal of striking features, two of which are sensory encoding of the tutor 
song, and a cooperation of sensory and motor learning guided by auditory feedback 
(Mooney, 2009b).  
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Functional Anatomy of Song Learning 
In zebra finches, song acquisition involves a group of interconnected brain 
regions that are specialized for learning and producing song called the song system 
(Figure 1.8). The song system is divided into two separate pathways, one that is 
required throughout a zebra finch’s life for producing normal song (song motor 
pathway), and one that resembles the mammalian basal ganglia pathways that is 
involved in juvenile song learning (anterior forebrain pathway) (Nottebohm et al., 1990; 
Nottebohm et al., 1982). The song motor pathway spans from the telencephalon to the 
brainstem vocal respiratory organs. HVC and the robust nucleus of the archistriatum 
(RA) are the main nuclei that comprise this pathway. HVC, the apex of the song motor 
pathway, projects to RA, and is where auditory information merges with song-motor 
representations in the brain. Additionally, HVC is important in generating time signals for 
song (Mooney, 2009b). Recurrent pathways from the brainstem to HVC also contribute 
to song patterning (Ashmore et al., 2005). RA directly innervates the brainstem 
vocal/respiratory system, thus neurons in this area generate signals that drives related 
neurons (e.g. X II ts motor neurons) during singing. In contrast to the slow-firing neurons 
that project from HVC to RA, neurons within RA fire up to 10 times per song motif. 
Experts hypothesize that the RA transforms the timing signals generated from HVC into 
a more specific signal that parallels more with the acoustic features of the bird’s song 
(Leonardo and Fee, 2005). The AFP, on the other hand, bisects the telencephalon and 
striatum, and is comprised of two regions: lateral magnocellular nucleus of the anterior 
neostriatum (lMAN) and Area X. lMAN, which projects to Area X, is responsible for 
integrating different sensory modalities that strengthen song learning; specifically, lMAN  
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Figure 1.8. Auditory and vocal pathways of the songbird brain within the context of the 
new consensus view of avian brain organization.  Only the most prominent and/or most 
studied connections are indicated. a ) The auditory pathway. Most of the hindbrain 
connectivity is extrapolated from non-songbird species. For clarity, reciprocal 
connections in the pallial auditory areas are not indicated. b ) The vocal pathways. 
Black arrows show connections of the posterior vocal pathway (or vocal motor 
pathway), white arrows indicate the anterior vocal pathway (or pallial–basal ganglia–
thalamic–pallial loop) and dashed lines show connections between the two pathways. 
[Taken with permission from Jarvis et al., 2005].  
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aids in producing auditory-dependent song plasticity during vocal learning, and has 
been implicated in the socialization aspects of song learning. lMAN lesions during 
sensorimotor development result in perpetual state of plastic song, whereas adult lMAN 
lesions do not affect song integrity after crystallization (Bottjer et al., 1984a). A few 
researchers suggest that lMAN projects to RA in order to provide instructive signals to 
the brain, based on the bird’s evaluation of its vocalizations during song learning 
(Mooney, 2009b). Area X is the mammalian basal ganglia analog within the songbird 
telencephalon, and has been shown to be necessary for proper song learning, however 
many other aspects of its function remain unclear at present. Fee and colleagues 
hypothesize that during learning, medium spiny neurons within Area X receive a global, 
extremely fast afferent signal that conveys the quality of ongoing song, and then this 
region computes and generates, based on singing performance, a premotor signal that 
is transmitted through an AFP accessory region, to produce premotor bias in lMAN. 
They also hypothesis that since mammalian dopaminergic neurons are responsible for 
encoding discrepancies between anticipated and actual outcomes, and then sending 
signals to the basal ganglia that influence plasticity, these neurons may play a vital role 
in Area X function as well (Fee and Goldberg, 2011). 
Neural Representations of Song Memories 
In addition to the song system, other accessory auditory regions are important for 
vocal learning, and memorization of song template. Auditory feedback is relayed to HVC 
from a thalamic Nucleus Ovoidalis (Ov), to Field L, a primary auditory region, to the 
caudal medial nidopallium (NCM), a site of experience-dependent plasticity which 
provides an indirect source of auditory input to the song system. NCM is believed to be 
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the site of song template storage, as conspecific, novel  song can induce IEG 
expression that negatively  correlates with how well the bird recognizes the song (Mello 
et al., 1992). 
Preliminary Observations 
In a physiological profile similar to humans, in the past our lab confirmed the 
expression of CB1 receptors within analogous areas of the zebra finch telencephalon. 
This study used male birds reared in naturally-tutored environments; we observed low 
density CB1 receptor staining within the four song system regions, accessory auditory 
regions, subcortical regions and cerebellum during the first 25 days of life, which 
represents the time at which sensory learning ensues (Figure 1.9). This pattern of 
receptor expression persists within these regions, but gradually increases in density, 
and peaks at the onset of sensorimotor learning (from 46 days to 78 days old). As 
animals reach adulthood and songs crystallize, receptor densities wane significantly. 
These experiments provided us with crucial information to develop the following 
hypotheses: 1) The receptor distribution and expression patterns observed throughout 
vocal development indicate that cannabinoid signaling likely plays a role in sensory 
perception and learning-related synaptic plasticity, 2) this system is the most active 
during late postnatal development, and 3) the administration of exogenous cannabinoid 
agonists during this vulnerable time in development will most likely lead to persistent 
learning-related disruptions in behavior (Soderstrom and Tian, 2006). 
Following these experiments, we tested the third hypothesis, and demonstrated 
that this phenomenon indeed does occur.  Using sibling pairs of young male zebra 
finches tutored by the same adult male as each other’s control,  
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Figure 1.9. Images (12.5X) of immunohistochemical staining of zebra finch brain with 
anti-zebra finch CB1 receptor antibody. Sections shown were reacted together. A–D: 
Parasaggital sections representplanes about 2.5 mm lateral from the midline. Rostral is 
to the left. [Taken with permission from Soderstrom and Tian, 2006].  
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Figure 1.10. Representative adult song patterns produced by a sibling pair. (a) Vehicle-
treated animal B379 and (b) WIN55212-2-treated animal B379. Shown are sonograms 
produced at 110 days of age. Introductory notes are indicated by ‘i’. Song notes are 
indicated alphabetically according to order of production by the control animal. A unique 
note type (with similarities to notes ‘h’ and ‘f’) produced by the WIN55212-2-treated 
animal is indicated by ‘*’. Evident are fewer note types and decreased stereotypy in the 
song pattern produced by the WIN55212-2-treated sibling.  
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administeration once daily doses of WIN (1mg/kg) to young zebra finches during 
sensorimotor development persistently altered the quality of learned song produced in 
adulthood, specifically via a reduction in the number and order of learned notes 
produced). Similar to what is seen in humans and rats, and correlating with the 
previously observed patterns of receptor expression during this time, treatment of adult 
males that were administered identical treatments of WIN after song learning occurred 
were rendered ineffective at producing learning-related behavioral effects (Soderstrom 
2003).  
The Purpose of this Study 
As this literature review has shown, adolescent cannabinoid abuse is a great health 
concern, as regular consumption could potentially hinder the cognitive and physiological 
development of the brain in manners that persist throughout life. There is a desperate 
need to understand the molecular mechanisms underlying cannabinoid-interference 
with the neural growth and rewiring that occurs exclusively during late postnatal 
development, and how these drugs alter signaling pathways involved in normal 
processes of learning and memory. The goals of this study are threefold:  
 To identify distinct and persistent physiological changes associated with 
inappropriate CB1 receptor activation during periadolescent development 
 To begin to identify structural proteins and cell signaling involved in these specific 
changes 
These goals were met by pursuing the following specific questions: 
1. To what extent does cannabinoid signaling control dendritic spine morphology? 
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2. Is there a correlation between the behavioral/morphological effects of 
cannabinoid receptor activation and changes in levels of proteins related to cell 
signaling and morphology? 
3. Can we provide a physiological mechanism by which cannabinoid administration 
disrupts mechanisms directly related to synaptic plasticity, thus potentially 
contributing to the altered song learning effect seen? 
These questions were answered in the experiments described below
CHAPTER 2: LATE-POSTNATAL CANNABINOID EXPOSURE PERSISTENTLY 
ELEVATES DENDRITIC SPINE DENSITIES IN AREA X AND HVC SONG REGIONS 
OF ZEBRA FINCH TELENCEPHALON   
ABSTRACT: 
Centrally acting cannabinoids are well known for their ability to impair functions 
associated with both learning and memory but appreciation of the physiological 
mechanisms underlying these actions, particularly those that persist through life, 
remains incomplete.  Our earlier studies have shown that song stereotypy is persistently 
reduced in male zebra finches that have been developmentally exposed to 
cannabinoids.   In the present work, we examined the extent to which changes in 
neuronal morphology (dendritic spine densities and soma size) within brain regions 
associated with zebra finch vocal learning are affected by late-postnatal cannabinoid 
agonist exposure.   We found that daily treatment with the cannabinoid agonist 
WIN55212-2 (WIN, 1 mg/kg IM) is associated with 27 % and 31 % elevations in 
dendritic spine densities in the song regions Area X and HVC, respectively.  We also 
found an overall increase in cell diameter within HVC. Changes in dendritic spine 
densities were only produced following developmental exposure; treatments given to 
adults that had completed vocal learning were not effective.  These findings have 
important implications for understanding how repeated cannabinoid exposure can 
produce significant, lasting alteration of brain morphology, which may contribute to 
altered development and behavior. 
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INTRODUCTION 
We and others have used zebra finches as an animal model to study 
neurophysiological processes underlying vocal development because like humans 
zebra finches undergo vocal learning; the ability to modify vocalizations as a result of 
experience (Doupe and Kuhl, 1999).   This sensorimotor song learning occurs from 
about 35-75 days of age, a period of late-postnatal development that approximates 
adolescence.   Zebra finch songs are relatively simple and highly stereotyped once 
crystallized, rendering them easy to analyze and compare across developmental 
manipulations. 
We have previously found that when young zebra finches are exposed to modest 
dosages of the cannabinoid agonist WIN55212-2 (WIN) during sensorimotor learning, 
stereotypy of adult song is significantly reduced (Soderstrom and Johnson, 2003; 
Soderstrom and Tian, 2004).  Interestingly, this altered song persists through adulthood, 
and is not produced following cannabinoid treatment of adults that have already learned 
song.  Currently we are working to identify neurophysiological changes produced by 
early cannabinoid exposure that are responsible for persistently altered vocal behavior.   
Developmental periods for learning are often marked by gradual refinements of neural 
features that reflect both activity-and experience-driven synaptic changes.  Earlier 
studies indicate that songbird vocal learning involves distinct changes in neuronal cell 
morphology in a number of brain regions; for example, developmental decreases in 
lMAN dendritic spine densities have been shown to occur between post-hatch day 35 
and post-hatch day 65 in male zebra finches raised in normal environments (Changeux, 
1997; Changeux and Dehaene, 1989).   Furthermore, Rausch and Scheich report that in 
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young mynah birds trained to imitate human speech, vocal learning is accompanied by 
significant reductions in spine densities, enlargement of remaining spine heads, 
lengthened dendrites, as well as gradual increases in perikaryon diameter in HVC 
(Rausch and Scheich, 1982).  Proper vocal learning and processing of sensory 
information depends upon developmental changes within a number of brain regions 
(Airey et al., 2000; Devoogd et al., 1985; Lauay et al., 2005), including telencephalic 
regions lMAN, Area X, HVC and RA that distinctly and densely express CB1 
cannabinoid receptors (Soderstrom and Tian, 2006).  Thus, we hypothesized that 
cannabinoid-altered vocal learning may involve effects on spine densities and neuron 
size within these song learning and control regions.   This hypothesis was tested 
through the experiments described below. 
MATERIALS AND METHODS 
Materials 
Except where noted, all materials and reagents were purchased from Sigma (St. 
Louis, MO), or Fisher Scientific (Pittsburgh, PA).  The synthetic cannabinoid agonist 
WIN55212-2 (WIN) used for injections was suspended in vehicle from concentrated 
DMSO stocks (10 mM). Vehicle consisted of a suspension of 1:1:18 DMSO:Alkamuls 
EL-620 (Rhodia, Cranberry, NJ):saline.  
Animals 
The subjects used in these experiments were male zebra finches that were 
raised in our breeding aviaries. Birds were caged with free access to grit, water, mixed 
seeds (Sunseed VitaFinch), and cuttlebone, and provided multiple perches.  Animals 
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were maintained in visual isolation on a 14:10 light/dark cycle, and ambient temperature 
was maintained at 78° F.  Birds were housed from 25-50 days of age with an adult male 
tutor.  Birds were cared for and experiments conducted according to protocols approved 
by East Carolina University's Animal Care and Use Committee.  
Treatments 
Once daily 50 µl injections of vehicle or 1 mg/kg WIN were administered into the 
pectoralis muscle in the morning, 30 minutes before lights on for 25 consecutive days, 
starting at 50 days of age, and ending at 75 days.  It has previously been shown that 
these cannabinoid treatments given during the zebra finch sensorimotor period from 50-
75 days permanently alter vocal development (Soderstrom and Johnson, 2003).  
Following the completion of treatments, animals were allowed to mature to at least 110 
days of age in visual isolation.  After maturation, animals were killed by Equithesin 
overdose, and brains prepared for Golgi-Cox impregnation as described below.  After 
analyzing results of this developmental experiment and determination of a significant 
treatment effect, a second, independent experiment was done using adult animals in 
order to assess the developmental dependence of treatment effects.  This adult 
experiment was done employing the same regimen of 25 daily treatments given to adult 
animals (>110 days of age) that had already learned song.   
Golgi-Cox Treatments 
A mixture containing 5 volumes of 5 % potassium dichromate solution, 5 volumes 
of 5 % mercuric chloride, and 4 volumes of 5 % potassium chromate solution was 
prepared and allowed to ripen in the dark five days before use.  Following Equithesin 
overdose, birds were transcardially perfused with phosphate-buffered saline (PBS, pH = 
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7.4), brains removed and rinsed briefly with ice-cold distilled water, and immersed in a 
filtered (0.45 micron) aliquot of Golgi-Cox supernatant for 14 days in the dark at room 
temperature.  The brains were then transferred to an ice-cold 30 % sucrose solution for 
five days. Following sucrose treatment, brains were blocked down the midline, and left 
hemispheres were sectioned parasagittally on a vibrating microtome. 200 micron 
sections of zebra finch brain were then gold-toned in order to preserve staining as 
follows.  The sections were exposed to chilled solutions of 80, 60, 40, and 20 % 
glycerol, rinsed with water, then transferred to a 0.05 % ice-cold gold chloride solution 
for 80 minutes.  After being briefly transferred to an ice-cold 0.2 % oxalic acid solution 
for two minutes, sections were immersed in 1 % sodium thiosulfate for a total of 60 
minutes.  The sections were reduced in a 7 % ammonium hydroxide solution at room 
temperature, in the dark for thirty minutes, followed by further processing in Kodak 
Fixer.  Sections were then mounted and dehydrated on glass slides, and neurons within 
song regions assessed for dendritic spine densities and average cell diameters as a 
function of treatment. Tissue was stained and processed in multiple batches; however, 
in order to eliminate possible variance associated with reaction conditions, each of the 
treatment groups were represented in each batch. 
Light Microscopy 
Staining was examined in lMAN, HVC, RA, and Area X at 1000 X with an 
Olympus BX51 microscope. Images were captured with a Spot Insight QE digital 
camera and Image-Pro Plus software (Media Cybernetics, Silver Spring MD).  Using 
Image-Pro Plus software, ten grayscale images of individual neurons were captured 
within each brain region of interest per subject (n = 8 per treatment group).  All spines 
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associated with all visible primary and secondary dendrites emanating from each 
imaged neuron were counted.  Neurons suitable for counting were not obtained within 
Area X of two animals, reducing the total neurons counted from a planned 1280 to 
1260.  Average cell diameters and dendritic spine densities of selected neurons were 
determined as described below.   
Measurement of Dendritic Spine Densities 
Dendritic spine densities, presented as the average number of spines per length 
(µm) of each dendrite, were analyzed based on criteria adapted from Norrholm, et al 
(Norrholm and Ouimet, 2001).  Spines along the entire length the primary and 
secondary dendrites of 10 neurons per each of the 4 representative brain regions of 
animals treated with both WIN and vehicle (n = 8 for each age group) were counted 
from captured images. Measurements included all spines observable in each image.  
Neurons were that were selected for measurement were fully impregnated, intact, 
located in areas of tissue free of debris and other imperfections, and possessed 
dendritic processes greater than 20 microns in length.  Note that spines within the z-axis 
were not visible, and therefore were not counted.  Thus, our spine density measures are 
qualitative and not quantitative and therefore only useful for relative comparisons. 
 Measurement of Cell Body Major Diameters. 
The same neurons that were employed for analysis of spine densities were also 
used to obtain measurements of mean cell body diameter (10 measurements per each 
of the 4 song regions, for both WIN-and vehicle-treated groups). Given that some 
neurons tend to be amorphous in shape, mean cell diameter measurements composed 
of a measured average of both the widest vertical length, and the greatest horizontal 
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width of each soma.  These measures were calculated from the same calibrated, grey-
scale images used for counting dendritic spines using Image-Pro Plus analysis 
software.    
 Statistical Analyses. 
Data analyses were performed using SigmaStat, GraphPad Prism, and Microsoft 
Excel PC software.  Relationships between mean cell diameters, dendritic spine 
densities and drug treatments were determined through two-way ANOVA with treatment 
(1 mg/kg WIN vs. vehicle) and brain region (lMAN, HVC, RA, Area X) as factors.  Only 
results relevant to the hypotheses tested (that treatment would affect spine densities 
and cell diameters) were considered, and all statistics presented refer to effects of 
treatment only.  Following ANOVA determination that dendritic spine densities and cell 
diameters significantly differed across treatments (p ≤ 0.05), Student-Newman-Keuls 
post-tests were performed.  
RESULTS 
 Dendritic Spine Densities. 
Two-way ANOVA revealed that developmental treatment with the cannabinoid 
agonist WIN resulted in a significant difference in mean dendritic spine densities 
compared to controls  (F(1,632) = 19.52; p ≤ 0.01) Student-Newman-Keuls post-tests 
revealed that spine densities were significantly higher within Area X (from vehicle 
control mean = 0.61 ± 0.04 to 0.77 ± 0.05 spines/micron in WIN-treated animals, q = 
4.10, p ≤ 0.01) and HVC (from vehicle control mean = 0.36 ± 0.03 to 0.46 ± 0.04 
spines/micron in WIN-treated animals, q = 2.75, p ≤ 0.05, see Figure 2.2 A and C).  
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Spine density differences were not found within the other two song regions examined 
(lMAN, RA, see Figure 2.2 A and D).  In adults, cannabinoid treatment did not result in a 
significant difference in dendritic spine densities (F(1,612) = 0.99; p ≤ 0.01). The adult 
dendritic spine densities are summarized in Figure 2.3.  
Cell Body Diameters 
We found that developmental treatment with WIN resulted in significantly larger 
average soma sizes as compared to control groups (F(1,632) = 13.70; p ≤ 0.01, see 
Figure 2.4 panel B); post-hoc analyses further revealed that differences lie within HVC 
(from vehicle control mean = 9.77 ± 0.50 to 11.80  ± 0.43 microns in WIN-treated 
animals, q = 3.58, p ≤ 0.01).  No differences were observed in other song regions 
examined (lMAN, RA, Area X, refer to Figure 2.4 panel A, C and D).  Interestingly, WIN 
treatment produced a decrease in mean adult cell diameters within HVC (from vehicle 
control mean = 12.64 ± 1.17 to 10.22 ± 0.40 microns in WIN-treated animals, q = 2.85, p 
≤ 0.05), but was ineffective in lMAN, Area X and RA.  The average cell diameters 
following treatment of adults are summarized in Figure 2.5. 
DISCUSSION 
Dendritic spines are thought to modulate synaptic signaling by regulating the 
volume and biochemical content of postsynaptic terminals (reviewed by (Koch and 
Zador, 1993).   Densities of dendritic spines generally decrease with age (reviewed by 
(Dickstein et al., 2007).   For example, in macaque monkeys, spine densities on 
neurons projecting from temporal to prefrontal cortex were 25 % greater in adolescents 
(10 – 12 year olds) than adult monkeys (24 – 25 year olds, (Duan et al., 2003).  This is 
in reasonable agreement with the magnitude of persistent cannabinoid-related spine 
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density elevations that we report here (27 % in Area X and 31 % in HVC).  Age-related 
decreases in spine density appear to be under cellular regulation, and therefore may be 
considered part of normal late-postnatal development(Lieshoff and Bischof, 2003).  This 
implies that the cannabinoid-related elevation of spine densities that we found within 
Area X and HVC of adult animals may involve a disregulation of normal development.  
This contention is further supported by the fact that cannabinoid treatments only 
maintained elevated dendritic spine densities following developmental exposure; 
treatments administered to adults were ineffective. 
The dynamics of dendritic spine formation and loss in vertebrate brain change 
over the course of development (Bhatt et al., 2009).  During normal development, 
growth factors (BDNF and NT4/5) stimulate proliferation of spiny dendrites (Wirth et al., 
2003).  A fraction of these spines are subject to elimination during late-postnatal CNS 
development, a process that is completed prior to adulthood.  Adulthood is associated 
with increased stability of dendritic spine number (Zuo et al., 2005).  The mechanisms 
for these dynamic, developmental activity-dependent changes are not completely 
understood, but increasing evidence points to effects of calcium and related kinase 
signaling cascades (reviewed by (Bloodgood and Sabatini, 2007).  The CB1 
cannabinoid receptor (that is likely responsible for the effects reported herein) is thought 
to be primarily coupled to Gi/o G-protein subtypes that inhibit adenylyl cyclase, reducing 
intracellular concentrations of cAMP, that, in turn reduces activity of cAMP-dependent 
protein kinase (PKA).  In neurons, PKA is known to activate ryanodine receptor 
channels that release calcium from intracellular stores (Zhuang et al., 2005).  Thus, the 
established intracellular signaling pathways associated with cannabinoid agonism are 
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well-positioned to disregulate the calcium-dependent signaling involved in spine 
regulation.  The emerging view is that a finite range of calcium concentrations promote 
spine maintenance; disregulation to levels outside this range, either greater or less than, 
results in resorption or pruning (Dur et al., 2011; Holthoff et al., 2002; Segal et al., 
2000).  Thus, it seems reasonable to suggest that activation of a potential postsynaptic 
population CB1 receptors, and resulting inhibition of calcium release from intracellular 
stores, may inappropriately maintain spines that would normally be pruned due to 
elevated intracellular calcium.  It may also be the case that a presynaptic population of 
CB1 receptors is responsible for the elevated spine densities observed, as cannabinoids 
are established to act presynaptically to inhibit transmitter release in many other 
systems (Elphick and Egertova, 2001b).  Reduced transmitter release may alter 
signaling patterns and potentially disrupt activity-dependent spine regulation. 
Because spine dynamics are tied to altered synaptic activity, including long-term 
potentiation (LTP) and depression (LTD, (Feldman, 2009), they are implicated in cellular 
mechanisms of learning and memory.  Thus, cannabinoid-altered vocal development 
may follow disregulation of memory retrieval of song templates, or impaired 
sensorimotor consolidation caused by inappropriately elevated dendritic spine densities. 
Selective maintenance of elevated spine densities within a subset of telencephalic song 
regions may provide insight into the mechanism of cannabinoid-altered vocal 
development.  Within rostral striatum, Area X is clearly critical for song learning (Bottjer 
et al., 1984b), but not necessary for production of adult song that has already been 
learned (Scotto-Lomassese et al., 2007; Sohrabji et al., 1990).  This implies that activity 
within Area X is necessary for forming the long-term memory or ‘template’ of the tutor’s 
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song that is accessed and practiced during sensorimotor development.  Because the 
treatments in our experiments were administered after tutoring was complete, it’s 
unlikely that altered template encoding was involved.  Thus, if disregulation of Area X 
development is involved in cannabinoid-altered vocal development, the mechanism is 
more likely related to real-time sensorimotor comparison of practiced song with the 
previously memorized template; a process involving both memory retrieval and sensory 
integration.  The importance of Area X in this process is suggested by a correlation of 
the amount of singing during sensorimotor learning with distinct expression of the vocal 
development-critical transcription factor, FoxP2 (Teramitsu et al., 2010).  HVC, on the 
other hand, is necessary both for learning and motor production of song and links the 
rostral vocal motor pathway to the anterior forebrain pathway that is critical for song 
learning (Margoliash, 1997).  Ablation studies involving HVC have demonstrated that 
this region is essential for production of a stereotyped song (Thompson and Johnson, 
2007) and HVC clearly contributes to both temporal and spatial aspects of song 
(Margoliash, 1997).  Thus, differences in neuronal activity associated with persistently 
increased dendritic spine densities within HVC suggest a mechanism by which 
developmental cannabinoid exposure alters vocal learning and decreases song 
stereotypy through adulthood.  
Each of the telencephalic regions that we have studied have been the subject of 
other spine density studies, although ours is the only one to include all four as part of a 
single study.  For example, in eastern marsh wrens, spine densities within HVC, but not 
RA, are directly related to the complexity of song repertoires learned.  Lower HVC spine 
densities are associated with smaller repertoires (Airey et al., 2000).  Thus, the elevated 
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spine densities that we have measured following cannabinoid treatment are consistent 
with the learning of high-complexity songs, which seems to contrast with the 
characteristic reduction in the number of notes learned by cannabinoid-treated zebra 
finches (Soderstrom and Johnson, 2003).  This apparent conflict may indicate that there 
is a “correct” density of spines that should be maintained to properly learn a particular 
vocal pattern.  Inappropriate densities, either greater or less than those necessary for 
learning a particular song, may result in impairment.   
Other regions, including lMAN, have received attention in the context of sex 
differences, as lMAN is a song region readily detectable in females.  Normal 
development in males is associated with a decrease in dendritic spine densities within 
lMAN (Nixdorf-Bergweiler, 2001),  while males raised without exposure to a tutor during 
development maintain high spine densities (Wallhausser-Franke et al., 1995), 
suggesting that the process of learning a particular song is associated with decreased 
spine densities.  Because we did not detect a treatment effect within lMAN, this 
suggests that cannabinoid-altered song is mechanistically distinct from that following 
isolation. 
Vocal developmental-related changes in dendritic spine densities within Area X 
have been studied by others in the context of FoxP2-dependent reductions (Schulz et 
al., 2010).  This recent report demonstrates that shRNA-inhibition of FoxP2 expression 
in Area X is associated with a premature decrease of dendritic spine densities.  FoxP2 
is normally upregulated during periods of sensorimotor learning (e.g. 50 days, see 
(Haesler et al., 2004), a developmental period that is also associated with distinctly 
high-level CB1 receptor expression (Soderstrom and Tian, 2006).  We have found 
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previously that FoxP2 expression within zebra finch striatum is persistently increased, 
through adulthood, following the same cannabinoid treatment regimen used in our 
current report (Soderstrom and Luo, 2010).  Therefore it seems reasonable that 
cannabinoid-induced persistently-increased FoxP2 expression may play a role in the 
elevated dendritic spine densities within Area X reported herein.   
Another recent and particularly elegant 2-photon imaging study has measured 
the turnover rate of dendritic spines within HVC as a function of tutor song exposure 
(Roberts et al., 2010).  As discussed above, spine dynamics change during 
development, with maturation associated with reduced turnover (Zuo et al., 2005).  Thus 
it appears that tutor exposure, and the associated memorization of a song template, 
induces a stabilization of dendritic spine densities early in auditory vocal development.  
Assuming that Area X- and lMAN-like decreases in spine densities also occur within 
HVC following the sensorimotor stage of song learning through adulthood, a second 
pruning stage must follow spine stabilization associated with auditory learning.  If this is 
the case then (as indicated above for lMAN) cannabinoid-altered vocal development 
must be mechanistically distinct from effects produced by social isolation, as lack of a 
tutor decreases HVC spine densities measured in adults (by 24 %, (Lauay et al., 2005).  
Combined with our findings, this suggests that normal vocal development is associated 
with finite range of dendritic spine densities within HVC, as both increased and 
decreased densities are associated with altered song learning. 
Developmental changes in neuronal cell diameters have not received a great 
deal of experimental attention.  In hamsters and mice, telecncephalic neuron diameters 
increase from birth through approximately adolescence, after which a plateau is 
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reached that lasts through adulthood (Haddara, 1956; Ptacek and Fagan-Dubin, 1974).  
Thus, our finding of cannabinoid-related increased cell diameters within HVC may 
represent an extension of normal developmental increases and/or inhibition of initiating 
the plateau phase.  The HVC-selectivity of this effect suggests that it isn’t attributable to 
elevated spine densities, as these also occurred within Area X (e.g. compare Figure 2.2 
B and C with Figure 2.4 B and C).   Selective cannabinoid effects within song regions of 
caudal telencephalon (HVC and RA) and not rostral regions (lMAN and Area X) have 
been previously reported in the context of c-fos expression (Soderstrom and Tian, 
2008), and suggest distinct cell-signaling roles for the population of CB1 receptors 
present within each region.  Decreased mean HVC cell diameter was the only persistent 
effect that we observed following adult treatments and represents an interesting 
contrast to effects produced following developmental treatments.  We know that the 
developmental treatment regimen employed persistently reduces anti-CB1 receptor 
immunoreactivity within HVC, while the same treatment in adults increases it 
(see(Soderstrom et al., 2011)).  Therefore, the differential efficacy of developmental vs. 
adult treatments on HVC cell diameters may involve distinct receptor expression 
densities.    
In summary, repeated exposure to modest dosages of a cannabinoid agonist 
during periods of sensorimotor vocal development results in elevated dendritic spine 
densities within two song regions of zebra finch telencephalon:  Area X and HVC, brain 
regions important to vocal learning and production.  Additional effects to increase 
neuronal cell diameters within HVC were noted. These persistent physiological changes 
may contribute to the reduced stereotypy and note numbers produced by zebra finches 
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treated with cannabinoids during the sensorimotor stage of vocal development 
(Soderstrom and Johnson, 2003; Soderstrom and Tian, 2004).  Because these effects 
were only observed following treatment of animals in sensorimotor stages of 
development, our results contribute to accumulating evidence for distinct, late-postnatal 
cannabinoid sensitivity within the developing CNS that may alter developmental course.  
This underscores the problem of cannabis abuse among adolescents, and provides 
insight to mechanisms that may underlie associated persistent alterations of learning 
and other behaviors. 
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Figure 2.1. Representative image of Golgi-Cox impregnated spiny dendrites used for 
analysis within HVC of birds developmentally treated from 50 - 75 days of age with WIN 
(A), or vehicle (B).  Animals were allowed to mature to adulthood (> 110 days), and 
brains were dissected and stained with Golgi-Cox solution (see Methods).  Bar = 10 
microns. (C) Representative high power image of a typical HVC neuron used for 
analysis. Measurements pertaining to cell diameters and corresponding dendrites were 
made for 10 randomly selected neurons for each of the 4 representative song regions of 
both WIN and vehicle-treated animals. Bar = 30 microns. 
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Figure 2.2. Effect of developmental treatments from 50 – 75 days on song region spine 
densities at adulthood (n = 8).  Developmental WIN treatment resulted in significantly 
elevated dendritic spine densities within Area X and HVC but not lMAN or RA.  (p ≤ 
0.05).  
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Figure 2.3. Effect of treatments given to adults for 25 days on song region spine 
densities (n = 8).  WIN (1 mg/kg/day) did not result in a significant change in dendritic 
spine densities in the four song regions of adult males which had already learned song. 
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Figure 2.4. Effect of developmental treatments from 50 – 75 days on song region 
average cell diameter at adulthood (n = 8).  Developmental WIN treatment (1 
mg/kg/day) resulted in significantly increased average cell diameter within HVC, but not 
other regions (lMAN, Area X, HVC, p ≤ 0.05).  
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Figure 2.5. Effect of treatments given to adults for 25 days on song region average cell 
diameter at adulthood (n = 8).  Despite a trend for decreased cell diameter within HVC, 
significant differences were not found. 
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CHAPTER 3: CANNABINOID TREATMENT DURING ADOLESCENT DEVELOPMENT 
PERSISTENTLY ALTERS AXONAL PHOSPHORYLATED NF-200 AND DENDRITIC 
MAP2 EXPRESSION IN BRAIN REGIONS IMPORTANT FOR VOCAL LEARNING 
ABSTRACT: 
The contributions of cannabinoid signaling to learning and memory are 
multifarious, making it difficult to pinpoint underlying mechanisms responsible. 
Previously, we demonstrated that developmental cannabinoid administration impairs 
vocal learning and reduces the expression of neural correlates of long-term potentiation, 
memory formation and perception in the zebra finch song learning model. These 
alterations are associated with elevated dendritic spine densities that suggest lack of 
plastic changes associated with learning in a subset of brain regions important to vocal 
learning and control, and where the CB1 receptor is expressed in high density. In this 
study, gross morphological and densitometric changes in axonal marker Nf-200 and 
dendritic marker MAP2 were analyzed following developmental treatment with the CB1,2 
agonist WIN55,212-2 (WIN), with the hypothesis that developmental cannabinoid 
treatment is associated with an increased expression of both phosphorylated Nf-200 
and MAP2. Following WIN treatment, significantly elevated Nf-200 densities were 
observed within three of four song control regions (HVC, RA, Area X) as opposed to 
vehicle treatments, but not in the midbrain, indicating a persistent telencephalic 
misaccumulation of axonal protein within these areas. Developmental treatment with 
WIN led to robust increases in MAP2 expression and irregular morphology in Area X, 
HVC, RA, lMAN as well as midbrain region DLM, indicative of disregulated CNS 
development and altered dendritic function. Cannabinoid treatments administered to 
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adult control animals that previously learned song were ineffective. These results further 
support our previous data and hypothesis that cannabinoids persistently alter gross 
neuronal morphology, and contribute to altered vocal learning, memory and 
developmental effects seen. 
 INTRODUCTION 
The 2012 world drug report by the United Nations Office on Drugs and Crime 
states that cannabinoids, specifically marijuana, are the most widely used illicit drug in 
the world (Nations, 2012). Cannabinoid receptors are the most abundant G-protein 
coupled receptor in the brain, and consequences of their activation vary from 
pleasurable subjective effects such as increased sensations of tranquility, analgesia, 
euphoria, and anxiolysis along with altered memory formation, respiratory function, 
sensory perception, and coordinated movement (Ameri, 1999; Herkenham et al., 1990; 
Pini et al., 2012).  Moreover, the cognitive impairments produced by cannabinoids and 
other drugs (alcohol, cocaine) were reported to be additive (Schulze et al., 2012).  
Changes in behavior and function are often preceded by morphological change.  Given 
the ubiquity of these agents and receptors within the brain and other body systems, the 
overwhelming effects that cannabinoids have on cognition and behavior, and the wide 
usage amongst periadolescents and adults, more research is needed in order to better 
clarify the specifics of cannabinoid-altered physiology.   
Our previous work has demonstrated that when young male zebra finches are 
administered a once-daily dose of the cannabinoid agonist WIN 55,212-2 (WIN, 1.0 
mg/kg) during the developmental period in which they learn song, the stereotyped order 
in which these learned notes are produced during adulthood is persistently disrupted 
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(Soderstrom and Johnson, 2003; Soderstrom and Tian, 2004).  This altered pattern of 
song production is not seen in adults that had previously learned song. These 
observations are correlated with inappropriate maintenance of dendritic spine densities 
within song regions HVC and Area X, which normally occur during learning (Gilbert and 
Soderstrom, 2011).  These regions (including but not limited to lMAN, RA, Ov, and 
cerebellum) distinctly and robustly express CB1 receptors during sensorimotor learning 
(Soderstrom and Tian, 2006). However, the current understanding of the role(s) of 
cannabinoid signaling is limited:  clearly, a vast neurochemical system involving CB1 
receptor activity exists within the developing brain, but to what degree does this 
influence CNS neuronal morphology, and ultimately behavior?  Moreover, what are the 
physiological features and processes under the control of cannabinoid signaling during 
this period?  We argue that persistent deficits in song learning and production seen 
during cannabinoid-altered vocal development involves cannabinoid-altered disruption 
of protein expression vital for proper neuronal cytoarchitecture and function, specifically 
phosphorylated 200 kDa neurofilaments (Nf-200) and microtubule-associated protein 2 
(MAP2). This contention is consistent with our hypothesis that endogenous cannabinoid 
signaling is not only a part of, but is essential to normal CNS development and function. 
MATERIALS AND METHODS 
Materials 
Except where noted, all materials and reagents were purchased from Sigma (St. 
Louis, MO), or Fisher Scientific (Pittsburgh, PA).  Immunochemicals were purchased 
from Vector Laboratories (Burligame, CA). The primary anti-phosphorylated Nf-200 and 
MAP2 monoclonal antibodies were purchased from Sigma (St. Louis, MO).  Equithesin 
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was prepared from reagents (40% propylene glycol, 10% ETOH, 5% chloral hydrate, 
1% pentobarbital). The synthetic cannabinoid agonist WIN 55212-2 was suspended in 
vehicle from concentrated DMSO stocks (10 mM). Vehicle consisted of a suspension of 
1:1:18 DMSO:Alkamuls EL-620 (Rhodia, Cranberry, NJ):phosphate-buffered saline. 
Dose was corrected for the free base form of the drug 
Animals 
 Both juvenile and adult male zebra finches bred and raised in our aviary were used 
as subjects in these experiments. Young birds were tutored by an adult male. After 
tutoring, birds were removed to visual isolation to prevent possible cross tutoring.  From 
three days prior to the start of experiments until the end of experiments, birds were 
housed singly in visual isolation with free access to grit, water, mixed seeds (Sunseed 
Vita Finch), and cuttlebone, and provided multiple perches.  Animals were maintained 
on a 14:10 light/dark cycle, and ambient temperature was maintained at 78° F. All 
experiments were approved by the Institutional Animal Care and Use Committee of East 
Carolina University. 
Treatments 
Once daily drug treatments of either vehicle or WIN 55,212-2 were administered 
via 50µl IM injections into either the right or left pectoralis muscle for 25 consecutive 
days, 30 minutes before lights on, starting at 50 days of age, and ending at 75 days.  
Injection sites were alternated daily (eg. day 1 right muscle, day 2 left muscle) in an 
effort to minimize damage to the skin, protect the administration route, and minimize 
discomfort. This cannabinoid treatment given during the zebra finch sensorimotor period 
from 50 to 75 days will permanently alter song learning and vocal development (Gilbert 
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and Soderstrom, 2011, Soderstrom and Johnson, 2003). Following the completion of 
treatments, animals were allowed to mature to at least 110 days of age in visual 
isolation.  
Western Blotting 
The presence of phosphorylated Nf-200 and MAP2 protein was detected within 
the zebra finch brain by using mouse monoclonal antibodies targeting phosphorylated 
Nf-200 and MAP2, respectively. To assess the selectivity of these antibodies against 
zebra finch protein, western blotting experiments were performed. Protein extraction 
protocols were adapted from methods described by Schafer and colleagues, (1998). 
Adult male zebra finches, subjected to song stimulation procedures described above, 
were killed by Equithesin overdose.  Brains were removed, homogenized with a polytron 
in an ice-cold extraction buffer containing 1 M Tris-HCl, pH = 7.0, 0.6 M KCl, 0.5 mM 
ATP, 1 mM DTT, 0.5 mM MgCl2, along with a cocktail of protease inhibitors (0.25 M 
sucrose/1 mM EDTA/4 mM phenylmethylsulfonyl fluoride/1 mM 4-amino 
benzamidine/0.1 % w/v bacitracin), and briefly micro-centrifuged at 1000 x g. 
Supernates were stirred on ice for 30 min, collected and centrifuged at 24,000 x g. 
Following this, protein preps were ultra-centrifuged at 100,000 x g for 1 hour. Pellets 
were discarded and supernatants were filtered through cheesecloth to remove traces of 
excess lipid, and dialyzed against 10 L of ice-cold distilled water for 4 hours at 4º C. The 
fractions were then dialyzed overnight against two changes of ice-cold extraction buffer 
containing 10 mM Tris-HCl, pH 8.0, 0.2 mM CaCl2, 0.5 mM ATP, 0.1 mM DTT, 100 mM 
KCl, and 0.1 mM phenylmethylsulfonyl fluoride. Samples were spun a final time at 
24,000 x g at 4º C to remove trace precipitate.  Supernatants were collected and protein 
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concentrations determined using the Bradford method. 30 µg of soluble protein was 
loaded into a 10 % polyacrylamide gel, separated by SDS-PAGE, and blotted onto a 
PVDF membrane. Blots were blocked with a non-mammalian blocking reagent 
(Odyssey Blocking Buffer, LI-COR Biosciences, Lincoln, NE) and incubated overnight at 
4º C in a 1:1500 dilution of the phosphorylated Nf-200 or MAP2 antibodies in Odyssey 
Blocking Buffer. The next day, the blots were washed three times with 1X PBS-T 
(Phosphate-Buffered Saline [pH = 7.4] with 0.05 % Tween-20), and incubated in 
secondary antibody solutions containing an infrared anti-mouse secondary antibody at 
1:25,000 ( IR Dye 800CW Goat α mouse IgG (H + L), LI-COR Biosciences # 926-
32210)) and 0.02 % SDS for 2 hours at room temperature in the dark. The blots were 
washed 4 times with 1X PBS (Phosphate-Buffered Saline [pH = 7.4]) for 10 minutes 
each, and visualized using the LI-COR Odyssey Infrared Imaging System. Masses of 
infrared bands were determined via standard curves fit to distances migrated by 
molecular weight standards using GraphPad Prism 5.0 software (GraphPad Software, 
San Diego, CA, USA).  
Immunohistochemistry 
The immunohistochemical methods used in this study were adapted from 
Soderstrom and colleagues (2006). After the birds reached either maturation of at least 
110 days, or the end of experiments, animals were killed by Equithesin overdose (50 
µl), PBS transcardially perfused, followed by phosphate-buffered 4% paraformaldehyde 
[pH = 7.0]. Brains were immersed in 4% paraformaldehyde overnight, and then 
transferred to an ice-cold 20% sucrose solution the next morning, in preparation for 
histological analyses. Once tissues sank in the sucrose solution, brains were blocked 
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down the midline and sectioned parasagittaly, using a vibrating microtome (Leica VT 
1000s, Leica Microsystems Inc., Buffalo Grove IL. Tissue was briefly rinsed in 1X PBS 
for 10 minutes followed by incubation in 1% H2O2 for 30 minutes, in an effort to quench 
endogenous peroxidase activity. The sections were again rinsed 3 times with 1X PBS, 
and then blocked with 5% normal goat serum for 35 minutes. Following blocking, 
sections were incubated overnight at room temperature in a solution containing primary 
antibody (1:5000 dilution), 1% normal goat serum, 0.01% sodium azide, and 0.3% 
Triton-X 100 in PBS. The following day, tissues were rinsed three times in PBS and 
incubated in a biotinylated anti-mouse antiserum for 60 minutes followed by a 
preassembled avidin-biotin complex solution (VECTASTAIN ABC Elite kit, Vector 
Laboratories Inc., Burlingame, CA).  Specific antibody labeling was revealed using a 3, 
3-diaminobenzidine (DAB) solution in the presence of hydrogen peroxide. DAB solution 
was inactivated by three washes in 1X PBS. Tissue sections were mounted on glass 
slides coated with 0.3 % gelatin.  After sections on slides were allowed to dry overnight, 
sections were dehydrated with graded concentrations of ethanol (70 %, 95 %, and 100 
% respectively), cleared with xylenes, and coverslipped with Permount (Fisher). 
Optical Density Measurements 
Immunohistochemical staining was examined in various brain regions at 40, 100, 
and 1000 X using an Olympus BX51 microscope with Nomarski DIC optics. For 
measurements, images were captured at 100 X using a Spot Insight QE digital camera 
and Image-Pro Plus 5.0 software (MediaCybernetics, Silver Spring, MD) under identical, 
calibrated exposure conditions. All images were background-corrected, and converted 
to 8-bit grey scale; borders that outlined brain regions of interest were traced manually. 
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Two dimensional optical density measurements of both labeled processes from areas 
enclosed within traced areas were performed on images without knowledge of treatment 
condition for each brain region of interest. With the exception of cerebellum, (Figures 
4.4, 4.8, 4.12, and 4.16) all intact sections containing brain regions of interest were 
included for analysis, and analyzed using Image-Pro Plus 5.0 software. Mean optical 
densities (within brain region counts of stained nuclei and neuropil/area of the region) 
were compared across each treatment group using two-way ANOVA as described 
below.  
Statistical Methods 
All data are expressed as means ± SEM. Statistically significant differences 
between groups were assessed by the Student’s t-test; relationships between optical 
densities and drug treatments were assessed through two-way ANOVA with brain 
region (HVC, RA, lMAN, Area X, DLM, Ov) and treatment (vehicle vs. 1 mg/kg WIN) as 
factors. Statistical significance was defined as a two-tailed probability of less than 0.05. 
Results pertaining to the hypothesis tested (that drug treatment would alter 
phosphorylated Nf-200 and/or MAP2 protein expression) were presented in our analysis 
of data. After a significant treatment effect was determined by two-way ANOVA, 
Student-Newman-Keuls post-hoc tests were performed. All statistical analyses were 
performed using GraphPad Prism 5.0, SigmaStat, and Microsoft Excel PC software.  
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RESULTS 
Western Blotting 
Western blotting was performed in an effort to assess the selectivity of the 
antibodies against the two neurocytoskeletal proteins assessed in 
immunohistochemistry experiments. SDS-PAGE separation of 30 µg of brain 
cytoskeletal fractions revealed the presence of a single predominant band of 
approximately 200 kDa labeled by the anti-phosphorylated Nf-200 antibody; SDS-PAGE 
separation of 30 µg of brain cytoskeletal fractions revealed the presence of two 
predominant protein bands likely representing the high-molecular weight isoforms of 
MAP2 (MAP2a and MAP2b, at approximately 230 kDa), and the lower molecular weight 
isoforms of MAP2 (MAP2c and MAP2d, at approximately 70 kDa), labeled by the anti-
MAP2 antibody used. The sizes of these selectively labeled proteins was consistent 
with that reported from other mammalian species, including mouse, rat, horse and 
human (Alexanian et al., 2008; Lin et al., 2010; Russo et al., 2012; Saraceno et al., 
2012). 
Phosphorylated Nf-200 Optical Densities 
In this study, two-way ANOVA revealed that developmental treatment with the 
cannabinoid agonist WIN during sensorimotor learning resulted in a significant increase 
in phosphorylated NF-200 protein expression as compared to vehicle-treated groups 
(F(1,393) = 31.070, p < 0.001). Further Student Newman-Keuls post-hoc analyses 
revealed that these differences lie within the caudal regions HVC (from vehicle control 
mean = 0.0569 ± .004 to 0.099  ± 0.010 in WIN-treated subjects, q = 4.343, p = 0.002, 
Figure 3.1I), RA (from vehicle control mean 0.062  ± 0.010 to 0.107  ± 0.010 in animals 
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treated with WIN, q = 4.602, p = 0.001, Figure 3.1J), rostral region Area X (from vehicle-
treated control mean 0.083  ± 0.010 to 0.132  ± 0.014, WIN-treated mean, q = 4.945, p 
< 0.001) and midbrain thalamic regions Ov (from vehicle-treated control mean 0.089 ± 
0.010 to 0.113 ± 0.012 WIN-treated mean, q = 4.836, p < 0.001) and DLM (from vehicle-
treated control mean 0.103 ± 0.009 to 0.130 ± 0.013, WIN-treated mean, q = 4.906, p < 
0.001).  
Distinct, dense staining patterns of phosphorylated Nf-200 were observed within 
HVC, as opposed to surrounding tissue (see Figure 3.1A-B) of adult groups treated with 
vehicle during development. At 1000X, the presence of long, thin neuronal processes 
was detected with the phosphorylated Nf-200 antibody used. We observed very little 
pericellular phosphorylated Nf-200 staining, therefore separate protein strands 
measuring approximately 0.5 – 1 µm in diameter were easier to detect (Figure 3.1C). In 
WIN-treated HVC, Nf-200 protein appeared to be increasingly denser, and more darkly 
stained. Within these treated regions, it was difficult to distinguish distinct cell bodies 
from masses of neuropil (Figure 3.1B, D).   
 In caudal region RA, however, morphological differences in phosphorylated Nf-
200 staining between both developmentally treated groups were grossly apparent.  
Thick axonal projections emanating from HVC appear to terminate in different 
subregions within RA (data not shown). Positive phosporylated Nf-200 staining was 
noted within the entire arcopallium, however staining was generally heavier, and more 
distinct within RA (see Figure 3.1E-F, 4.5E-F). Light perisomal phosphorylated Nf-200 
expression was evident within vehicle-treated RA regions (see Figure 3.1E, G and 
Figure 3.5E, G), however in animals treated developmentally with WIN, Nf-200 appears 
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thick and grossly accumulated within the soma.  Within RA, axons emanating from the 
cell body appear to contain large amounts of phosphorylated Nf-200 at the point at 
which projections radiate, indicative of an unfavorable state of massive protein 
misaccumulation within the cell. For an illustration, please refer to Figure 3.1F, H.  
In lMAN, phosphorylated Nf-200 staining was apparent, but not restricted to the 
boundaries of this region. Staining was diffuse throughout axons and around somata, 
giving the region an overall “scratched” appearance. WIN exposure during development 
resulted in a noticeable, but not statistically significant increase in phosphorylated Nf-
200 protein within lMAN (Figure 3.2B, D) as opposed to vehicle treatments (Figure 3.2A, 
C). Rostral-ventral regions including Area X and surrounding striatum were positive for 
phosphorylated Nf-200 staining. At 1000X under vehicle control conditions, 
phosphorylated Nf-200 morphology appears to parallel that of HVC; distinctly long, thin 
processes, light perisomatic expression, and very little neuropil staining were frequently 
noted (see Figure 3.2E, G).  However, as summarized in Figure 3.2F, and 2H, 
developmental WIN treatment was associated with significantly increased 
phosphorylated Nf-200 within the neuropil, and thicker, more fragmented axons.  
General staining patterns of midbrain regions Ov and DLM are similar to HVC in 
that phosphorylated Nf-200 expression is distinctly expressed within these regions as 
opposed to a more general staining. Within Ov, under vehicle control conditions, 
neuropil staining is hardly discernible above background, and long, thinner axonal 
process emanating from round, moderately-sized neurofilament-lined cell bodies are 
clearly seen (Figure 3.3A, dashed box, Figure 3.3C).  Administration of WIN across 
development results in increased protein expression throughout Ov neuropil and 
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processes. Many thicker, irregularly-stained fibers surround unstained somata, giving 
the axons within the matrix a matted, tangled appearance (Figure 3.3B, dashed box, 
Figure 3.3D).  Additionally, we found that neuronal morphology within DLM is very 
similar to Ov under vehicle control conditions, in that phosphorylated Nf-200 is densely 
labeled within axons and around somata; however the axon projections themselves are 
sparse (Figure 3.3A, solid box, Figure 3.3E).   
Because of the robust pattern of heavy anti-CB1 immunoreactivity identified 
within the cerebellum of zebra finches and other vertebrate species (Egertova and 
Elphick, 2000; Herkenham et al., 1991; Pettit et al., 1998), we hypothesized that CB1 
agonism may presynaptically disregulate axonal morphology within this area as well. 
However, due to an insufficient number of tissue sections available to quantify from a 
number of treatment groups, this data was not included in our statistical analysis.  
Nevertheless, similar to what is described within other regions, phosphorylated Nf-200 
expression appeared to be elevated in animals developmentally treated with 
cannabinoids. Specifically, three layers of cerebellum (molecular, Purkinje, and granular 
layers) were stained positively with anti-phosphorylated Nf-200 antibody under vehicle-
treated conditions (Figure 3.4A, C), but phosphorylated Nf-200 expression appears to 
vary considerably within terminals in the dense granular layer, and within the axons 
emanating from Purkinje cells after developmental WIN treatment (Figure 3.4B). Upon 
closer inspection (at 1000X), phosphorylated Nf-200 expression also appears thicker, 
darker, and more irregular around Purkinje cell bodies (Figure 3.4D). This was 
previously reported for Nf-200 staining within cerebellums of periadolescent rats 
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chronically-treated with WIN, and is in harmony with patterns reported for CB1 receptor 
staining in zebra finch cerebellum (Soderstrom and Tian, 2006; Tagliaferro et al., 2006). 
 There were no interactions to report between phosphorylated Nf-200 staining in 
the brain regions evaluated and drug treatments administered. The results of this 
experiment are summarized in Figures 3.1-2, I-J, and Figure 3.3G-H. After analyzing 
results of the developmental experiment, and determination of significant treatment 
effects, a second, independent experiment was performed using adult animals in order 
to assess the developmental dependence of treatment effects.  The results of this 
experiment are found in Figures 3.5-6, I-J, and Figure 3.7G-H. Accordingly, daily 
cannabinoid treatment did not produce significant differences in adult phosphorylated 
Nf-200 staining (F(1,384) = 0.049, p = 0.825) within any of the analyzed telencephalic 
areas or midbrain regions DLM and Ov.  At high power, the morphology of these 
regions (regardless of treatment regimen) is extremely similar to adults that received 
vehicle treatments during development, further validating earlier observations made in 
our lab (Gilbert and Soderstrom, 2011; Soderstrom and Tian, 2008).  For illustrations 
and data, please refer to Figures 3.5-7. 
MAP2 Optical Densities 
Comparison of vehicle-control groups and those treated with WIN during 
development revealed a significant increase in MAP2 immunoreactivity (F (1,384) = 
48.097, p < 0.001). These differences were found within all four of the telencephalic 
song regions (HVC, from 0.065 ± 0.0007 to 0.130 ± 0.010, RA, from 0.049 ± 0.010 to 
0.085 ± 0.010,  Area X, from 0.710 ± 0.007 to 0.104 ± 0.008, and lMAN, from 0.064 ± 
0.007 to 0.089 ± 0.010, results summarized in Figures 3.9-10). MAP2 staining within 
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DLM was decreased by WIN treatment (from vehicle-control mean 0.648 ± 0.009 to 
0.094 ± 0.010 in treated animals), but not within Ov.  A graphical representation of these 
data can be found in Figure 3.11. There were no interactions found between the 
variables tested; the intensity of staining observed within each brain region is contingent 
upon the treatment administered.  Differences in MAP2 immunoreactivity between those 
adults treated with vehicle for 25 days and those that were administered consecutive 
treatments of WIN daily for 25 days were not statistically significant (see Figures 3.13-
15).  
In general, we noted a great deal of similarity in MAP2 staining patterns between 
different telencephalic regions analyzed under vehicle-treated conditions, regardless of 
whether treatment occurred during development or as adults. Compared to surrounding 
areas, MAP2 immunoreactivity was present, but presented in a virtually negative 
staining pattern to that of phosphorylated Nf-200 (for an example, compare Figure 
3.11A, E to Figure 3.9A, E). Upon closer inspection, we noted that in these regions, no 
staining was observed within or around somata, however, MAP2 expression was 
prominent throughout dendritic processes, and occasionally detected within neuropil 
(Figure 3.9C). In some regions, namely Ov and HVC, small, stable bundles of MAP2 
protein were noticeable within dendrites. Staining patterns observed in control birds are 
region-specific, but much lighter in intensity compared to surrounding areas, whereas 
chronic developmental cannabinoid administration results in overall staining patterns 
that are heavier and more concentrated in dendritic processes located within distinct 
regions. This very pronounced morphological consequence of drug treatment was 
surprising. In HVC regions of developmentally WIN-treated adult brain tissue, MAP2 
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antibodies show intense labeling of thick dendritic processes, and the boundaries of 
neuronal cell bodies (Figure 3.9B, D). In contrast to most other regions observed, HVC 
MAP2 neuropil staining intensities do not seem to vary with developmental cannabinoid 
treatment. However, denser, more numerous MAP2 bundles are easily observed at 
1000X (Figure 3.9D).  Some of the most drastic changes in MAP2 morphology and 
expression with developmental drug treatment lie within caudal region RA. 
Developmental WIN administration significantly increases the presence of MAP2 protein 
within RA in addition to the surrounding arcopallium (Figures 3.9F, H).  It appears as 
though a change in the densities of dendrites per area is only partially responsible for 
the increase in MAP2 expression observed: neurites within WIN-treated RA are 
considerably thicker in diameter and appear more irregular than vehicle-treated 
controls.  
In lMAN, immunostaining for MAP2 was limited to the neuropil in both control and 
WIN-treated animals, so therefore it was not possible to render visual analyses of the 
staining within labeled processes within this region (see Figure 3.10A-D). Nevertheless, 
heavier MAP2 staining was present within the tissue matrices of those developmentally 
exposed to WIN.  The pattern of immunoreactivity within Area X closely mirrored that of 
lMAN in respect to neuropil staining, however this region displayed considerably more 
positive dendritic staining that varied with drug treatment.  
Again, the overall light diffuse MAP2 staining observed in both Ov and DLM 
under control conditions presented as negative images surrounded by more distinct 
immunoreactivity in surrounding areas (Figure 3.11A). This pattern was drastically 
altered within both Ov and DLM in WIN-treated groups (compare Figure 3.11A to Figure 
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3.11B).  In DLM, developmental cannabinoid treatment resulted in very intense MAP2 
labeling within neuropil and around neuronal cell bodies (Figure 3.11B, solid box, Figure 
3.11F). Within DLM, positive staining was limited to a very small number of dendrites 
within the matrix. Nonetheless, these processes were observed to be very thick, wavy, 
and irregular (Figure 3.11F). The method of image analysis employed in this study failed 
to detect any significant differences between MAP2 staining intensities in 
developmentally-treated vehicle control Ov and developmental WIN-treated Ov regions 
(see Figure 4.11C-D, G). These results are consistent with other studies performed, that 
demonstrated that although CB1 receptors are abundantly expressed in Ov, neither the 
presentation of novel song stimuli, nor acute cannabinoid treatment alters the 
expression of Arc, another dendritic and synaptically-associated protein that upon 
synaptic activation, interestingly triggers dendritic remodeling by interacting with MAP2 
(Chapter 5, (Fujimoto et al., 2004; Soderstrom and Tian, 2006). 
Likewise, MAP2 immunoreactivity within the cerebellum was restricted to light 
staining of dendritic processes and more pronounced staining of cell bodies within the 
granular layer. However, due to an insufficient number of tissue sections available to 
quantify from a number of treatment groups, data pertaining to the cerebellum was not 
included in our statistical analysis (For illustrations, see Figure 3.12).   
There were no interactions between MAP2 staining in the brain regions 
evaluated and drug treatments administered. The results of this experiment are 
summarized in Figures 3.9-10 I-J, and Figure 3.11G-H. After analyzing results of the 
developmental experiment, and determination of significant treatment effects, a second, 
independent experiment was performed using adult animals in order to assess the 
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developmental dependence of treatment effects.  The results of this experiment are 
found in Figures 3.13-14, I-J, and Figure 3.15G-H. Daily cannabinoid treatment did not 
produce significant differences in adult MAP2 staining (F (1,419) = 0.546, p = 0.580) 
within any of the analyzed telencephalic areas or midbrain regions DLM and Ov 
DISCUSSION 
The results of the experiments conducted in this study indicate that repeated 
developmental exposure to cannabinoids during critical periods for sensorimotor 
learning leads to persistent, abnormal gross morphological disruptions in the expression 
of axonal marker Nf-200, and dendritic marker MAP2. This study was conducted within 
songbird CNS regions previously shown to express CB1 cannabinoid receptors in high 
levels: HVC, RA, lMAN, AreaX, Ov, DLM, and cerebellum (Soderstrom and Tian, 2006). 
Increases in receptor activation significantly alter the morphological and likely functional 
dynamics of neurons located within these regions critical for zebra finch development of 
stereotyped song.  This work represents the first attempt to identify enduring 
neurocytoskeletal morphological correlates within zebra finch song regions of the brain 
that parallel developmental cannabinoid treatments known to cause persistent 
disruptions in adult singing behavior.  
The functional characteristics of dendrites and axons are conferred to them by 
their distinct morphological attributes: On average, dendritic processes are relatively 
short, have multiple degrees of arborization, and tend to taper off in diameter. The 
growth of both types of neurites involves rapid, highly coordinated cytoskeletal 
reorganization and membrane trafficking (Farah and Leclerc, 2008; Ye et al., 2007).  
Both microtubule-associated proteins and neurofilaments constitute major elements of 
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the neuronal cytoskeleton, and aberrant misaccumulations of these macromolecules 
within cells have long been speculated to be a major underlying contributor to 
neurodegenerative conditions.   
Neurofilament H, or Nf-200, named for its molecular weight of 200 kDa, is the 
largest subunit of the three polymers that compose the axon, and so is essential for 
maintaining correct axonal caliber. Recent advances made in understanding 
neurofilament molecular biology and transgenic mouse models have established a vital 
role for these proteins in myelinated motor and sensory axonal radial growth, thus 
regulating conduction velocity, axonal mobility, and interactions with other cytoskeletal 
elements (Q. Ashton Acton). The precise consequences of neurofilament 
misaccumulation within cortical areas are less clear, although traditionally, most critical 
functions of neurofilaments within the axon have been strongly correlated with the 
degree to which phosphorylation occurs.  Irregular accumulation of 
hyperphosphorylated neurofilament is often used as a biomarker of axonal injury, and 
an indicator for a slew of neurodegenerative diseases, including Alzheimer’s disease, 
Multiple Sclerosis, Parkinson’s disease and amyotrophic lateral sclerosis (Boylan et al., 
2009; Collard et al., 1995; Julien and Mushynski, 1998; Shaw et al., 2005). In these 
conditions, perikaryal phosphorylation of neurofilament leads to a state of somal 
misaccumulation without protein transfer to the axon. This scenario eventually leads to 
the formation of neurofibrillary tangles and inclusions that ultimately result in 
neurodegeneration and loss (Takahashi and Ishizuka, 2012).  
In a similar respect over the past half-century, new mechanisms underlying the 
involvement of microtubule-associated proteins in dendritic morphology have rapidly 
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accumulated. Microtubule-associated proteins were first characterized as rod-like anti-
parallel dimers that bind longitudinally along the length of microtubule protofilaments 
(Kim et al., 1979).  Isolation of MAP2 from brain tissue revealed that this protein 
stimulates the rate and extent to which microtubules assemble by reducing the 
dissociation rate for tubulin. Rapid regulation of MAP2 dynamics is essential for 
governing microtubule growth, signaling, and transport, molecular associations, as well 
as cell migration (Kapitein et al., 2010).   In a recent study involving non-neuronal cells, 
overexpression of MAP2 promotes microtubule formation and stabilization also 
(Weisshaar et al., 1992).  MAP2, one of the most abundant microtubule-associated 
proteins in dendrites, possesses a biological activity (binding capacity) heavily 
dependent upon the degree to which it is phosphorylated within the dendrite (Brugg and 
Matus, 1991; Lindwall and Cole, 1984; Sanchez et al., 2000). The levels of MAP2 
expression are correlated with the degree to which it stabilizes elements within the 
cytoskeleton, and altering expression patterns leads dendritic malformation on virtually 
every level, spanning from irregular neurite morphology and branching, to a lack of 
microtubule entry into dendritic spines (Chamak et al., 1987; Ruiz-Canada et al., 2004).  
Indeed, one could expect that if environmental conditions became favorable for such 
action, dendritic microtubules would likely extend uncontrollably, or erroneously lose 
characteristics of dynamic instability when neurons are continuously exposed to drugs 
that induce microtubule polymerization (such as cannabinoids). This is a phenomenon 
that is tightly regulated by the expression levels and conformation states of MAPs. 
Most neuronal cytoskeletal proteins are linked one another in some fashion: Nf-
200 binds to microtubules and MAP2 binds to  Nf-200 (Heerlein and Richter, 1991).  In 
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addition, MAP2 and Nf-200 are known to share common epitopes.Furthermore, these 
proteins are often found bound together in a conglomerated state in diseased states, in 
the form of neurofibrillary tangles and plaques, suggesting normal interactive roles for 
these proteins in neuritogenesis not previously identified (Galloway et al., 1990).  Given 
this information, it is possible that heavy exogenous cannabinoid consumption produces 
a similar pattern of pathology within the neuron: cannabinoid-induced protein 
overexpression or inappropriate lack of protein turnover likely results in an abnormal 
promotion of synaptic and dendritic maintenance. 
Cannabinoids are widely known to modulate various aspects of cognition, 
specifically the acquisition, processing, and maintenance of sensory information. Other 
laboratories have demonstrated that cannabinoid signaling plays a significant role in 
governing neuronal plasticity as well as generation, stabilization, and maintenance of 
synaptic connections (Katona and Freund, 2012; Kim et al., 2008; Oudin et al., 2011).  
Our hypothesis is that chronic cannabinoid agonism with WIN inappropriately alters the 
excitability of neurons affected within these songbird CNS regions, resulting in either a 
stagnation, or early termination of plastic changes in axonal and dendritic protein 
expression that should occur during developmental learning. We theorize that these 
actions likely occur through a number of mechanisms: First, cannabinoid inhibition of 
presynaptic N and P/Q-type calcium channels (the channels largely responsible for 
presynaptic calcium entry within this context), resulting in altered calcium flux in 
response to the action potential (Daniel et al., 2004; Diana et al., 2002). Indeed, 
exposure to either THC or WIN directly inhibits presynaptic calcium release, which 
prevents synaptic density loss in rat primary hippocampal neurons in a concentration-
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dependent manner (Kim et al., 2008). Second, CB1 receptor modulated direct activation 
of G-protein coupled inwardly-rectifying (GIRK) and ATP-sensitive K+ channels results 
in a rise in ion conductance, and a hyperpolarized presynaptic membrane that reduces 
neuronal firing rate and plastic changes (Lovinger, 2008; Turu and Hunyady, 2010). 
These data are in agreement with other noted observations, in which WIN exposure 
was observed to potently induce K+ currents in AtT20 cells stably transfected  with rat 
CB1 receptor (Mackie et al., 1995). And third, another potential mechanism whereby 
abnormal CNS cannabinoid receptor activation results in a change in neuronal 
excitability and leads to reduced plasticity is that CB1 receptor agonism alters the 
frequency of vesicular fusion with the presynaptic membrane.  Furthermore, 
cannabinoid signaling plays a role in depolarization-induced suppression of excitation 
(DSE), and depolarization-induced suppression of inhibition (DSI), two closely related 
forms of short-term synaptic plasticity that directly mediate the firing rate of presynaptic 
cells (Diana and Marty, 2004).  
Many important CNS developmental events (such as those governing neurite 
maintenance and axonal growth needed to innervate correct targets) heavily involve 
cannabinoid signaling (Anavi-Goffer and Mulder, 2009).  In mice, genetic deletion of the 
CB1 receptor is associated with a rapid accumulation of neurocytoskeletal defects, 
increased activation of caspase cell death pathways, and a significant loss of Nf-200 
within axons (Jackson et al., 2005).  The steady-state enzyme regulator of the 
endocannabinoid 2-AG (DAGL-α)-dependent endocannabinoid signaling through the 
CB1 receptor is essential and sufficient for developmental axonal growth, and functions 
by driving calcium influx into growth cones (Gao et al., 2010; Oudin et al., 2011). With a 
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developmental expression pattern almost paralleling that of MAP2, DAGL-α is 
expressed in very high levels early during neuronal differentiation and axonal 
development, but eventually diminishes within axons but not somatodendritically, as the 
system allows for a functional switch between a state of growth and guidance within 
axons to a state of retrograde synaptic signaling at functional synapses (Galloway et al., 
1990).  Likewise, cannabinoid activation aids in neuronal migration, and synapse 
generation (Galve-Roperh et al., 2006; Mulder et al., 2008). As a result of these 
aforementioned facts, we believe endogenous cannabinoid signaling is a part of,  and 
essential to normal CNS development and function.  Thus, one may presume that with 
periadolescent cannabinoid exposure as observed in our zebra finch developmental 
learning model, prolonged exogenous cannabinoid administration inapproriately 
perpetuates the activated period of the CB1 receptors within distinct CNS regions, and 
perhaps hijacks normal endocannabinoid signals to evoke molecular and protein 
rearrangements, ultimately leading to erroneous wiring of neuronal networks.  
Similar to humans, songbird adolescent development involves active synaptic 
remodeling and plasticity, and as such, this phase of growth is particularly vulnerable to 
the effects of exogenous pharmacological challenges. A substantial increase in both 
phosphorylated Nf-200 and MAP2 protein densities occurs with once daily 
periadolescent cannabinoid exposure (see Figures 3.1-4, 9-12). Within all song regions 
analyzed, excluding lMAN, developmental cannabinoid administration produced striking 
increases in the overall content of phosphorylated Nf-200 expression per neurite within 
both telencephalic and midbrain relay regions. Differences in MAP2 densities do not 
appear to occur within Ov as a function of developmental cannabinoid treatment 
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although this region expresses CB1 receptors in high levels. It is possible that Ov-
localized cannabinoid expression possesses a function unrelated to vocal learning and 
production, the specifics of which are not currently known at this time. Not only does this 
critical data indicate that cannabinoid sensitivity to changes in neuronal cytoarchitecture 
is restricted to higher-order information processing regions, but it strongly suggests that 
cannabinoid signaling is likely an important governor of specialized sensory/integrative 
systems in which neurons may employ as needed.  
Taken together, with the exception of Ov, developmental cannabinoid exposure 
leads to significantly increased MAP2 densities within all regions analyzed. This data is 
in harmony with previous developmental anatomical studies conducted within our 
laboratory that show similar trends, and is likely indicative of an unintended 
consequence of prolonged exogenous cannabinoid agonism: decreases in plasticity and 
the overall dynamic instability within neurites,  a process that is absolutely essential for 
synaptic reorganization during developmental learning (DeLuca, 2010; Gilbert and 
Soderstrom, 2011; Soderstrom and Johnson, 2003; Yenjerla et al., 2010).  
In contrast with patterns observed in adults treated with cannabinoid across 
development, we have repeatedly demonstrated that the same consecutive systemic 
treatments administered to adults in control studies are rendered ineffective in 
producing significant changes in phosphorylated Nf-200 or MAP2 expression. The 
reduced sensitivity to WIN treatments during adulthood is likely due to the fact that early 
in development, song stereotypy in non-seasonal songbirds requires a certain level of 
congruence between stored tutor song memories and its vocal production. This 
congruence is heavily dependent on constant auditory feedback, a process essential for 
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learning and maintenance of vocal behaviors (Brainard and Doupe, 2000; Tschida and 
Mooney, 2012). The inability of WIN to alter adult phosphorylated Nf-200 and MAP2 
protein densities within song regions is associated with a decrease in an adult 
songbird’s ability to alter previously learned song repertoires. Indeed, the absence of 
song crystallization does not allow for new song motif learning in adulthood (Funabiki 
and Funabiki, 2009; Zevin et al., 2004). The lack of morphological disruption in densities 
of phosphorylated Nf-200 and MAP2 protein within neuronal processes is perhaps due 
to a more complete maturation of synaptic connections in adulthood (Gilbert and 
Soderstrom, 2011; Soderstrom and Johnson, 2003).  
In summary, the results of this study are the first to provide direct evidence for a 
neurocytoskeletal system heavily influenced by developmental exposure to a 
cannabinoid agonist.  Novel strategies are needed to understand cannabinoid 
involvement in mechanisms governing neurite growth and maintenance, as we 
hypothesize that abnormal cannabinoid signaling inappropriately promotes region-
specific neurite survival at the great cost of a reduced strength and participation in the 
synaptic network.  
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Figure 3.1. Photomicrographs of Nf-200 staining within caudal song regions of adult 
male zebra finch telencephalon following postnatal developmental treatment with either 
vehicle (panels A, C, E, G) or WIN (1 mg/kg, panels B, D, F, H) using DAB 
immunohistochemistry.  Panel A with C inset depict normal distribution of Nf-200 protein 
within axons of HVC; protein has significantly accumulated within this region as a result 
of developmental cannabinoid administration (Panel B with D inset).  In RA, a similar 
developmental pattern of Nf-200 staining ensues as what is seen within HVC over the 
course of normal brain development (Panel E with G inset).  However, developmental 
administration of WIN results in a significant, persistent misaccumulation of protein 
within axons (Panel F with H inset).  I-J: Optical density measurements of Nf-200 
staining in both HVC (I) and RA (J) after vehicle and WIN administration, respectively.  
In both regions, protein increases by approximately twofold are observed following daily 
WIN treatment. 100X scale bar = 300 μm, 1000X scale bar = 30 μm.  
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Figure 3.2. DAB-immunohistochemical staining of Nf-200 protein within rostral song 
regions lMAN and Area X of adult male zebra finch telencephalon following 
developmental  vehicle treatment (panels A, C, E, G) or treatment with WIN (1 mg/kg, 
panels B, D, F, H).  Developmental WIN exposure results in a noticable, but not 
statistically significant increase in Nf-200 protein within lMAN (Panel B with D inset) as 
opposed to vehicle treatments (Panel A with C inset).  Significant differences between 
Nf-200 staining of vehicle-treated striatal Area X (Panel E with G inset) and 
cannabinoid-treated Area X (Panel F with H inset) were noted.  I-J: Optical density 
measurements of Nf-200 staining in both adult lMAN (I) and Area X (J) after 
developmental vehicle and WIN administration, respectively. 100X scale bar = 300 μm, 
1000X scale bar = 30 μm. 
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Figure 3.3.  Representative low and high-power micrographs of Nf-200 staining of adult 
male zebra finch midbrain thalamic regions Ov and DLM using DAB 
immunohistochemistry.  Animals were subjected to either developmental treatment with 
vehicle (Panel A, insets C, E) or WIN (1 mg/kg, Panel B, insets D, F) and brain tissue 
processed at adulthood. Axonal staining within Ov (Panel A-B, bottom left corner) and 
DLM (Panel A-B, top right corner) is clearly visible within these distinct areas. Daily 
administration of WIN during sensorymotor development (Panel B, insets D, F) results 
in a significant increase in Nf-200 staining and altered neuronal morphology within both 
Ov and DLM that persists well into adulthood.  G-H: Optical density measurements of 
Nf-200 staining within thalamic areas Ov and DLM. 100X scale bar = 300 μm, 1000X 
scale bar = 30 μm. 
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Figure 3.4.  Representative images of DAB-immunohistochemical staining of Nf-200 
protein within the cerebellum of adult male zebra finches developmentally treated with 
either vehicle (Panel A, inset C) or WIN (1 mg/kg, Panel B, inset D). The number of 
tissue sections available from each treatment group was not sufficient for statistical 
analysis, however distinct treatment differences can still be observed.  Nf-200 staining 
within both the molecular and Purkinje cell layer is uncharacteristically denser after 
developmental cannabinoid treatment (Panel B, inset D) as opposed to vehicle 
treatment (Panel A, inset C). 100X scale bar = 300 μm, 1000X scale bar = 30 μm. 
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Figure 3.5. Photomicrographs of Nf-200 staining within caudal song regions of adult 
male zebra finch telencephalon following 25 days of treatment with either vehicle 
(panels A, C, E, G) or WIN (1 mg/kg, panels B, D, F, H), using DAB 
immunohistochemistry.  No significant treatment differences were observed within HVC 
or RA of these adults which previously learned song.  100X scale bar = 300 μm, 1000X 
scale bar = 30 μm 
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Figure 3.6. DAB-immunohistochemical staining of Nf-200 protein within rostral song 
regions lMAN and Area X of adult male zebra finch telencephalon following 25 
consecutive days of vehicle treatment (panels A, C, E, G) or treatment with WIN (1 
mg/kg, panels B, D, F, H).  WIN treatment did not result in significant elevations in Nf-
200 within either region as compared to vehicle-treated counterparts.   I-J: Optical 
density measurements of Nf-200 staining in both adult lMAN (I) and Area X (J) after 
vehicle and WIN administration, respectively. 100X scale bar = 300 μm, 1000X scale 
bar = 30 μm. 
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Figure 3.7. Representative low and high-power micrographs of Nf-200 staining of adult 
male zebra finch midbrain thalamic regions Ov and DLM using DAB 
immunohistochemistry.  Animals were subjected to either 25 consecutive treatments 
with vehicle (Panel A, insets C, E) or WIN (1 mg/kg, Panel B, insets D, F) after song 
learning had occurred.  Axonal staining within Ov (Panel A-B, bottom left corner) and 
DLM (Panel A-B, top right corner) is clearly visible within these areas. Daily 
administration of WIN during sensorymotor development (Panel B, insets D, F) did not 
lead to a significant increase in Nf-200 staining within either Ov or DLM. G-H: Optical 
density measurements of Nf-200 staining within thalamic areas Ov and DLM. 100X 
scale bar = 300 μm, 1000X scale bar = 30 μm.  
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Figure 3.8. Representative images of DAB-immunohistochemical staining of Nf-200 
protein within the cerebellum of adult male zebra finches treated with either vehicle 
(Panel A, inset C) or WIN (1 mg/kg, Panel B, inset D) after song learning. The number 
of tissue sections available from each treatment group was not sufficient for statistical 
analysis. Upon observation, the Purkinje cell layer of adult animals treated with WIN 
possesses a more sparse density of Nf-200 than that of their vehicle-treated counter 
parts.  100X scale bar = 300 μm, 1000X scale bar = 30 μm. 
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Figure 3.9. Photomicrographs of dendritically associated MAP2 staining within caudal 
song regions of adult male zebra finch telencephalon following developmental treatment 
with either vehicle (panels A, C, E, G) or WIN (1 mg/kg, panels B, D, F, H) using DAB 
immunohistochemistry.  Panel A with C inset depict normal distribution of MAP2 protein 
within HVC dendrites; protein has significantly accumulated within this region as a result 
of developmental cannabinoid administration (Panel B with D inset).  In RA, a similar 
developmental pattern of MAP2 staining ensues as what is seen within HVC over the 
course of normal brain development (Panel E with G inset).  However, developmental 
administration of WIN results in a significant, persistent amassing of dendritic protein 
(Panel F with H inset) within this area.  I-J: Optical density measurements of MAP2 
staining in both HVC (I) and RA (J) after vehicle and WIN administration, respectively.  
In both regions, protein increases are observed following daily WIN treatment, however 
the cannabinoid effect appears to be more robust within HVC. 100X scale bar = 300 
μm, 1000X scale bar = 30 μm.  
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Figure 3.10. DAB-immunohistochemical staining of MAP2 protein within rostral song 
regions lMAN and Area X of adult male zebra finch telencephalon following 
developmental  vehicle treatment (panels A, C, E, G) or treatment with WIN (1 mg/kg, 
panels B, D, F, H).  Developmental WIN exposure results in a statistically significant 
increase in MAP2 protein accumulation within lMAN (Panel B with D inset) as opposed 
to vehicle treatments (Panel A with C inset).  Significant differences between MAP2 
staining of vehicle-treated striatal Area X (Panel E with G inset) and cannabinoid-treated 
Area X (Panel F with H inset) were also noted.  I-J: Optical density measurements of 
MAP2 staining in both adult lMAN (I) and Area X (J) after developmental vehicle and 
WIN administration, respectively. 100X scale bar = 300 μm, 1000X scale bar = 30 μm. 
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Figure 3.11.  Representative low and high-power micrographs of MAP2 staining of adult 
male zebra finch midbrain thalamic regions Ov and DLM, using DAB 
immunohistochemistry.  Animals were subjected to either developmental treatment with 
vehicle (Panel A, insets C, E) or WIN (1 mg/kg, Panel B, insets D, F) and brain tissue 
processed at adulthood. Staining within Ov (Panel A-B, bottom left corner) and DLM 
(Panel A-B, top right corner) is less intense, but visible within these distinct areas. Daily 
administration of WIN during sensorymotor development (Panel B, inset, F) results in a 
significant increase in MAP2  staining and altered cellular morphology within DLM; 
however no significant differences are observed in Ov as a result of cannabinoid 
treatment(Panel B, inset E).  G-H: Optical density measurements of MAP2 staining 
within thalamic areas Ov and DLM. 100X scale bar = 300 μm, 1000X scale bar = 30 μm. 
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Figure 3.12.  Representative images of DAB-immunohistochemical staining of MAP2  
protein within the cerebellum of adult male zebra finches developmentally treated with 
either vehicle (Panel A, inset C) or WIN (1 mg/kg, Panel B, inset D). The number of 
tissue sections available from each treatment group was not sufficient for statistical 
analysis, however distinct treatment differences can still be observed.  MAP2 staining 
within the granular layer is considerably less dense after developmental cannabinoid 
treatment (Panel B, inset D) as opposed to vehicle treatment (Panel A, inset C). 100X 
scale bar = 300 μm, 1000X scale bar = 30 μm. 
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Figure 3.13. Photomicrographs of MAP2 staining within caudal song regions of adult 
male zebra finch telencephalon following 25 days of treatment with either vehicle 
(panels A, C, E, G) or WIN (1 mg/kg, panels B, D, F, H), using DAB 
immunohistochemistry.  No significant treatment differences were observed within HVC 
or RA of these adults which previously learned song.  100X scale bar = 300 μm, 1000X 
scale bar = 30 μm. 
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Figure 3.14. DAB-immunohistochemical staining of MAP2 protein within rostral song 
regions lMAN and Area X of adult male zebra finch telencephalon following 25 
consecutive days of vehicle treatment (panels A, C, E, G) or treatment with WIN (1 
mg/kg, panels B, D, F, H).  WIN treatment did not result in significant elevations in 
MAP2 within either region as compared to vehicle-treated counterparts.   I-J: Optical 
density measurements of MAP2 staining in both adult lMAN (I) and Area X (J) after 
vehicle and WIN administration, respectively. 100X scale bar = 300 μm, 1000X scale 
bar = 30 μm. 
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 Figure 3.15. Representative low and high-power micrographs of MAP2 staining of adult 
male zebra finch midbrain thalamic regions Ov and DLM using DAB 
immunohistochemistry.  Animals were subjected to either 25 consecutive treatments 
with vehicle (Panel A, insets C, E) or WIN (1 mg/kg, Panel B, insets D, F) after song 
learning had occurred.  Dendritic staining within Ov (Panel A-B, bottom left corner) and 
DLM (Panel A-B, top right corner) is sparse, but visible within these areas. Daily 
administration of WIN during sensorymotor development (Panel B, insets D, F) did not 
lead to a significant increase in MAP2 staining within either Ov or DLM. G-H: Optical 
density measurements of MAP2 staining within thalamic areas Ov and DLM. 100X scale 
bar = 300 μm, 1000X scale bar = 30 μm. 
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Figure 3.16. Representative images of DAB-immunohistochemical staining of MAP2 
protein within the cerebellum of adult male zebra finches treated with either vehicle 
(Panel A, inset C) or WIN (1 mg/kg, Panel B, inset D) after song learning. The number 
of tissue sections available from each treatment group was not sufficient for statistical 
analysis. 100X scale bar = 300 μm, 1000X scale bar = 30 μm. 
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CHAPTER 4: CANNABINOID DISRUPTION OF NOVEL SONG-STIMULATED 
ARC/ARG 3.1 EXPRESSION IN ZEBRA FINCH AUDITORY TELENCEPHALON: 
NEURAL CORRELATES OF AUDITORY STIMULATION AND RECOGNITION 
 
ABSTRACT: 
Cannabinoids produce an array of cognitive effects; however an understanding of 
the physiological mechanisms responsible remains incomplete.  Arc, an immediate-
early gene (IEG) product involved in dendritic spine dynamics and necessary for 
plasticity changes such as long-term potentiation, is rapidly induced within zebra finch 
caudal medial nidopallium (NCM) following novel song perception, a response that 
habituates after repeated stimuli. Arc appears unique in its rapid dendritic expression 
and is induced postsynaptically following excitatory input.  Previously, we found that 
vocal development-altering cannabinoid treatments are associated with elevated 
dendritic spine densities.  Given Arc’s dendritic morphological role, we hypothesized 
that cannabinoid-altered spine densities may involve Arc-related signaling. To test this, 
we examined the ability of the cannabinoid agonist WIN 55,212-2 (WIN) to: (1) acutely 
disrupt song-induced Arc expression; (2) interfere with auditory recognition memory 
and; (3) alter dendritic spine densities associated with learning. We found that WIN (3 
mg/kg) acutely reduced Arc expression within both NCM and Field L2. WIN also 
blocked Arc habituation in an antagonist-reversible manner. WIN did not alter Arc 
expression in the thalamic auditory relay Nucleus Ovoidalis (Ov), which suggests the  
cannabinoid system is important for higher-order sensory processing. Novel song 
stimulation rapidly increased dendritic spine densities within integrative auditory 
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telencephalon, an effect blocked by WIN pretreatments. Taken together, cannabinoid 
inhibition of both Arc induction and its habituation to repeated stimuli implicates this 
protein in the mechanism underlying cannabinoid-altered spine densities, and reduced 
ability to encode/consolidate auditory information that is essential for sensorimotor 
learning. 
INTRODUCTION 
The cannabinoid system has an important role in many central nervous system 
functions including (but not limited to) increased feeding behaviors, analgesia, 
antiemesis, as well as an array of psychoactive effects (Cocchetto et al., 1981; Guindon 
and Hohmann, 2009; Soderstrom et al., 2004).  Cannabinoid chemicals (both naturally 
and synthethically derived), are known to modulate the degree of neurotransmission 
between synapses through primary activation of the cannabinoid receptor: particularly, 
the central actions of these compounds are attributed to activation of the cannabinoid 
receptor 1 (CB1).  CB1 receptors are localized in high concentrations in certain brain 
areas, including the cerebellum, hippocampus, frontal cortex, and basal ganglia, which 
correlates with well-documented influences on locomotor coordination, anxiolysis, and 
increases in reward-like behaviors present in models of drug addiction (El Manira and 
Kyriakatos, 2010; Fernandez-Ruiz et al., 2010; Kinsey et al., 2011). Less well 
understood are the physiological effects cannabinoids have on the neural aspects of 
learning and memory acquisition. We previously demonstrated that in zebra finches, a 
once daily administration of the cannabinoid agonist WIN 55,212-2 is associated with an 
inappropriate maintenance of dendritic spine densities in regions critical for both 
sensorimotor learning and production of stereotyped song. Changes in dendritic spine 
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densities are only produced following developmental exposure; treatments given to 
adults that had completed vocal learning are not effective (Gilbert and Soderstrom, 
2011).  It is postulated that cannabinoid diminution of activity within the neuron disrupts 
the acquisition and consolidation of sensory stimuli, and ultimately cognition, though the 
specifics remain unclear.  Recent observations have led to the hypothesis that the 
dendritically located immediate early gene product Arc/Arg3.1 (Arc) plays a role in at 
least one form of cannabinoid-induced disruption of cognitive function.   
The vertebrate brain is truly remarkable, in that it is capable of converting 
sensory experiences of the world around us into discrete physiological changes in both 
synaptic activity and connectivity.  This intricate process involves activity-dependent 
presynaptic membrane depolarization and subsequent calcium influx into selective 
neurons within a specific circuit (Bramham et al., 2010; Shepherd and Bear, 2011). 
These actions often result in the transcription of a wide array of activity-induced genes 
distinctly expressed within the neuron that can be classified into two groups:  classic 
immediate-early genes (such as c-fos, egr-1, and c-jun) which encode for transcription 
factors that indirectly influence neuronal activity before any new proteins can be 
synthesized, and “effector” immediate early genes (BDNF, Homer 1, Neuritin and 
particularly Arc) which encode for effector proteins that directly regulate axonal 
outgrowth and plasticity at the synapse (Fosnaugh et al., 1995; Rickhag et al., 2007; 
Tischmeyer and Grimm, 1999). The immediate-early gene Arc, also known as activity-
regulated cytoskeleton-associated protein, or activity-regulated gene 3.1, is a single 
copy gene whose mRNA is trafficked directly to dendritic spines and undergoes rapid, 
local translation (Bramham et al., 2010; Bramham et al., 2008). Recent studies 
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demonstrated that Arc, in its translated form (also referred to as Arc), co-precipitates 
with polymerized F-actin, shares a near identical intracellular distribution as actin in 
dendritic spines, and is a necessary component of actin-dependent neuronal structures 
(Guzowski et al., 2005; Lyford et al., 1995). Furthermore, Arc mRNA and protein are 
both highly conserved within the vertebrate species, and their induction during 
behavioral learning is so robust, distinct, and reproducible that it is often used as an 
indicator for neural circuitry that underlies learning and memory (Guzowski et al., 2001; 
Guzowski et al., 2005). Arc has been identified as a key component of protein 
synthesis-dependent long-term potentiation, and is necessary for the consolidation of 
synaptic plasticity and formation of long term memories (Bramham et al., 2008; 
Pastuzyn et al., 2011; Plath et al., 2006; Ploski et al., 2008).  In particular, reductions in 
Arc mRNA/ protein are strongly correlated with reduced performances in spatial 
memory and fear conditioning in mammals (Guzowski et al., 2000; Zhang et al., 2011). 
Accordingly, inappropriate activation of the CB1 receptor is linked to marked reductions 
in memory consolidation and performances of the very same tasks (Abush and Akirav, 
2010; Mackowiak et al., 2009).  Thus, given the essential roles that both Arc and the 
CB1 receptor play in this component of learning and memory, it is reasonable to 
postulate that these two elements have a relationship that culminates in the disruption 
of dendritic spine plasticity, the specifics of which currently remain unknown. 
Auditory perception provides an excellent example of the importance of sensory 
experience to cognitive processing. Songbirds, similar to other vertebrates, possess an 
ascending pathway that conducts auditory information to higher-order integrative brain 
regions.  Interestingly, within the caudomedial region of the zebra finch telencephalon, a 
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circuit of pallial regions comprise a domain that is homologous to the mammalian 
primary and secondary auditory cortex (Pinaud and Terleph, 2008). Auditory information 
enters the avian cochlea, and then travels via a series of projections to a midbrain 
nucleus of the auditory pathway, the dorsal lateral nucleus of the mesencephalon (MLd, 
homologous to the mammalian inferior colliculus). This area then projects to a thalamic 
relay region between it and the auditory cortex, referred to as Nucleus Ovoidalis (Ov, 
avian homolog of the mammalian medial geniculate nucleus (Krutzfeldt et al., 2010)). 
Projections from Ov then reach the telencephalon through the primary auditory 
projection area, Field L, and finally target a region specialized for perceiving conspecific 
vocal signals, caudal medial nidopallium (NCM, homologous to mammalian 
supragranular layers (Jarvis et al., 2005; Mello and Clayton, 1994; Mello et al., 2004; 
Terleph et al., 2007; Zaretsky, 1978)). For an illustration of these regions, see Figure 
4.1. Young songbirds must hear, experience, and memorize the stereotyped song of an 
adult male tutor by use of both auditory feedback and sensory integration, during a 
critical period known as sensorimotor learning (Tschida and Mooney, 2012). This 
process involves constant communication between these auditory regions and areas 
that comprise the passerine song system. In a number of studies, this laboratory has 
examined the impact of daily developmental cannabinoid exposure on the quality of 
song learning and recall later on in adulthood, and found that these animals have 
significant reductions in stereotypy in comparison to the song of their tutors (Soderstrom 
and Tian, 2004; Soderstrom and Tian, 2008). Presumably, the diminished ability to 
produce quality song in adulthood is attributed to cannabinoid modulation of sensory 
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input within auditory and song regions by altering the normal dendritic spine plasticity 
known to occur during vocal learning.  
In effect, when utilized in conjunction with other methods, immediate-early gene 
expression analysis within passerines can yield significant insights, particularly 
regarding the spatial organization of the brain’s response to sensory stimulation. 
Because immediate-early genes are activity-dependent, are not induced in the absence 
of stimulation, and are robustly expressed in response to stimulation leading to cellular 
depolarization, they are very sensitive indicators of neuronal activation (Sagar et al., 
1988; Sheng and Greenberg, 1990). Accordingly, most accept the expression of 
immediate-early genes within a given neuron reflects previous activation of said neuron 
by the stimulus under study (Mello et al., 2004).  In songbirds, many genomic regulatory 
events corresponding to the brain’s response to sensory stimuli have been elucidated; 
perhaps one of the most studied targets has been an  immediate-early gene referred to 
as zif-268, egr-, NGFI-A, Krox-24, or “zenk”. In early experiments, it was determined 
that zenk was strongly induced in NCM in response to a short period of novel, 
conspecific song; however it was induced at a significantly lower level after exposure to 
song of a heterospecific species, and none at all in response to tone bursts (Mello and 
Clayton, 1994; Mello et al., 1992). Since then, a multitude of studies have evaluated the 
induction of a number of immediate-early genes and their translated products in 
response to sensory stimulation in many different scenarios. For example, Velho and 
colleagues (2005) not only established that Arc is significantly induced in auditory 
forebrain areas in response to novel birdsong, but that it is co-expressed with many 
other immediate-early genes and effectors that are activated by the same natural 
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sensory experience, namely zenk and c-fos (Mello et al., 2004; Velho et al., 2005). 
Furthermore, CB1 receptor activation with WIN 55,212-2 selectively inhibited novel zenk 
protein expression within NCM, a result suggesting a role for cannabinoids in 
influencing cognition at the perceptual level (Whitney et al., 2003).   Here, we used 
behavioral, pharmacological, and, histological methods in order to examine the role of 
WIN 55,212-2 to acutely disrupt song-induced Arc expression, interfere with auditory 
recognition memory of a song stimulus, and alter dendritic spine densities normally 
associated with learning. 
MATERIALS AND METHODS 
 Materials 
Except where noted, all materials and reagents were purchased from Sigma (St. 
Louis, MO), or Fisher Scientific (Pittsburgh, PA).  Immunochemicals were purchased 
from Vector Laboratories (Burligame, CA), and the primary anti-Arc/Arg3.1 antibody was 
purchased from Abcam (Cambridge MA, Catalog # AB85656).  Equithesin was 
prepared from reagents (40 % propylene glycol, 10 % ETOH, 5 % chloral hydrate, 1 % 
pentobarbital). The synthetic cannabinoid agonist WIN and inverse agonist SR141716A 
were suspended in vehicle from concentrated DMSO stocks (10 mM). Vehicle consisted 
of a suspension of 1:1:18 DMSO:Alkamuls EL-620 (Rhodia, Cranberry, NJ):phosphate-
buffered saline. 
 Animals 
Animals were cared for and experiments conducted according to protocols 
approved by East Carolina University's Animal Care and Use Committee. Adult male 
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zebra finches bred and raised in our aviary were used as subjects in these experiments. 
Prior to the start of experiments, birds were housed singly with free access to grit, 
water, mixed seeds (Sunseed VitaFinch), and cuttlebone, and provided multiple 
perches.  Animals were maintained on a 14:10 light/dark cycle, and ambient 
temperature was maintained at 78° F. 
Acute/Chronic Treatments 
Twenty-four hours prior to the start of experiments, animals were housed singly 
in visual and auditory isolation, in recording chambers, based on a design developed by 
engineering personnel in the Florida State University Neuroscience Program (Whitney 
et al., 2003).  The method developed to induce Arc protein expression in the zebra finch 
auditory telencephalon was adapted from protocols used for Arc and Zenk mRNA co-
induction, and Zenk protein expression (Lonergan et al., 2010; Mello and Ribeiro, 1998; 
Velho et al., 2005). Birds were exposed to a tape recording of 15 s of novel conspecific 
song, followed by 45 s of silence, repeated 30 times. The novel song consisted of a 
collection of five second song bouts from three adult males from an outside aviary. 
Song playbacks were presented in a fifteen second medley, followed by forty five 
seconds of silence, for a total of a one minute.  This procedure was repeated a total of 
thirty times.  Unstimulated control groups were only exposed to silence. Following these 
30 minute stimulus periods, birds were left in silence for an additional 90 minutes to 
reach peak protein expression. 
 In experiments that involved drug treatments, injections were given thirty 
minutes prior to the beginning of the song stimulus procedure. A well-established 
protocol was used in order to determine whether WIN treatment would disrupt 
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habituation of Arc induction following repeated presentation of the same song stimulus 
(Whitney et al., 2003).  Animals were exposed to the same 30 minute song playbacks 
for three days. On two consecutive days, birds received an intramuscular injection of 
WIN (3 mg/kg), SR141716A (6 mg/kg), or vehicle 30 minutes before the start of song 
playbacks.  Silent controls not exposed to song were given either a single intramuscular 
injection of WIN (3 mg/kg) or vehicle for two days.   On the third day of song exposure, 
all groups were given a single injection of vehicle.  At the end of experiments on the 
third day, animals were given an overdose of Equithesin (100 µl), and brain tissue was 
processed for immunolabeling of Arc protein.  
Western Blotting 
The presence of Arc protein was detected in the zebra finch brain by using a 
rabbit polyclonal antibody targeting the internal sequence of amino acids 288-337 of 
Human Arg 3.1 (LDLPQKQGEP LDQFLWRKRD LYQTLYVDAD EEEIIQYVVG 
TLQPKLKRFL.) This epitope was compared to the zebra finch sequence, and found to 
differ by a single residue (LDLPQKEGEP LDQFLWRKRD LYQTLYVDAD EEEIIQYVVG 
TLQPKLKRFL, Genbank accession number XP_002186861).  To assess the selectivity 
of the Arc antibody against zebra finch protein, western blotting experiments were done. 
Protein extraction protocols were adapted from methods described by Schafer et al., 
1998. Adult male zebra finches, subjected to song stimulation procedures described 
above, were killed by Equithesin overdose.  Brains were removed, homogenized with a 
polytron in an ice-cold extraction buffer containing 1 M Tris-HCl, pH = 7.0, 0.6 M KCl, 
0.5 mM ATP, 1 mM DTT, 0.5 mM MgCl2, along with a cocktail of protease inhibitors 
(0.25 M sucrose/1 mM EDTA/4 mM phenylmethylsulfonyl fluoride/1 mM 4-amino 
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benzamidine/0.1% w/v bacitracin), and briefly micro-centrifuged at 1000 x g. 
Supernatants were stirred on ice for 30 minutes, collected and centrifuged at 24,000 x 
g. Following this, protein preps were ultra-centrifuged at 100,000 x g for 1 hour. Pellets 
were discarded and supernatants were filtered through cheesecloth to remove traces of 
excess lipid, and dialyzed against 10 L of ice-cold distilled water for 4 hours at 4º C. The 
fractions were then dialyzed overnight against two changes of ice-cold extraction buffer 
containing 10 mM Tris-HCl, pH 8.0, 0.2 mM CaCl2, 0.5 mM ATP, 0.1 mM DTT, 100 mM 
KCl, and 0.1 mM phenylmethylsulfonyl fluoride. Samples were spun a final time at 
24,000 x g at 4º C to remove trace precipitate.  Supernatants were collected and protein 
concentrations determined using the Bradford method. 30 µg of soluble protein were 
loaded into a 10% polyacrylamide gel, separated by SDS-PAGE, and blotted onto a 
PVDF membrane. Blots were blocked with a non-mammalian blocking reagent 
(Odyssey Blocking Buffer, LI-COR Biosciences, Lincoln, NE) and incubated overnight at 
4º C in a 1:1000 dilution of the Arc antibody in Odyssey Blocking Buffer. The next day, 
the blot was washed three times with 1X PBS-T (Phosphate-Buffered Saline [pH = 7.4] 
with 0.05% Tween-20), and incubated in a secondary antibody solution containing an 
infrared anti-rabbit secondary antibody (LI-COR Biosciences # 926-68021, 1:25,000) 
and 0.02% SDS for 2 hours at room temperature in the dark. The blot was washed 4 
times with 1X PBS (Phosphate-Buffered Saline [pH = 7.4]) for 10 minutes each, and 
visualized using the LI-COR Odyssey Infrared Imaging System. Masses of infrared 
bands were determined standard curves fit to distances migrated by molecular weight 
standards using GraphPad Prism 5.0 software (GraphPad Software, SanDiego, CA, 
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the immunizing peptide were performed as a negative control (Abcam, Cambridge, MA).  
Additional western blotting experiments were performed with synaptosomal 
membrane preparation isolated from caudal telencephalon (containing NCM and Field 
L2) following drug treatments and song exposure procedures as described above. After 
behavioral experiments, animals were quickly anesthetized, decapitated, and brains 
rapidly dissected on ice.  Brain sections containing regions NCM and Field L2 were 
placed into a glass and Teflon grinder containing 25 volumes of ice-cold 0.32 M sucrose 
in 5 mM Tris, pH = 7.4, and ground to homogeneity. Following this, homogenates were 
centrifuged at 1000 x g at 4º C for 15 minutes. Pellets were discarded; supernatant was 
removed and placed into a fresh centrifuge tube on ice, and centrifuged at 30,000 x g at 
4º C for 60 minutes. Pellets were then snap-frozen at -80º C overnight, and 
resuspended in 150 volumes of 50 mM Tris, 10 mM EDTA, pH = 7.4.  Membrane 
fractions were incubated at 4º C for 2 hours in an effort to chelate endogenous cations 
and dissociate endogenous ligands from receptors. These fractions were again 
centrifuged at 30,000 x g at 4º C for 60 minutes, after which pellet fractions were 
collected.  Pellets were washed by homogenizing with a glass and Teflon grinder in 150 
volumes of 50 mM Tris, 5 mM MgCl2, pH = 7.4.  Homogenates were centrifuged at 
30,000 x g at 4º C for 60 minutes and resuspended in 50 mM Tris, 5 mM MgCl2, pH = 
7.4 a final time, and protein concentrations determined by the Bradford method.  In 
addition to anti-Arc detection, these blots were also probed with an antibody directed 
-actin as an internal control (Sigma # A3853). Relative intensities of Arc and 
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actin bands were determined and compared across treatment conditions. Potential 
treatment effects were assessed using t-tests. 
 Immunohistochemistry 
Immediately following the end of song exposure procedures described above, 
animals were killed by Equithesin overdose (100 µl) and transcardially perfused with 
PBS, followed by phosphate-buffered 4% paraformaldehyde [pH = 7.0]. Brains were 
immersed in 4% paraformaldehyde overnight, and then transferred to an ice-cold 20% 
sucrose solution the next morning. Once tissues sank in the sucrose solution, brains 
were blocked down the midline and sectioned parasagittaly, using a Leica VT 1000 
vibrating microtome.  For experiments that required capture of NCM and Field L2, 
consecutive free-floating sections were collected from the midline (0.0mm) to 2.0 mm 
lateral of the midline. All tissue was processed using a standard immunohistochemical 
procedure adapted from (Whitney et al., 2000).  Tissue was briefly rinsed in 1X PBS for 
10 minutes followed by incubation in 1% H2O2 for 30 minutes, to quench endogenous 
peroxidase. The sections were again rinsed 3 times with 1X PBS, and then blocked with 
5% normal goat serum for 35 minutes. Following blocking, sections were incubated 
overnight at room temperature in a solution containing anti-Arc antibody (1:3000 
dilution), 1% normal goat serum, 0.01% sodium azide, and 0.3% Triton-X 100 in PBS. 
The following day, tissue was rinsed three times in PBS and incubated in a biotinylated 
anti-rabbit antiserum followed by an avidin-biotin complex from a kit following the 
manufacturer’s instructions (VECTASTAIN ABC Elite kit, Vector Laboratories Inc., 
Burlingame, CA).  Antibody labeling was developed using a 3,3-diaminobenzidine 
(DAB) solution in the presence of hydrogen peroxide followed by three washes in 1X 
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PBS. Tissue sections were mounted on glass slides coated with 0.3 % gelatin.  After 
sections on slides were allowed to dry overnight, sections were dehydrated with graded 
concentrations of ethanol (70 %, 95 %, and 100 % respectively), cleared with xylenes, 
and coverslipped with Permount (Fisher). 
 Golgi-Cox Impregnation 
A mixture containing 5 volumes of 5% potassium dichromate solution, 5 volumes 
of 5% mercuric chloride, and 4 volumes of 5% potassium chromate solution was 
prepared and allowed to ripen in the dark five days before use.  After the end of song 
exposure procedures described above, birds were killed by Equithesin overdose and 
transcardially perfused with PBS, brains removed and rinsed briefly with ice-cold 
distilled water, and immersed in a filtered (0.45 micron) aliquot of Golgi-Cox supernatant 
for 14 days in the dark at room temperature.  The brains were then transferred to an ice-
cold 30 % sucrose solution for five days. Following sucrose treatment, brains were 
blocked down the midline, and left hemispheres were sectioned parasagittally on a 
vibrating microtome. 125-micron sections of zebra finch brain were then gold-toned in 
order to preserve staining as follows.  The sections were exposed to chilled solutions of 
80, 60, 40, and 20% glycerol, rinsed with water, then transferred to a 0.05% ice-cold 
gold chloride solution for 80 minutes.  After being briefly transferred to an ice-cold 0.2% 
oxalic acid solution for two minutes, sections were immersed in 1 % sodium thiosulfate 
for a total of 60 minutes.  The sections were developed in a 7 % ammonium hydroxide 
solution at room temperature, in the dark for 30 minutes, followed by further processing 
in Kodak Fixer. Sections were then mounted and dehydrated on glass slides, and 
neurons of zebra finch auditory nuclei assessed for dendritic spine densities and as a 
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function of treatment. Tissue was stained and processed in multiple batches; however, 
in order to eliminate possible variance associated with reaction conditions, each of the 
treatment groups were represented in each batch.  
 Optical Density Measurements 
Immunohistochemiscal staining was examined in various brain regions at 40, 
100, and 1000 X using an Olympus BX51 microscope with Nomarski DIC optics. 
Images were captured using a Spot Insight QE digital camera and Image-Pro Plus 5.0 
software (MediaCybernetics, Silver Spring, MD) under identical, calibrated exposure 
conditions. All images were background-corrected, and converted to 8-bit grey scale; 
borders that outlined brain regions of interest were traced manually. Two dimensional 
optical density measurements of both labeled nuclei and neuropil from areas enclosed 
within traced areas were performed on images without knowledge of treatment condition 
for each brain region of interest. For measurements pertaining to NCM and Field L2, All 
intact sections containing NCM brain regions from the midline (0.0 mm to 2.0 mm from 
the midline per animal were included for analysis), and analyzed using Image-Pro Plus 
5.0 software. Field L2 regions between the midline and 0.5 mm from the midline were 
not included for analysis. Mean optical densities (within brain region counts of stained 
nuclei and neuropil/area of the region) were compared across each treatment group 
using one-way ANOVA as described below. 
 Measurement of Dendritic Spine Densities 
Dendritic spines were visualized at 100 X and 1000 X under oil immersion using 
a Zeiss AxioImager M2 microscope with QIClick digital CCD optics, and analyzed using 
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Neurolucida 3D reconstruction imaging software (MBF Bioscience, Williston VT). 
Dendritic spine densities, expressed as the mean number of dendritic spines per length 
(µm) of each dendrite, were analyzed based on criteria adapted from Norrholm, et al. 
(Norrholm and Ouimet, 2001).  Neurons that were selected for measurement were fully 
impregnated, intact, located in areas of tissue free of debris and other imperfections, 
and possessed dendritic processes greater than 20 microns in length. In order to ensure 
random sampling, all neurons that fit the criteria above were assigned a number, and 5 
neurons were randomly selected from each of 5 separate tissue sections containing 
NCM for each treatment.  3-D serial reconstructions were created for each neuron 
directly from slides, and quantitative morphometric analyses were conducted for each 
neuron (cell body, dendrites, and dendritic spines), and data pertaining to each outline 
was exported into Microsoft Excel Spreadsheet.  All observable spines along the entire 
length of dendrites of 25 randomly selected neurons per each NCM brain region of 
animals in each representative treatment group (vehicle + novel song exposure, WIN + 
novel song exposure, and un-stimulated silence control groups, n = 4 for each treatment 
group) were analyzed.  
 RESULTS 
 Anti-Arc Antibody Selectivity 
In an effort to capture Arc protein expression at its maximum levels, brains of 
male animals exposed to novel song were used for the following experiments. Western 
blotting was performed to assess selectivity of the anti-Arc antibody used.  SDS-PAGE 
separation of 30 µg of brain protein revealed the presence of a single predominant band 
of approximately 55 kDa labeled by the anti-Arc antibody. The size of this labeled 
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protein is consistent with that reported from other mammalian species, including mouse, 
rat and human (see Figure 4.2A, and Bramham et al., 2008). Anti-Arc immunoreactivity 
was eliminated following preabsorption of antisera with the immunizing peptide (see 
Figure 4.2A).   
To determine the cellular localization of anti-Arc binding within neurons, images 
of double immunofluorecence labeling of dendritically-associated MAP2 (Figure 4.3B, 
red) with activity-stimulated arc protein within NCM (Figure 4.3B, green) were captured 
at 630 X and 1000 X, via confocal laser scanning microscopy. There was considerable 
spatial overlap between the dendrite-associated protein MAP2 (Figure 4.3B, red) and 
the Arc protein, that appears present both somatically and dendritically (see Figure 
4.3B, yellow merge). Note the robust expression of Arc protein both within dendrites 
(Figure 4.3B, solid arrows), and cell bodies (Figure 4.3B, dashed arrows).   
Cannabinoid Inhibition of Novel Song-Stimulated Arc Expression 
Arc mRNA expression within zebra finch auditory telencephalon following novel 
conspecific song stimulation has been previously characterized (Velho et al., 2005). 
Auditory information enters the avian cochlea and travels to a midbrain nucleus of the 
auditory pathway, the dorsal lateral nucleus of the mesencephalon (MLd, homologous 
to the mammalian inferior colliculus) then passes a thalamic relay region between it and 
the auditory cortex, referred to as Nucleus Ovoidalis (Ov, avian homolog of the 
mammalian medial geniculate nucleus (Krutzfeldt et al., 2010). From here, stimuli 
reaches telencephalon through the primary auditory Field L2, and finally targets a region 
specialized for perceiving conspecific vocal signals the caudal medial nidopallium 
(NCM, homologous to mammalian supragranular layers (Jarvis et al., 2005; Mello and 
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Clayton, 1994; Mello et al., 2004; Terleph et al., 2007; Zaretsky, 1978). Therefore we 
began our study of Arc protein expression within these previously-studied areas through 
a series of immunohistochemistry experiments followed by optical density 
measurements of anti-Arc staining from 100X grayscale images. As prior dose-
response experiments indicated that 3 mg/kg of the cannabinoid agonist, WIN was the 
lowest fully-effective dosage for inhibition of song-stimulated Zenk expression, we 
employed this dosage in the current experiments (Whitney et al., 2003).  
We found that levels of Arc expression varied significantly within both NCM and 
Field L2 as a function of treatment: (F (2,252) = 48.22; p < 0.001) and (F (2,226) = 
23.77; p < 0.005) for NCM and Field L2, respectively. Tukey’s post hoc analyses further 
revealed that within NCM, there were significant differences across all three treatment 
groups (Vehicle + Silence, Vehicle + Song, WIN + song). Basal levels of Arc expression 
following periods of silence were low within NCM and Field L2 (see Figure 4.4A-C).  
Thirty minutes of novel song significantly elevated levels of Arc expression within both 
NCM and Field L2 relative to control groups (see Figure 4.4D-F). For NCM, average 
optical densities were significantly increased in novel song exposed animals (0.091 ± 
0.004) versus animals treated with vehicle and only exposed to silence (0.049 ± 0.003, 
q = 13.28, p < 0.05).  In the case of Arc expression within Field L2, average optical 
densities were significantly increased in novel song exposed animals (0.093 ± 0.005) 
versus animals treated with vehicle and only exposed to silence (0.051 ± 0.003, q = 
9.63, p < 0.05). In striking contrast to vehicle treatments, acute pretreatment with WIN 
before song stimulation resulted in significantly reduced magnitude of arc protein 
expression within both NCM and Field L2 relative to vehicle-treated controls (see Figure 
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4.4G-I).  Within NCM, mean optical densities were significantly reduced by WIN from 
0.059 ± 0.002 to 0.049 ± 0.003 (q = 3.414, p < 0.05).  Within Field L2 mean optical 
densities were significantly reduced from 0.068 ± 0.005 to 0.050 ± 0.003 (q = 3.922, p < 
0.05). These results are summarized in Figures 4.4J-K. In order to confirm that 
cannabinoid effects on novel stimulus-induced Arc expression were specific to higher-
order telencephalic regions and not due to a general stimulation, we examined optical 
densities of Arc staining within the midbrain thalamic relay region, Ov. Interestingly, 
optical densities of Arc labeled cells within this thalamic auditory relay region did not 
vary as a function of novel song exposure or cannabinoid treatment (F (2,105 = 0.1118; 
p > 0.05), see Figure 4.5A-F; the optical densities within Ov for each treatment group 
are summarized in Figure 4.5G). 
WIN Prevents Habituation of Arc Expression Following Repeated Auditory Stimulation 
Prior work demonstrates that Zenk expression is decreased following habituation 
to sequential presentations of the same conspecific song, supporting a relationship 
between Zenk expression and novel song recognition (Mello et al., 1992; Whitney et al., 
2003). Similar patterns of Arc expression within auditory telencephalon led us to test 
whether Arc also habituates following repeated presentation of the same song, and 
whether this habituation is influenced by CB1 receptor activation.  
As reported by others for Zenk (Mello et al, 1992; Whitney et al., 2003), repeated 
presentation of the same conspecific song resulted in habituation of Arc expression 
within both NCM and Field L2 (compare Figure 4.6A-C to Figure 4.6 G-I, and Figure 4.6 
P, Vehicle + Silence to Vehicle + Song). One-way ANOVA confirmed treatment 
differences in Arc immunoreactivity (F (4,247) = 31.68; p < 0.0001) and (F (4,143) = 
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13.14; p < 0.0001) for areas NCM and Field L2, respectively.  Further analysis revealed 
that pretreatment with WIN prior to the first two song presentations prevented this 
habituation from occurring in response to the same song on the third day within NCM 
(compare Figure 4.6 G-I to Figure 4.6 J-L, and Figure 4.6 P Vehicle + Song to Day 1-2 
WIN, Day 3 Vehicle, from 0.139 ± 0.033 to 0.199 ±0.063 (q = 11.56, p < 0.0001).  
Habituation was also prevented by WIN treatment within Field L2 where mean optical 
densities were significantly elevated from 0.129 ± 0.027 to 0.165 ± 0.0239 (q = 7.892, p 
< 0.0001). Importantly, in both NCM and Field L2, agonist-induced prevention of 
habituation was reversed by pretreatment with the CB1-selective inverse agonist, 
SR141716A, demonstrating CB1 mediation of the effect (compare Figure 4.6J-L to 
Figure 4.6M-O, and Figure 4.6P Day 1-2 WIN, Day 3 Vehicle to Day 1-2 WIN 
/SR141716A,  Day 3 Vehicle). 
WIN Disrupts Auditory Perception-Induced Increased Dendritic Spine Densities within 
NCM 
We previously demonstrated that developmental cannabinoid treatment persistently 
elevates dendritic spine densities within telencephalic regions essential for song 
learning and production (Gilbert and Soderstrom, 2011). In addition, others have shown 
that activity-induced Arc expression is essential for maintenance of LTP, and is 
positively correlated with various forms of learning and memory, and is required for 
more durable forms of synaptic plasticity (Chowdhury et al., 2006; Guzowski et al., 
2000; Guzowski et al., 1999; Plath et al., 2006). These observations, combined with the 
findings above for cannabinoid inhibition of Arc expression that is a molecular correlate 
of auditory recognition, suggests a potential physiological mechanism by which 
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exogenous cannabinoid exposure may disregulate synaptic plasticity that takes place 
during learning (Roberts et al., 2010).  As our prior experiments investigated effects of 
chronic cannabinoid exposure, we have extended these results to assess potential 
acute influences of novel song on dendritic spine densities, and potential cannabinoid 
modulation of this effect.  
Novel song stimulation of vehicle-treated animals resulted in a robust and rapid 
increase in dendritic spine densities within NCM (Figure 4.7C).  WIN administration 30 
minutes prior to novel song stimuli reversed these song-stimulated spine increases to 
levels not significantly different from non-song stimulated, vehicle-treated controls 
(Compare Figures 4.7B and 4.7D, F (2, 1053) = 53.67; p < 0.0001). 
DISCUSSION 
In addition to demonstrating for the first time that sensory perception- and 
integration-related Arc expression (within Field L2 and NCM, respectively) is mitigated 
by CB1 receptor activation, our results importantly demonstrate that these cannabinoid 
effects on Arc are associated with rapidly-altered dendritic spine densities that suggests 
a role in processes important to learning and memory. Such a role is consistent with 
that observed within mammalian hippocampus where Arc is critical for memory-related 
neuronal plasticity, including LTP and LTD (reviewed by Bramham et al., 2008). Equally 
significant, we have demonstrated the specific contributions of cannabinoid receptor 
agonism to disrupting the portion of Arc protein expression exclusively located within 
functional nerve terminals (see Figure 4.3). Endocannabinoid signaling is directly 
involved in short-term synaptic plasticity changes (depolarization induced suppression 
of inhibition [DSI] and –excitation [DSE]) as well more persistent LTD, with a modulatory 
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role in LTP (reviewed by Chevaleyre et al., 2006). Together, clear involvement of both 
Arc expression and endogenous cannabinoid signaling in long-term forms of synaptic 
plasticity suggest that CB1-altered Arc expression may be a general mechanism critical 
for regulating changes in synaptic strength. The current report is the first to demonstrate 
a relationship between memory-essential Arc and CB1 activation. 
Evidence demonstrating the importance of Arc signaling to neural plasticity has 
rapidly accumulated. For example, Arc co-precipitates and shares nearly identical 
intracellular distribution with F-actin in dendritic spines, and is a necessary component 
of actin-dependent morphological change (Bramham et al., 2010; Bramham et al., 2008; 
Guzowski et al., 2005; Lyford et al., 1995). Both Arc mRNA and protein sequences are 
highly conserved across vertebrates, and their expression during learning is so robust, 
distinct, and reproducible that it is used as an indicator of neural circuitry that underlies 
learning and memory (Guzowski et al., 2001; Guzowski et al., 2005). Arc has been 
identified as a key component of protein synthesis-dependent LTP, and is necessary for 
the consolidation of synaptic plasticity and formation of long term memories (Bramham 
et al., 2008; Pastuzyn et al., 2011; Plath et al., 2006; Ploski et al., 2008). Reductions in 
Arc mRNA and protein are associated with reduced performance in fear conditioning 
and spatial memory tasks (Guzowski et al., 2000; Zhang et al., 2011). Interestingly, 
inappropriate activation of CB1 receptors is linked to impaired memory consolidation and 
performance in the very same tasks (Abush and Akirav, 2010; Mackowiak et al., 2009). 
In other systems, Arc is associated with AMPA receptor expressing, calmodulin 
kinase-positive neurons (Vazdarjanova et al., 2006). As cannabinoid receptors are 
largely expressed presynaptically (Elphick and Egertova, 2001), this suggests that 
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effects reported herein are likely attributable to receptor activation on glutamatergic 
terminals within both NCM and Field L2, that will effectively reduce excitatory 
glutamatergic signaling. If confirmed, this arrangement has similarities to the circuitry 
between CB1–expressing, CA3-emanating Schaeffer collaterals that synapse on 
dendrites of pyramidal neurons within the CA1 region of mammalian hippocampus 
(Hoffman et al., 2010), and further implicates nidopallial regions in formation of novel, 
auditory-related memories. This is further supported by evidence demonstrating potent 
WIN inhibition of auditory sensory gating activity in rat CA3 (Dissanayake et al., 2008). 
Our results also provide additional insight into the memory-related, hippocampus-like 
function of songbird nidopallium that accumulating evidence suggests retains the song 
“template” memorized during early, auditory stages of vocal development (Gobes et al., 
2010; Terpstra et al., 2004; Thompson and Gentner, 2010). 
The pattern of novel song-stimulated Arc protein expression that we observed 
differs from that of mRNA expression previously reported. Specifically, song-stimulated 
expression of Arc mRNA appears distinctly higher within NCM than within Field L2 
(Velho et al., 2005).  In contrast we have found similar levels of protein expression 
within these regions. This suggests that Arc expression is differentially-controlled within 
regions of primary and integrative auditory telencephalon, with possible temporal 
differences in mRNA regulation. Our experiments included a 90 minutes post-
stimulation period to capture peak protein expression within NCM. The prior in situ 
hybridization studies prepared tissue earlier, and immediately following the period of 
song-stimulation (see Figure 4.4). 
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The similar efficacy of cannabinoid-decreased Arc expression within both Field 
L2 and NCM may be unexpected given distinct differences in the magnitude of CB1 
densities in the regions; much higher level expression is present within Field L2 than 
within surrounding nidopallium (Soderstrom and Tian, 2006). High-density Field L2 
expression includes several features; staining is present within cell bodies, neuropil and 
within distinct, small puncta that may represent terminal fields. Almost exclusive 
punctual staining is observed within NCM, implicating it in the Arc inhibition observed 
within both regions. This suggests that the non-punctal staining present within Field L2 
is involved in additional, endocannabinoid-mediated processes that are yet to be 
established. This also illustrates that relatively low-level cannabinoid receptor 
expression is capable of significant physiological efficacy. It is important to note that 
neither song stimulation nor WIN administration changed Arc expression within the 
thalamic auditory relay region, Ov that is also associated with distinct and dense CB1 
receptor expression.  This clearly demonstrates a selective role for Arc in perceptual 
(Field L2) and integrative (NCM) processes, that it is not simply attributable to general 
neuronal activation. 
 Conclusion 
In summary, our results demonstrate that Arc is induced by perception of novel 
auditory stimuli in a manner inhibited by CB1 receptor activation. Stimulation of Arc 
expression within auditory telencephalon is associated with rapid increases in dendritic 
spine densities, a process that is also acutely cannabinoid-reduced. Taken together, 
these results suggest an Arc-dependent mechanism involved in cannabinoid-modulated 
processes of auditory perception, integration and memory. These findings may extend 
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and provide insight to endocannabinoid signaling in other sensory systems, and CB1-
related roles in memory extinction, stress responses and deleterious effects following 
exogenous cannabinoid exposure, particularly during CNS development.  
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Figure 4.1. Simplified schematic representation of the avian auditory brain regions 
studied. The thalamic region nucleus ovoidalis (Ov) transmits primary auditory sensory 
information to thalamorecipient Field L2 (L2, shown in light grey), which projects to 
caudal medial neostriatum (NCM, shown in darker grey).   
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Figure 4.2. (A) Representative Western blot of the soluble fraction of protein isolated 
from male NCM brain homogenates. Similar to other species, the anti-Arc antibody 
labels a single predominant band of about 55 kDa (left lane).  Staining is abolished by 
preabsorption with 20 µM of the immunizing peptide (right lane). (B) Novel song 
stimulation increases Arc protein levels in zebra finch caudal telencephalon that 
contains auditory regions NCM and Field L2 (compare Silence to Song). This 
stimulation was prevented by pretreatment with the cannabinoid agonist WIN (WIN + 
Song). Blots were reprobed with an antibody directed against β-actin as an internal 
control. (C) Summary of the relative intensities of Arc:β-actin bands. Shown are means 
+/- SEM of five pooled experiments. Novel song stimulation (Song) increased Arc 
expression over that of silence-exposed controls (Silence). WIN treatment prior to novel 
song exposure (Song + WIN) reduced Arc expression. Asterisk indicates significant 
difference from Silence group, dagger indicates difference from Song group (p < 0.05, 
1-tailed t-test). 
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Figure 4.3. Double immunofluorescence labeling of Arc protein with dendritically-
associated MAP2 (630,1000X), visualized via confocal laser scanning microscopy. In an 
effort to capture Arc protein expression at its maximum level, brains of male animals 
exposed to novel song were used for these experiments. Images demonstrating Arc 
distribution alone (green), and colocalized with MAP2 (yellow, image overlays) show 
both cellular and dendritic distribution of protein. Bar = 20 µm.  
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Figure 4.4. Immunohistochemical staining of NCM (solid boxes in A,D,G) and Field L2 
(dashed boxes in A,D,G) with Arc antibody. Animals were exposed to either vehicle (D-
F) or WIN pretreatment (G-I) 30 minutes before novel song exposure.  Unstimulated 
control animals (A-C) received only silence.. At 1000X magnification, novel song 
stimultion increases cellular and neuropil Arc expression within both NCM (E) and Field 
L2 (F). J-K: Optical densities of NCM (J) and Field L2 (K) Arc expression after novel 
song exposure, and after WIN pretreatment. Novel song stimulation increases Arc 
expression by about 90%, but only by about 20% after WIN exposure. Bar in G = 300 
µm.  Bar in H-I = 30 µm. 
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Figure 4.5. Optical densities (G) and immunohistochemical staining (A-F) of Arc 
expression within Ov in unstimulated controls, after acute novel song exposure, and 
after pretreatment with WIN. The absence of cannabinoid-mediated effects on Arc 
expression within this region indicates higher-order involvement of cannabinoid 
signaling in integrating perceptual information within the auditory telencephalon. Scale 
Bar in E = 300µm. Scale Bar in F = 30µm. 
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Figure 4.6. Birds were exposed to the same 30 min song for 3 days. On days 1 and 2, 
birds received WIN (3 mg/kg), the CB1-selective antagonist SR141716A (6 mg/kg), or 
vehicle injections 30 min before song stimulations. On day 3, all groups received vehicle 
injections prior to song exposure, were euthanized 90 min afterward and brains 
processed for anti-Arc immunolabeling (A-O).  (G-I):  Habituation to novel song-induced 
Arc expression occurs in vehicle treated group as evidenced by a return to baseline 
levels. WIN exposure disrupts habituation (J-L) however, the effect is reversed with the 
antagonist SR141716A (M-O). 
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Figure 4.7. (A) Representative high power image of an NCM spiny neuron used for 
analysis. Bar = 30 μm. (B-D) Representative Golgi-Cox impregnated dendrites included 
in analysis of dendritic spine densities within (B) unstimulated control, (C) 30 min of 
novel song exposure and (D) cannabinoid-pretreated groups (3 mg/kg WIN 30 min prior 
to song exposure). (E) Novel song perception results in significant increases in dendritic 
spine densities within NCM. Note that this effect was produced rapidly after acute 
auditory exposure (animals were killed 90 min following song exposure). Cannabinoid 
pretreatment (30 min prior to song exposure) with 3 mg/kg WIN prevents rapid 
increases in spine densities. 
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CHAPTER 5: GENERAL CONCLUSIONS 
INTRODUCTION 
Cannabis is the most commonly used illicit substance in the world among 
teenagers and young adults, and has been demonstrated to clearly possess the 
potential for addiction in humans (Gardner, 2002). In fact, close to 20% of users who 
begin during adolescence develop an addiction to these agents, a rate doubling that 
reported for users that begin in adulthood (Chen et al., 1997; Rubino and Parolaro, 
2008). The age of first marijuana use has significantly decreased, which has caused 
much concern within the healthcare community (Earleywine, 2002). Furthermore, there 
have been increasing reports of adolescents requiring medical attention as a result of 
using designer cannabinoid drugs, which on average are 25 times more potent than the 
organic plant resin. Despite this upward trend in cannabinoid consumption among 
adolescents, relatively little is known about the lasting neurophysiological consequences 
of this behavior. It is disturbing to recognize that an agent so widely consumed among 
individuals of this age group has the potential to alter behavior and neural function in 
manners that lasts throughout adulthood (Gilbert and Soderstrom, 2011) (Bossong and 
Niesink, 2010).  Adolescence is marked by a period in which several active neuroplastic 
changes occur that render the organism capable of mature behaviors, including circuit 
maturation and reorganization, and changes in neurotransmitter system levels.  
Because of this, it is unsurprising that more than any other period in life, this period of 
brain development is simultaneously vulnerable to the effects of psychoactive drug 
exposure, gonadal hormones, and environmental factors (Rubino and Parolaro, 2008).  
These findings are extended by the fact that most of the persistent changes in behavior 
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and brain morphology are not produced following similar cannabinoid exposure to adults 
(Ehrenreich et al., 1999; Wilson et al., 2000).  Our laboratory has utilized the zebra finch 
song learning model because it offers a number of advantages over other systems of 
drug altered cognitive performance; Firstly, zebra finches are one of the few species of 
animals that undergo vocal learning as humans do. This unique feature allows us to 
draw very close parallels between what we morphologically observe following persistent 
cannabinoid-disrupted learning and memory formation, and what is hypothesized to 
occur in analogous regions of the human telencephalon. Secondly, not only is the vocal 
behavior produced after learning highly stereotyped, and reproducible, but learning 
takes place during a restricted time period.  This feature results in less variability 
between animal subjects, and offers us more control within experiments. In addition, the 
restricted time period in which song takes place is adolescence, the time in human 
postnatal life that possesses the most potential for neuroplasticity, and subsequently is 
most vulnerable to the effects of exogenous drug consumption. Lastly, the density, 
distribution, and expression patterns of CB1 receptors are extremely similar to what is 
seen in humans.  
  Thus, experiments with the zebra finch model of cannabinoid-altered vocal 
development have enabled us to study the pharmacological effects of these agents in 
the context of vocal learning. The fact that drug abuse typically both begins in 
adolescence and involves Cannabis, makes the distinct efficacy of cannabinoids on the 
CNS during late-postnatal development of particular relevance to the problem of human 
substance abuse (Fontes et al., 2011).    
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Our previous experiments determined that once daily developmental cannabinoid 
agonist treatment during zebra finch adolescent sensorimotor vocal learning reduces 
numbers of song notes, and causes reduction in song stereotypy – characterized by 
disordered and repetitive note production (see (Soderstrom and Johnson, 2003)). We 
also determined that this ability of cannabinoids to alter vocal learning is restricted to 
development, as treatment of adults already having undergone song learning are 
rendered ineffective in this manner. Interestingly, developmental cannabinoid exposure 
produces greater effects on stereotypy when given early in adolescence, and greater 
effects on note number later (Soderstrom and Tian, 2004).  Together these results 
suggested that the behavioral differences seen might correlate with certain alterations in 
CNS morphology, in reverse of what is normally seen during postnatal development.  
It is a well-known fact that changes in neurophysiology often precede changes in 
behavior, and as a result, this project sought to identify some of these changes that 
accompany cannabinoid-altered zebra finch CNS development. Behavior is the result of 
a great number of physiological processes working in concert to produce responses to 
our surrounding environment, thus, we aimed to identify three distinct and persistent 
physiological changes associated with inappropriate CB1 receptor activation during 
periadolescent development.  
CANNABINOID-ALTERED VOCAL DEVELOPMENT CORRELATES WITH 
INNAPROPRIATE DENDRITIC SPINE INCREASES 
First, and most importantly, we were able to establish a framework for 
cannabinoid-altered gross morphology within the zebra finch CNS, and gain insight into 
the extent to which cannabinoid signaling controls dendritic spine and somatic 
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morphology. CNS gross anatomy is established early in postnatal development, in 
humans by age five (Giedd et al., 2009).  Despite gross similarities between brains of 
juvenile and adult vertebrates, more subtle developmental changes associated with 
adolescence also occur.  These changes are characterized by increased myelination, 
decreased grey matter, reduced synapse numbers and dendritic spine densities in 
adulthood (Rakic et al., 1994). 
Zebra finch vocal learning is accompanied by normal decreases in telencephalic 
dendritic spine densities within regions essential for auditory learning and vocal motor 
production.  Song region spine densities increase rapidly following initial exposure to 
tutor song during the early auditory learning stage of zebra finch vocal development 
(Roberts et al., 2010).  Similar to the Initial profusion of dendritic spines within song 
regions are diminished with experience and behavioral maturation.  Spine densities 
normally decrease within some telencephalic song regions from adolescence to 
adulthood, coincident with vocal practice and auditory feedback associated with 
sensorimotor learning (Wallhausser-Franke et al., 1995).  Coincident spine density 
changes and normal vocal development led us to test whether cannabinoid-altered 
vocal development may be attributable to effects on dendritic spines.  Cannabinoid 
treatments that altered vocal development persistently resulted in elevated dendritic 
spine densities compared to control brains, and suggest that adolescent exposure 
interferes with normal reductions in dendritic spines (Gilbert and Soderstrom, 2011).   
  We found that IM injections of WIN intosong-tutored juveniles during 
sensorimotor learning (50 – 75) days, not only produces the persistently altered song 
behaviors demonstrated previously (Soderstrom and Johnson, 2003), but results in a 
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27% increase in dendritic spine densities within Area X, and a 31% increase in spine 
densities within HVC. In addition, neuronal cell morphology was significantly altered 
within HVC. Concomitantly, we did not observe any of these morphological differences 
within the song regions of adult zebra finches that had completed sensorimotor learning.  
HVC is considered the apex of the zebra finch song system; it is the site where the SMP 
and AFP converge upon one another (Mooney, 2009a).  As stated previously, HVC 
plays important roles in both song production and sensorimotor learning.  The zebra 
finch brain is organized quite differently than the human brain (instead of having a 6-
layered cortex, they possess nucleated regions), but they do possess analogs (Jarvis et 
al., 2005).  HVC is thought to be the avian analog of Broca’s area, the brain region that 
governs speech and language functions; this is supported by a great deal of evidence. 
Human speech, language acquision and other language-related neural activity display 
left-sided dominance (Friederici and Alter, 2004; Raboyeau et al., 2010).  Moorman and 
colleagues recently discovered that when zebra finches were exposed to tutor song and 
novel song, HVC displays identical lateralization to that of Broca’s area, regardless of 
the type of song stimulus presented. Furthermore, like Broca’s area, zebra finches 
display temporal left-sided dominance associated with memory formation early in 
development (sensory learning) that subsequently fades after memory formation 
(Moorman et al., 2012). In a striking comparison to the motor/cognitive capabilities of 
Broca’s area, HVC provides sensorimotor integration, and precise movement of the 
vocal organs.  Altered speech-related behavioral manifestations seen in our animal 
model after developmental cannabinoid administration are very similar to what is seen 
in aphasiac patients (Hutsler and Zhang, 2010). Additionally, there are correlations 
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between high dendritic spine densities within Broca’s area, and decreased language-
related function in other vocal communication- related disorders such as ASD (Hutsler 
and Zhang, 2010);  perhaps these findings are extended to patients with Broca’s 
aphasia as well. Surprisingly, only eight differences exist between the human FOXP2 
gene and Foxp2 in zebra finch, which means these genes share a very high degree of 
homology (Haesler et al., 2004).  FOXP2 is implicated in modulating language-related 
neural plasticity within the brain, especially Broca’s area; mutations in human FOXP2 
cause severe deficits in speech and language, and genetic deletion of Foxp2 in zebra 
finch Area X result in very similar deficits in vocal learning, an effect that is correlated 
with increased spine densities within this region (Schulz et al., 2010). The morphological 
findings in our study may provide evidence for a neurochemical vocal communication 
network mediated by the cannabinoid system.  
VOCAL DEVELOPMENT-ALTERING CANNABINOID EXPOSURE PERSISTENTLY 
CHANGES EXPRESSION PATTERNS AND DENSITIES OF AXONAL AND 
DENDRITIC PROTEINS IN ZEBRA FINCH SONG REGIONS 
Next, we sought to correlate the behavioral and neuromorphological changes 
seen previously with changes in levels of proteins related to cell signaling and 
morphology.  During CNS development, CB1 receptors located on growth cones 
mediate axonal and dendritic guidance through a Gi/O-dependent mechanism, by 
eliciting chemotactic responses  (Berghuis et al., 2007) (Vitalis et al., 2008; Watson et 
al., 2008). These turning responses correlate positively with increased activation of 
RhoA, an actin-depolymerizing enzyme involved in neurite retraction and growth cone 
collapse (Gallo and Letourneau, 2004; Tagliaferro et al., 2006).  Mechanisms of 
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cannabinoid regulation of axonal and dendritic differentiation established in vitro are 
now being studied in the context of developing brain.  Embryonic initiation of cortical 
pyramidal cell axonal outgrowth appears to be promoted by CB1 activation (Mulder et 
al., 2008), an effect that suggests that cannabinoid signaling plays opposing roles at 
different developmental stages, by initially promoting neurite outgrowth, but proceeds to 
stagnate growth following differentiation (Soderstrom and Gilbert, 2012). 
A combination of CB1 deficient mice and conditional mutants capable of 
expressing GFP in thalamocortical- and corticothalamic projection neurons, were used 
by Wu and co-workers to  demonstrate that CB1 activation is critical for appropriate 
axonal pathfinding and target recognition (Wu et al., 2010).  Pathfinding deficits in these 
developing mice were associated with aberrant migration through the striatocortical 
boundry.  This region is enriched with DAGL, suggesting that appropriate 
endocannabinoid signaling is critically important for successful axon migration through 
this region. Compelling evidence also suggests that the endogenous cannabinoid 
system also functions as a homeostatic mechanism, protecting the CNS from 
overstimulation by balancing excitatory and inhibitory synaptic input through 
mechanisms such as DSE and DSI (Marsicano et al., 2003).   
Less understood, and more critical, are the physiological consequences of 
chronically over-stimulating the cannabinoid system during adolescence.  Cannabinoids 
produce lasting changes in synaptic transmission by decreasing the probability of 
vesicular transmitter release and raising the threshold for depolarization, ultimately 
decreasing synaptic strength (Domenici et al., 2006; Katona et al., 1999; Kim et al., 
2008). These lasting changes are associated with altered neuronal morphologies (Kim 
192 
 
et al., 2008). Altered morphology is associated with significant increases in a number of 
cytoskeletal proteins and synaptic markers (Tagliaferro et al., 2006). These findings 
prompted us to investigate whether similar alterations in neuronal cytoarchitecture 
existed in our model of cannabinoid-altered vocal learning.  With the aid of 
immunohistochemical methods, we examined changes in the anatomy of the 
neurocytoskeletal network within the four song regions (HVC, RA, lMAN, Area X), 
thalamic relay regions (Ov, DLM) and cerebellum that occur with prolonged 
developmental cannabinoid exposure. Specifically, we measured levels of: 
phosphorylated neurofilament 200 (Nf-200), a protein enriched in axons and MAP2, a 
prominent dendritic and synaptic marker. We determined that spatial distribution of Nf-
200 expression was significantly increased following developmental cannabinoid 
treatments in all regions examined except for lMAN. Consistent with previous studies, 
treatment of song-crystallized adults resulted in an almost complete integrity of the 
axonal cytoarchitecture, as no significant differences were found.  We found that the 
density of dendritic- and synapse-associated protein (MAP2) was significantly elevated 
within all four song regions, and midbrain auditory region Ov following cannabinoid-
induced maintenance of dendritic spines.  
CANNABINOID AGONISM ALTERS CNS DEVELOPMENT BY INTERFERING WITH 
STRUCTURALLY-RELATED IMMEDIATE EARLY GENE EXPRESSION 
Cannabinoids influence CNS development by altering gross dendritic 
morphology; however, it is now becoming clear that in addition to this, CB1 receptors 
modulate activity and regulation of structural proteins by influencing activity-induced 
immediate early gene expression.  Immediate-early gene based mediation of synaptic 
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plasticity plays an important role in the maturation of neural circuits; this suggests a 
period exists in which the brain is particularly sensitive to these effects. For example, 
THC exposure during adolescence coincides with lasting deficits in  long-term 
recognition memory, an effect that is coupled with  significant long-term reduction in 
hippocampal expression of several oxidative stress- and cytoskeleton-related proteins 
(Soderstrom and Gilbert, 2012).  These proteins include mortalin/GRP75, important to 
cellular differentiation and malignant transformation (Quinn et al., 2008; Wadhwa et al., 
2002) and NP25, a CNS-specific, F-actin binding protein necessary for actin assembly 
(Mori et al., 2004).  The idea that cannabinoid-altered vocal development is associated 
with inappropriate maintenance of dendritic spine densities (Gilbert and Soderstrom, 
2011) led us to question whether CB1 regulation of activity-induced effector protein 
expression may play a role in these structural differences.  Such structurally-relevant 
proteins with established involvement in the zebra finch vocal development model 
include postsynaptically- restricted caspase-3 (Huesmann and Clayton, 2006) and Arc 
(Moorman et al., 2011; Velho et al., 2005). 
Similar to caspase-3, Arc is an effector-type immediate early gene induced by 
activity-dependent presynaptic depolarization (Tzingounis and Nicoll, 2006).  It has 
been well-studied in hippocampus and is necessary for LTP, LTD and memory 
consolidation (Bramham et al., 2008).  Arc regulation of synaptic plasticity appears 
related to promotion of AMPA receptor internalization, which involves an interaction with 
morphologically-relevant proteins including endofilin, dynamin and cofilin that 
subsequently modulate F-actin function (Huang et al., 2007; Waung et al., 2008). Our 
results demonstrate that CB1 activation effectively prevents novel song-induced Arc 
194 
 
protein expression and habituation to repeated song stimulation to correlate this 
morphological change in behavior with a CB1 receptor-mediated aberrant modulation of 
dendritic spine densities. How does CB1 receptor activation result in inhibition of 
auditory perception-related Arc expression?  It is hypothesized that CB1 receptor 
activation reduces the probability of presynaptic excitatory transmitter release (Elphick 
and Egertova, 2001a).  As Arc expression appears limited to AMPA receptor-containing 
terminals (Waung et al., 2008), the signaling relationship in zebra finch auditory 
telencephalon appears similar to that between CB1-expressing Schaffer collateral 
terminals that synapse on AMPA receptor-expressing dendrites of hippocampal CA1 
pyramidal cells (Hoffman et al., 2010; Soderstrom and Gilbert, 2012).  Through DSE, 
cannabinoid exposure raises the threshold for depolarization-dependent immediate 
early gene expression.  A reduction in postsynaptic excitation also decreases AMPA 
receptor internalization, increasing sensitivity to later excitatory input (Vazdarjanova et 
al., 2006).  Disregulated glutamatergic sensitivity will disrupt activity-dependent 
processes important to developmental selective stabilization of neural circuits. This 
hypothesis, adapted from Changeux and Dehaene, is summarized in Figure 5.1. 
(Changeux and Dehaene, 1989; Soderstrom and Gilbert, 2012). 
NEUROPHYSIOLOGICAL IMPLICATIONS 
Given the clear function of the endocannabinoid system in the general reduction 
of presynaptic neurotransmitter release, we hypothesize that high-level expression of 
the cannabinoid system during normal adolescent development, likely provides a 
neuroprotective effect against glutamate-mediated excitotoxic damage resulting from 
the increased level of synaptic plasticity during this time.  Theoretically, if CB1 receptors 
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were perpetually activated like in the case of chronic daily cannabinoid consumption, 
this would compromise the protective effect of the system, and lead to a disturbance of 
the neuron’s delicate LTP/LTD balance by causing excess glutamatergic activation, and 
consequently, an influx of postsynaptic Ca2+.  This scenario could very well lead to 
either pruning or a lack thereof, of anywhere from the synapse to the dendritic tree.  
This ultimately results in a persistent perturbance in regional neuronal circuitry and 
behavior. 
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Figure 5.1. Diagrammatic models illustrating potential mechanisms responsible for 
cannabinoid mitigation of neuronal morphological change. Panel A is adapted from the 
model proposed by Changeux and Dehaene, 1989 for late-postnatal refinement of 
neural circuitry. Panel B illustrates the potential for CB1-mediated presynaptic inhibition 
of glutamate release to prevent activation of structurally-relevant proteins important to 
zebra finch sensorimotor integration of auditory stimuli [Taken with permission from 
(Soderstrom and Gilbert, 2012)]. 
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Appendix B: PC12 experiments 
Introduction 
Cannabinoid receptor stimulation plays an essential role in the regulation of 
neurotransmitter release, thus acting to dramatically reduce neuronal plasticity in the 
CNS. It is generally agreed upon that the endogenous cannabinoid system is 
considered one of the brain’s homeostatic, de-novo mechanisms to protect itself from 
overstimulation by reducing excitatory synaptic input (Marsicano et al., 2003), but the 
physiological consequences of chronically overstimulating the cannabinoid system itself 
are not fully understood. Results from numerous studies indicate that periadolescents 
(including humans) exposed once daily to the cannabinoid agonist WIN during postnatal 
brain maturation and sensorimotor learning exhibit persistently altered patterns in 
learning and behavior. Furthermore, it is becoming increasingly clear that many of these 
observations regarding daily periadolescent cannabinoid exposure extend more directly 
to consequences such as persistently impaired CNS morphology and sensorimotor 
gating that  last throughout adulthood (Tahir et al., 1992).  For example, in the 
periadolescent zebra finch, we recently discovered that this development-altering 
cannabinoid treatment leads to an inappropriate maintenance in dendritic spine 
densities in a subset of brain regions responsible for vocal learning, an effect that is 
strongly associated with a marked decrease in production of learned stereotyped song 
(Gilbert and Soderstrom, 2011). In a CHO cell culture model, cannabinoid treatment is 
associated with a drastic reorganization of microfilaments and microtubules, both major 
factors in the control of neuronal shape and growth (Tahir et al., 1992).  In the 
hippocampus, cannabinoid receptor stimulation is associated with a tonic autoinhibition 
237 
 
of a population of GABAergic neurons, and causes a decrease in glutamate release in 
principal neurons (Domenici et al., 2006; Katona et al., 1999; Kim et al., 2008). These 
lasting changes in transmission alter cellular morphologies in many instances (Kim et 
al., 2008).  
Although mechanisms behind periadolescent cannabinoid altered learning and 
CNS development largely remain uninvestigated, a few studies recently indicated a 
number of potential neural targets that may be affected by inappropriate cannabinoid 
receptor activation. In particular, Tagliaferro et al. reported significant increases in a 
number of cytoskeletal proteins and synaptic markers with respect to chronic WIN 
treatment of adolescent Wistar rats (Tagliaferro et al., 2006). These findings prompted 
us to investigate our hypothesis of whether similar alterations in neuronal 
cytoarchitecture can be identified in our model of cannabinoid-altered vocal learning as 
well, and if so, whether these morphological changes persist throughout adulthood.  
In order to identify potential cannabinoid-induced morphological changes in real 
time, a neuronal cell culture model that adequately expresses CB1 receptor is 
necessary.  The previously observed morphological changes in zebra finch 
telencephalon following cannabinoid treatment promped us to consider cannabinoid 
effects on synaptic loss, neurite outgrowth and neurogenesis on the PC12 cell culture 
system. This cell line is a well-characterized system which can be induced to form 
neurites upon stimulation with nerve growth factor. This aspect is advantageous, as 
neuronal differentiation in this model heavily depends on the controlled reorganization of 
the cytoskeleton, a characteristic that cannabinoids are known to significantly disrupt in 
other systems. After assessing whether this cell line can endogenously express 
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functional CB1 receptors, we discovered that when in a low-glucose environment, CB1 
expression in these cells is undetectable, which allows heterologous expression of the 
zebra finch CB1 receptor in a neuronal system with a virtual “clean slate” in this respect.  
In order to begin to assess mechanisms involved in cannabinoid-altered gross neuronal 
morphology, we constructed a functionally expressing zebra finch CB1 HIV-based 
lentivector for stable infection of PC12 cells. These experiments will be performed on 
both pre-differentiated and undifferentiated PC12 cells in an effort to access the 
cannabinoid effects on processes related to neurite formation and regression, such as 
neurite length, number of branches per process (arborization), number of spines per 
process per neuron (spine densities), and cell densities as compared to a control 
group).  
Materials and Methods 
Materials  
All materials and reagents were purchased from Sigma (St. Louis, MO), or VWR 
International (Radnor, PA).  Disposable plasticware was purchased from Corning 
(Corning, NY).  cDNA synthesis, PCR, and reagents used for molecular cloning the 
zebra finch CB1 receptor were purchased from Invitrogen Laboratories (Grand Island, 
NY). HIV-based lentiviral packaging vectors and system were purchased from Systems 
Biosciences (Mountain View, NY).  RNA isolation solution was purchased from Fluka 
Chemicals (St. Louis, MO). Radiolabeled full CB1 agonist [
3H] CP 55,940 was 
purchased from Perkin Elmer (Boston, MA). Equithesin was prepared from reagents (40 
% propylene glycol, 10 % ETOH, 5 % chloral hydrate, 1 % pentobarbital). The synthetic 
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cannabinoid agonist WIN was suspended in vehicle from concentrated DMSO stocks 
(10 mM). Vehicle consisted of a suspension of 1:1:18 DMSO:Alkamuls EL-620 (Rhodia, 
Cranberry, NJ):phosphate-buffered saline. 
Preparation of Zebra Finch Synaptosomal Membranes 
 Washed P2 synaptosomal membranes were prepared from 50-day old male 
zebra finches as described in the Materials and Methods section, and as previously 
described in (Soderstrom and Johnson, 2000). 
Radiolabeled Receptor Binding of CB1   
 Radioligand binding experiments were conducted according to protocols 
developed by (Soderstrom and Johnson, 2001).  The 3H-labeled synthetic cannabinoid 
agonist CP-55,940 (180 Ci/mmol) was used in these experiments because it possesses 
a higher specific activity than many other radioligands, and because it has been used in 
the past to characterize cannabinoid receptors in the zebra finch and other species 
(Pertwee, 1997; Soderstrom and Johnson, 2001).  Binding reactions were conducted in 
a final volume of 200 μl solution containing 50 mM Tris/ 10 mM MgCl2, 5 mg/ml BSA, 
and 0.1 % DMSO. A total of 100 μg of zebra finch P2 membrane protein, and 100 µg of 
PC12 cell lysate were used in each replicate for saturation isotherms. Nonspecific 
binding was defined as binding of 3H-labeled CP-55,940 to other receptor sites and 
adsorption to the membranes in the presence of a vast molar excess of drug (1μM WIN, 
diluted from a 10X stocks).  Specific binding was calculated as the difference between 
the total binding and nonspecific binding. Saturation binding experiments were 
conducted in a 24-well format, incubated at 30° C for 90 minutes, and terminated by 
rapid filtration over GF/C glass fiber filters (Brandel Incorporated, Gaithersburg MD).  
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Filters were washed immediately after termination with 50 mM Tris/10 mM MgCl2, at 4° 
C. Following this, filters were dried for 1 hour, and then quantified using a Packard 
2200CA Tri-Carb liquid scintillation analyzer (Perkin Elmer, Boston MA). Tritium 
efficiency was approximately 50 %. Radioligand binding data were analyzed using 
GraphPad Prism 5.0 software (San Diego, CA). The relative appropriateness of one-site 
binding models was compared with two-site binding models was compared through F 
tests, in order to determine if additional parameters improve the fit of the data to more 
complex equations (Bylund and Toews, 1993; Frey and Albin, 2001). 
Cell Culture  
PC12 cells were maintained and propagated in complete RPMI 1640 media, and 
HEK-293TN cells were maintained and propagated in complete DMEM media. Both cell 
lines were incubated at 37° C supplemented, with 5 % CO2 and subcultured as 
described in the Materials and Methods section.  
Cloning of CB1 and Transfection of PC12 Cells 
A zebra finch CB1-expressing mammalian vector was first constructed in pcDNA 
3.1+ for transient lipid-based transfection of PC-12 cells.  Molecular cloning methods 
used were as described in the Materials and Methods section (Chapter number)? The 
forward primer 5’-ATGAAGCTTAGTC ATGAAGTCAATTCTAGATG and reverse primer 
5’-ATGCTCGAGTTACAACGCTTCAGCTGT were designed based on the complete 
coding sequence provided to GenBank by (Soderstrom and Johnson 2001), Accession 
number AF255388. The restriction sites XhoI and HindIII were incorporated into the 
design of the primers. Standard PCR procedures were performed with an annealing 
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temperature of 72°C. The amplified PCR product was then TA-subcloned into vector 
PCR 2.1, and used to transform DH5α E.Coli cells using protocols listed in the Materials 
and Methods section. Inserts were digested and sequenced, 3130 Genetic Analyser 
(Applied Biosystems, Carlsbad CA) then inserted into the mammalian expression vector 
pcDNA 3.1+ for further use.   
Because PC12 cells are notoriously difficult to transfect, and are extremely 
vulnerable to cytotoxicity during transfection. We attempted to transfect cells with the 
more gentle Lipofectamine LTX and Plus reagent. Approximately 1 µg of DNA was used 
per reaction, and transfection methods were performed as described in the Materials 
and Methods section.  
Transfection of HEK-293TN Cells 
Production of a high-titer of lentiviral particles was accomplished by simultaneous 
transfection with lentiviral expression and packaging plasmids into the HEK-293TN 
packaging cell line. Transfection protocols were adapted from instructions provided by 
Systems Biosciences (Mountain View, CA), and infections were adapted from methods 
used by (Soderstrom and Johnson, 2000).  One day prior to transfection, cells were 
counted and approximately 8.0 x 106 cells seeded into a sterile T75 flask, in DMEM 
containing 10 % FBS with no antibiotics/antimycotics. The next day, when cells reached 
17 % confluency, cells were transfected with the lentivector pCDH-CMV-MCS (Systems 
Biosciences Cat# CD500B-1), containing cDNA encoding the zebra finch CB1 receptor. 
Breifly, 1.6 ml of serum free DMEM was added to 4.5 µg of plasmid DNA, and mixed 
with 40 µl of Lipofectamine™ reagent, and mixed gently by pipetting. This mixture was 
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incubated for 30 minutes at room temperature in order to allow DNA-Lipofectamine™ 
complexes to form. Following this, the DMEM-plasmid-Lipofectamine™ mixture was 
added drowpise to the  T75 flask, and swirled around in order to ensure even 
distribution throughout the plate. Cells were returned to a quarantined incubator 
supplemented with 5 % CO2 at 37° C.  At approximately 72 hours after transfection, 
media was collected and centrifuged at 3000 x g, and stored at - 80° C until use. 
pseudoviral titers were determined  by transduction of PC12 cells with the lentivirus, 
followed by microscopic analysis.  
Lentiviral Infections 
The day before infection, undifferentiated PC12 cells were seeded in 6-well 
plates at a confluency of 50%, and differentiated PC12 cells were subcultured into 6-
well plates at a confluency of approximately 30%. The next day, culture medium was 
removed via serological pipetting, and 2 ml of complete DMEM culture media containing 
viral suspension and 5 µg/ ml of Polybrene was added to each well.  To determine the 
effect of viral incubation time on CB1 receptor expression, cells were incubated in viral 
media for varying time periods, then fixed and subjected to immunostaining described 
below. If applicable, media was replaced every 12 hours. Cultures co-transfected with 
EGFP-expressing vector were used as controls.   
Drug Treatments 
The day following transfections, cultures will be treated with various 
concentrations of WIN (0, 1, 3, 10, 30, 100 nM) for four days, with fresh drug-containing 
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media replaced daily. Morphological measures (neurite length, number of branches per 
process, number of spines per process per neuron and cell densities) will be recorded. 
Immunostaining of Infected Cells 
In an effort to immunostain cells for CB1, cultures were grown on 22 x 22 mm 
glass coverslips. Cells were briefly rinsed with warm PBS, and then treated with 1ml of 
ice-cold methanol per well, and incubated at -20° C for 10 minutes. Cells were then 
blocked with a solution containing 5% BSA in PBS for 30 minutes with gentle agitation. 
Culture dishes containing the glass coverslips were incubated in a primary antibody 
mixture (1:1000) containing anti-CB1 antibody in the 5 % BSA/PBS solution overnight at 
4° C. The next day, cells were washed three times with ice-cold PBS, and then 
incubated in FITC-conjugated goat anti-rabbit secondary antibody (1:1000) for thirty 
minutes at room temperature, for 1 hour in the dark. Finally, coverslips were washed 
three times with PBS-T, then wet-mounted on slides using an anti-fade fluorescent 
mounting medium (Invitrogen, Grand Island NY). Slides were stored in the dark at -20° 
C for extended use.  
Results 
Radioligand Binding 
Saturation binding experiments were performed in order to determine the 
densities of zebra finch CB1 binding sites within PC12 membranes. Experiments 
involving saturation binding of zebra finch P2 membranes were used as a positive 
control for radioligand binding techniques (Soderstrom and Johnson, 2001). Results 
revealed that in control experiments, zebra finch binding site density (Bmax = 1800 
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fmol/mg protein, 95% CI, 1626 - 2161) These results confirm previous findings 
presented by Soderstrom et al., who in their hands, determined that Bmax = 2100 
fmol/mg of protein; 95% CI, 1917–2283) and affinity (Kd = 1.51 ± 0.14 nM).  For PC12 
cell membranes, Bmax was significantly lower than control Bmax, (Bmax = 433 fmol/mg 
protein, 95% CI, -376 - 1615).  These results are discussed below.  
Transfection of PC12 Cell Line 
Transfection of the PC12 cell line with ZFCB1 using Lipofectamine LTX and Plus 
reagent did not yield intended results.  We witnessed both a significantly reduced PC12 
cell viability by about 75% following transfection when using this method. This reduction 
in cell count severely limited the growth of the viable cells still left in the dish. It appears 
as though the low seeding density caused the cells to grow very slowly and then detach 
from the bottom of the dish. This effect was presumably due to a concentration of 
secreted growth factors in the medium that was too low to thrive on. In addition, we also 
found that PC12 cells had a transfection efficiency of about 20 %.  Although a low 
efficiency was expected on some level because of the nature of this cell line, these 
results were deemed unsuitable for our experiments.  
Infection of PC12 Cell Line with HIV-Based Lentiviral Vector 
Because of the lack of results experienced with transfection agents, we decided 
to try a more stable method of delivery provided by the lentivirus. In an order to access 
functional expression of the zebra finch CB1 receptor delivered by the virus, PC12 cells 
were grown in complete medium to 70 % confluence on glass coverslips in 6-well 
plates, and infected with a predetermined concentration of lentivirus. Exactly 48 hours 
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after infection, cells were fixed, treated with anti-CB1 antibody, and subjected to 
immunofluorescent analysis via laser-scanning confocal microscopy. Microscopic 
analysis revealed that under the conditions the PC12 cells were grown in, the CB1 
receptor was not trafficked to the cell membrane or neurite surface. Therefore, 
pharmacological experiments aimed to examine the functionality of the CB1 receptor 
could not be completed.  However, we did find that the CB1 receptor is robustly 
expressed within the cytoplasm. 
Discussion 
In this study, we aimed to investigate the gross morphological changes conferred 
to neurons by various doses of cannabinoids in real-time, using a PC12 neuronal cell 
model heterologously-expressing zebra finch CB1. We originally predicted that similar to 
most other cell lines, PC12 cells constitutively express a certain density of CB1 
receptors possessing a high affinity for WIN, regardless of culturing conditions. 
Unfortunately, a quick literature review of this subject led us to understand that the 
current consensus regarding whether this cell line actually expresses a functional CB1 
receptor is very unclear.  
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Figure AB1.  Results of PC12 radioligand binding experiments, using zebra finch 
membranes as a control. For PC12 membranes, Bmax was significantly lower than Bmax 
of control  saturation experiments.  
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In an effort to confirm our hypothesis, we proceeded to characterize the CB1 
receptor in these cells by examining the density of functional CB1 receptors within the 
membrane as well as their affinity for an agonist ([3H] CP-55940). In order to determine 
Bmax for PC12 cells, saturation binding experiments were performed with PC12 cell 
lysates using zebra finch P2 membranes as a control. We found that binding was 
significantly low in experimental groups, which led to a series of possible scenarios: 
either (1) either the PC12 cells assayed possessed a very low CB1 receptor density, but 
a comparable affinity (low Kd) to the zebra finch CB1 receptor, or (2) these cells 
possessed a considerable CB1 receptor density, however these receptors possessed an 
extremely low affinity for the ligands used.  After reviewing the generated data in its 
entirety, we concluded that the former of the two scenarios had taken place. At first 
consideration, we found these data to be quite contradictory to our predictions, but 
recent studies regarding a novel role for CB1 in diabetic neuropathy shed light on this 
issue. In these studies, researchers determined that within PC12 cells, the CB1 receptor 
is selectively expressed under certain cell culturing conditions. In high-glucose 
conditions, CB1 becomes internalized, as evident by a lack of protein expression on the 
neuronal membrane (Zhang et al., 2007). In contrast, low concentrations of glucose, 
which is needed in order to differentiate PC12 cells into neurons, were associated with 
an increase in CB1 receptor expression. We were unable to utilize this cell line without a 
method of controlling CB1 receptor expression in the presence of different culturing 
conditions, so we made preparations to create a heterogolously-expressing zebra finch 
CB1/PC12 cell line. 
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 We were successful in constructing a zebra finch CB1-expressing mammalian 
vector (in pcDNA3.1+) for transient lipid-based transfection of PC12 cells, and 
subsequently a HIV-based CB1 lentiviral vector for stable infections. Pharmacological 
experiments were intended to be performed on pre-differentiated (with 50 ug/ml nerve 
growth factor for 3 days) and differentiating PC12 cells to assess effects on processes 
of neurite formation and regression, and immunochemical measures of PSD-95, MAP2, 
NF-200, and synaptotagmin were to be taken in separate cultures however, a number of 
setbacks occurred that prevented us from pursuing this study further. Unfortunately, the 
CB1 receptor failed to express at the PC12 cell membrane surface, so experiments were 
not moved forward (Figure AB2).  
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Figure AB2. A) Immunofluorescent confocal image of PC12 cells heterologously 
expressing CB1 receptor. Note the lack of expression on the cell membrane surface, 
and the high levels of expression within the cytoplasm. B) DIC darkfield image of the 
same cell field as pictured in A. C) Control PC12 cells infected with GFP-expressing 
lentivirus. 
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A number of mechanistic factors could have contributed to this issue. Firstly, It could be 
possible that within the PC12 cell line, cell signaling mechanisms that govern receptor 
internalization and recycling (such as cell anchoring cascades, microRNAs) are 
expressed more readily than those that govern CB1 receptor expression (Avraham and 
Yarden, 2012). Furthermore, it may be the case that this CPCR will only function as a 
homo/heterodimer in the PC12 cell line, and the adhesion molecules necessary for this 
to take place are not present, or are in low number within the cell. Also, it is possible tht 
the expression of other GPCRs may hinder factors and mocular machinery necessary 
for expression. Future experiments will aim to determine this caus
APPENDIX C: Caspase-3 Experiments 
INTRODUCTION  
Cannabinoids, the active constituents of marijuana, are known to produce an 
array of behavioral changes in most vertebrate species, including disruptions in learning 
and memory formation, reductions in locomotor activity, and various psychoactive 
effects. The central actions of these compounds have been attributed to activation of 
the cannabinoid receptor 1 (CB1).  CB1 receptors are enriched in various forebrain 
areas, including the cerebellum, hippocampus, forebrain, and basal ganglia which 
correlates with well-documented influences on locomotor coordination, anxiolysis, and 
increases in reward-like behaviors present in models of drug addiction (El Manira and 
Kyriakatos, 2010; Fernandez-Ruiz et al., 2010; Kinsey et al., 2011). 
More intriguing, and less understood, are the effects of cannabinoids on the 
neural aspects of learning and memory formation. It is thought that cannabinoids 
influence the acquisition and consolidation of sensory stimuli, though the precise 
specifics remain unclear.  Recent observations have led to the hypothesis that caspase-
3 likely plays a role in at least one form of cannabinoid-induced disruption of cognitive 
function.  It has been shown that the cysteine-aspartic protease caspase-3, a terminal 
mediator in a major cascade that leads to programmed cell death, plays a non-apoptotic 
role in healthy neural tissue during postnatal development, growth, and adulthood 
(Chen et al., 1998; Liu et al., 2008).  Throughout the scientific community the role of 
caspase-3 in the cell is most widely studied in the context of global apoptosis.  When 
cells undergo caspase- dependent apoptosis, 32 kDa pro-caspase 3 is processed by 
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caspases 8, 9, and 10 into 17 kDa and 12kDa subunits, which ultimately lead to the 
formation of an activated caspase-3 complex when assembled as a tetramer (Huppertz 
et al., 1999; White et al., 2008).  At this point, activated caspase-3 cleaves a site on 
caspase 9 that is usually bound by XIAP in a non-apoptotic state, which in turn prevents 
this inhibitor from sequestering caspase 9. Under these conditions, caspase-3 is free to 
destroy a number of proteins necessary for survival, and the cell is irreversibly 
committed to death (Denault et al., 2007; Huppertz et al., 1999).  However, studies have 
indicated that caspase-3 plays a major regulatory role in neuronal development, 
signaling, remodeling, and forms of learning and memory acquisition. For example, in 
Drosophila, descrete, localized caspase-3 activity has been shown to direct the 
phagocytic engulfment of severed dendritic spines during pruning (Williams et al., 
2006).  Administration of Z-DEVD-FMK, an inhibitor of caspase-3, inhibits long-term 
potentiation in rat hippocampal slices, and long term sensitization in the terrestrial snail 
helix (Bravarenko et al., 2006; Guliaeva, 2004; Gulyaeva et al., 2003).  By examining 
the role of caspase-3 in the song-specific zenk habituation response of the adult zebra 
finch, Huesmann and Clayton suggest a mechanism by which caspase-3 is tightly 
controlled at specific synaptic sites in an effort to regulate neuronal plasticity 
(Huesmann and Clayton, 2006).  In this model, hearing a novel conspecific song 
stimulus causes a robust induction in the immediate early gene zenk in NCM, a 
forebrain region involved in higher order processing of auditory stimuli (Chew et al., 
1996; Mello and Clayton, 1994; Mello et al., 1992).  However, after repeated 
presentations of the same song, the zenk response habituates, thus creating a 
molecular representation of context-specific memory (Chew et al., 1995; Stripling et al., 
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1997).  They effectively demonstrated that activated caspase-3 is constitutively present, 
but sequestered, in postsynaptic neurons, and is thought to be locally released upon 
demand. This activation was required in order to facilitate the zenk-induced long-term 
habituation response to song. In accordance with this data, it has been recently shown 
that cannabinoid administration reduces zenk mRNA levels in the NCM by almost 60% 
following novel song presentation, and blocks the zenk habituation response after 
repeated stimulus presentation (Whitney et al., 2003).  
The studies presented herein were conducted in order to test the hypothesis that 
the cannabinoid reduction of long term song habituation in zebra finch NCM involves a 
direct inhibition of activated caspase-3, which in turn blocks the emergence of the zenk 
response. 
EXPERIMENTAL PROCEDURE 
Materials 
Except where noted, all materials and reagents were purchased from Sigma (St. Louis, 
MO), or Fisher Scientific (Pittsburgh, PA). The synthetic cannabinoid agonist 
WIN55212-2 (WIN) used for injections was suspended in vehicle from concentrated 
DMSO stocks (30 mM). Vehicle consisted of a suspension of 1:1:18 DMSO:Alkamuls 
EL-620 (Rhodia, Cranberry, NJ):saline.  
Animals 
Adult male zebra finches aged over 110 days old were used in these experiments. Birds 
were obtained from our breeding aviary, and caged with free access to grit, water, 
mixed seeds (Sunseed VitaFinch), and cuttlebone, and provided multiple perches.  
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Animals were maintained on a 14:10 light/dark cycle, and ambient temperature was 
maintained at 78° F.  Birds were housed from 25-50 days of age with an adult male 
tutor, and then moved to a flight cage containing 12 adult males. Birds used in individual 
experiments were removed from adult flight cages and housed in visual isolation, in 
soundproof recording chambers in order to acclimate to the environment. Birds were 
cared for and experiments conducted according to protocols approved by East Carolina 
University's Animal Care and Use Committee.  
Activation of Caspase-3 in Zebra Finch NCM 
An established protocol was adapted(Whitney et al., 2003) in an effort to determine 
whether cannabinoid exposure interfered with caspase-3 activation in zebra finch NCM 
following novel song exposure.  Two birds were exposed to song, while one bird was 
exposed to continued silence.  Birds were injected with either 3mg/kg WIN 55212-2 
(WIN) or vehicle in the morning, thirty minutes before lights on. Naïve animals were 
exposed to a 10 minute song playback loop consisting of 15 seconds of a 5 second 
novel birdsong bout played three times back-to-back, followed by 45 seconds of 
recorded silence. This presentation was repeated for a total of 10 times. Immediately 
after 10 minutes of song exposure, birds were quickly anesthesized with an Equithesin 
overdose (0.05ml), and brains perfused with buffered saline, followed by 4% 
paraformaldehyde. Brains were submerged and left overnight in 4% paraformaldehyde, 
and stored in a 20% sucrose solution. 
Activated Caspase-3 Immunohistochemistry 
An antibody directed against the large fragment of caspase-3 resulting from cleavage 
(17 kDa) was purchased from Cell Signaling Technology (Danvers, MA). All serums, 
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secondary antibodies, and reagents used for immunohistochemistry were purchased 
from Vector Laboratories (Burbank, CA). The telencephalon was blocked at its lateral 
edge and sectioned at 30um, using a vibrating blade microtome (Leica Microsystems, 
Newcastle United Kingdom). Tissue was incubated in a 1% H2O2 solution for 30 
minutes, followed by a 35 minute block with 5% normal goat serum in 0.3% Triton-X-
100, and incubated overnight in antibody (1:3000 dilution).  Tissues were rinsed in PBS 
the following day, and incubated in biotinylated secondary antibody solution (1:3000 
dilution). Avidin/Biotin-HRP solutions were prepared as indicated by the instructions 
(Vector ABC elite), and reactivity was visualized with DAB solution. Tissue was 
mounted onto slides coated with 0.3% bovine gelatin, and allowed to dry. Slides were 
dehydrated in graded concentrations of ethanol (70%, 95%, and 100%) for 30 seconds 
each, followed by incubation in xylenes for 1 minute. Coverslips were immediately 
placed on slides with Permount.  
Optical Density Measurements and Statistical Analyses 
Punctate and neuropil staining was visualized using an Olympus BX51 microscope; 
Images were captured with a Spot Insight QE digital camera and Image-Pro Plus 
software (Media Cybernetics, Silver Spring MD) under identical exposure conditions. 
Using Image-Pro Plus software, these images were converted to 8-bit grayscale, and 
areas of interest were traced manually.  Data pertaining to Field L, a primary auditory 
region were reported as a ratio of mean optical densities in Field L, as compared to 
mean optical densities in tissue adjacent to this area (NCM).  The optical densities of 
treatment groups were reported relative to both vehicle and untreated animals +/- 
standard error of the mean. Data pertaining to NCM were reported as the mean number 
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of reactive nuclei per mm2 of NCM; these data were compared across all 3 treatment 
groups as well. All labeling quantification was made without knowledge of experimental 
treatments.  Data analyses were performed using Graph Pad Prism and Microsoft Excel 
PC software. 
RESULTS 
Under the treatment conditions, statistical analyses failed to detect significant 
differences between the numbers of immunoreactive nuclei in the NCM of either 
untreated, vehicle or cannabinoid treated groups. However, a one way ANOVA revealed 
that disparities between measured optical densities in Field L and NCM of untreated 
animals were significantly greater than differences between Field L and NCM of both 
vehicle and cannabinoid-treated groups (F (2,114) = 40.71, p = 0.0001). Mean optical 
densities decreased from 1.070, p < 0.05 for untreated groups, to 1.018 and 1.012, 
p<0.05 for vehicle and WIN treated groups, respectively.  
DISCUSSION 
Overall, our results strongly suggest that the methods employed in these experiments 
are not reliable for accurately assessing whether cleaved activated caspase-3 is 
induced to levels comparable to previous reports in the NCM following 10 minutes of 
stimulation with a novel song (Huesmann and Clayton, 2006).  While we acknowledge 
that a portion of data collected bore weak statistical significance, we speculate these 
differences between antibody staining intensities in auditory Field L of untreated and 
treated groups are most likely due to differences in tissue handling. Concomitantly, the 
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hypothesized manner in which cannabinoids may interact with activated caspase-3 to 
decrease song-induced habituation in zebra finches remains to be seen.   
It is likely that following one or a combination of several procedures in this study that 
differed from previously reported methods used to obtain similar data has led to 
deviations from expected results. Foremost, selection of more appropriate controls for 
our experiments will lead to the means to make more accurate comparisons.  Adding a 
negative control group, in which naïve birds are exposed to 10 minutes of silence during 
the time in which birds in treatment groups are exposed to song will allow us to 
accurately assess whether 10 minutes of song exposure induces activated caspase-3 
levels above the baseline in our hands, as is reported in the literature.  In addition, 
creating a more “novel” song recording may increase the probability of inducing 
adequate levels of caspase-3 expression. A number of researchers report using novel 
song recordings consisting of 5 seconds of song from three different conspecific males, 
played in sequence. The duration of this presentation is 15 seconds, separated by 45 
seconds of silence, and thus each 1 minute of presentation corresponds to 15 seconds 
of song. Although currently there is little criteria available for determining the novelty of 
perceived song in each individual case this method may in turn decrease the likelihood 
that the animals will habituate to recorded song loops early.  Activation of caspase-3 
levels in NCM following song stimulation is a transient event. Prolonged maintenance of 
cytoplasmic caspase-3 levels is presumably self-destructive to the neuron, thus rapid, 
local activation, followed by deactivation via sequestration is a necessary event 
(Mattson et al., 1998). During sessions in which animals are exposed to song, activated 
caspase-3 levels begin to rise significantly at 2 minutes, peak at 10 minutes, and then 
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rapidly decline to baseline levels around 20 minutes. Our procedure mandated that 
birds be anesthetized, and perfused with buffered saline followed by 4% 
paraformaldehyde.  With this approach, starting from the moment at which animals 
received Equithtesin injections, brain processing time averaged around 30 minutes, thus 
likely preventing us from capturing peak levels of enzyme activation. Perhaps utilizing  
more rapid techniques for capturing/processing tissue, such as using a gaseous mixture 
of 5 % isofluorane mixed with 95 % oxygen, or quickly decapitating the bird, dissecting 
the tissue of interest, and snap-freezing in cold ethanol will allow for better preservation 
of the signal (Huesmann, 2005).  In our experiments, an antibody directed against 
active caspase-3 was used in an attempt to directly measure signal induction in NCM; 
however, several problems with this method have been reported. Due to the nucleated 
structure of the avian forebrain, especially the NCM, neurons are anatomically 
organized into clusters, or “micro-nuclei” that can make visually distinguishing between 
labeled and non-labeled cells extremely challenging.  For example, Huesmann et al. 
report that upon titratrating the antibody to obtain optimal concentrations and observing 
a significant difference between groups, an unusually high amount of background 
staining was still present in the region. Alternatively, the authors used a biotinylated 
amino-acid short peptide (biotin-DEVD-cho) known to specifically bind to the substrate 
recognition pocket of cleaved activated caspase-3 in its tertiary folded form, and 
observed significantly lower background staining(Huesmann and Clayton, 2006). 
Perhaps applying this method of epitope detection in concert with the aforementioned 
strategies will aid in yielding more accurate results in our future experiments.
APPENDIX D: Notch1 Experiments 
ABSTRACT 
Traditionally, Notch receptor signaling is regarded as among the most essential 
constituents of mechanisms known to regulate vertebrate CNS development. However, 
because of significant advances in genetic and molecular neuroscience, it is becoming 
increasingly clear that Notch signaling possesses more integrative roles in controlling 
adult neural morphology and synaptic plasticity than previously thought of.  Notch1 is 
dynamically regulated by the immediate-early gene Arc in response to changes in 
activity at the synapse induced by novel stimulus learning; this action is required for the 
synaptic plasticity necessary for memory formation.  Through previous work in adult 
zebra finches, we identified a strong causal relationship between acute cannabinoid 
reduction in dendritic spine density changes that normally occur during learning, and a 
proportional acute cannabinoid-reduction in activity-induced Arc protein expression after 
presentation of a novel song stimulus.  While both studies suggest clear roles for 
context-dependent Notch1 signaling and CB1 in events necessary for sensorimotor 
learning and proper memory acquisition, it remains unclear whether these two proteins 
interact with Arc or other known plasticity genes that disrupts learning-related dendritic 
spine plasticity.  Using the zebra finch song-stimulus auditory habituation model, we aim 
to determine whether activity-induced Notch1 signaling is required for plastic changes 
within NCM neurons during novel stimulus learning. Furthermore, we aim to explore 
whether a relationship exists between the morphological and behavioral effects of 
inappropriate cannabinoid receptor agonism, and the consequences of cannabinoid-
disruption of Notch1 activity during auditory stimulus presentation. 
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INTRODUCTION 
Normal brain development is a multi-faceted process that requires precise timing 
of neural growth and differentiation programs, and Notch signaling is a well-known 
master regulator of these events. Originally discovered and cloned from Drosophila 
Melanogaster, the Notch locus is categorized within as a neurogenic gene, a 
homozygous mutation that results in hyperproliferation of neural tissue required to 
determine neural fate, along with Notch ligands Delta, and Jagged (Lehmann et al., 
1983; Wharton et al., 1985).  In evolutionary terms, the Notch signaling pathway is a 
highly-conserved system present in almost all multicellular organisms, known for 
mediating communication in events including regulation of angiogenesis, cardiac valve 
homeostasis, the transformation of common lymphoid precursors to active T-cells, and 
many others (Laky and Fowlkes, 2008; Liu et al., 2003; MacGrogan et al., 2011). 
Spanning the cell membrane in a single pass, these integral membrane receptors 
possess the uncommon ability to communicate via juxtacrine signaling, and consist of a 
Notch extracellular domain (NECD) and a Notch intracellular domain (NICD) that 
function primarily as two distinct functional entities. In more specific terms, these 
receptors possess a mechanism of action in which the extracellular domain acts as a 
regulatory element involved in ligand binding; the action of ligand binding to the receptor 
triggers proteolysis of the intracellular domain (the “business end” of the receptor), 
which eventually enters the cell nucleus and alters gene expression (Lardelli et al., 
1995; Munro and Freeman, 2000). 
 In the literature, Notch receptor signaling has been mostly regarded in the 
context of cell fate specification, and progenitor cell regulation during early prenatal 
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development. However, a growing body of evidence has also identified a non-canonical 
role for at least one receptor subtype, Notch receptor type 1 (Notch1) in postnatal and 
adult nervous systems (Groot et al., 1990). These include such frequently occurring 
events as compartmentalized dendritic spine plasticity in mature neurons following 
integration of sensory stimuli, and long term memory formation (Ge et al., 2004; 
Presente et al., 2004; Sakai and Kitamoto, 2006). Based on previous evidence that 
Notch1 regulates axon outgrowth, and that it continues to be expressed at high levels in 
adult neurons, many have speculated that Notch1 may regulate dendritic extension as 
well (Berezovska et al., 1998). Accordingly, a recent series of exciting studies have 
emerged within the literature that confirm that in addition to nuclear expression, both 
Notch1 receptor and ligands are densely expressed within postsynaptic densities of 
CNS neurons (Franklin et al., 1999).  In young developmental cortical cells, Notch1 
receptor signaling has been shown to mediate dendritic arborization and outgrowth 
(Costa et al., 2003; Wang et al., 2004).   However, up-regulation of Notch1 results in a 
decrease in dendritic growth in these cells (Berezovska et al., 1999; Redmond et al., 
2000; Sestan et al., 1999). In addition, mature cortical neurons that heavily express 
Notch1 exhibit very little dendritic growth, and pharmacological inhibition of these 
receptors promotes dendritic extension (Redmond et al., 2000; Sestan et al., 1999). 
Based on this data, a number of labs have begun to alter their view of Notch signaling in 
mature neurons as a potential molecular regulator of communication between individual 
synapses; indeed, several manipulation experiments of Notch1 have shown that Notch 
receptor signaling is heavily involved in neuronal circuit maturation during LTP and LTD, 
and suggest that Notch1 signaling in mature cortical neurons promotes dendritic 
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branching while simultaneously inhibiting dendritic extension (Redmond et al., 2000). 
Taken together, this information demonstrates a regulatory role for Notch signaling in 
CNS plasticity throughout life; it appears that in mature neurons, activity-induced 
formation of new synapses between dendritic spines up-regulates Notch activity while 
acting as a tonic inhibitor of dendritic growth.  
Continuing with the notions that Notch1 is localized at postsynaptic densities of 
mature postnatal neurons, and that Notch1 signaling is involved in mediating plastic 
changes at this level, others have since begun to explore the relationship between 
Notch1 signaling and the expression of induced immediate-early genes in response to 
direct synaptic activation. Using an antibody that recognizes the cleaved intracellular 
domain of Notch1 (NICD1, S3 fragment), researchers were able to demonstrate that  
activated Notch1 receptors and the immediate-early gene Arc are present at the same 
activated synapses within layer V of the rat somatosensory cortex (Alberi et al., 2011).  
Not only does Arc positively regulate γ-secretase-mediated cleavage of Notch1 NICD 
from NECD in somatosensory neuronal cultures, (a significant reduction of NICD1, S3 
fragment was observed in Arc mutants), but it is required for the activity-induced 
recruitment of Notch1 signaling at the synapse (Alberi et al., 2011). Furthermore, 
activity-induced Notch1 signaling promotes plasticity-associated spine density increases 
on hippocampal CA1 pyramidal dendrites, and the genetic deletion of Notch1 during 
postnatal development leads to altered CA1 dendritic spine morphology, and a 25% 
reduction in spine densities of the very same neurons (Alberi et al., 2011). 
In essence, the Notch pathway is often regarded as an early prenatal 
developmental pathway, but many components of Notch signaling are expressed and 
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active in the postnatal and adult brain. Similar to what is seen in studies in which CB1 
receptor activity is altered, both genetic and pharmacological manipulation of Notch1 
receptor signaling results in persistently altered neuronal morphology and behavior that 
parallel in comparison; specifically, in instances where CNS CB1 receptor activity is 
inappropriately increased, or postsynaptic Notch1 receptor activity is decreased, short-
term memory is spared, whereas long-term memory remains persistently impaired.  In 
vitro and in vivo, pharmacological activation of central CB1 receptors and inactivation of 
Notch1 receptors during postnatal development negatively impacts dendritic spine 
densities and morphology through Arc-dependent mechanisms (Alberi et al., 2011; 
Gilbert and Soderstrom, 2011).  Given that activity-regulated neuronal Notch1 signaling 
is heavily dependent upon Arc expression, and that acute cannabinoid administration 
disrupts Arc-dependent changes in dendritic spine densities during sensory integration, 
we have hypothesized that in a cascade disruptive to learning-related dendritic spine 
plasticity. By virtue of these facts, we have developed the hypothesis that cannabinoid 
administration disrupts novel song-induced Notch1 receptor activity and neuronal 
morphology within zebra finch NCM through an Arc-dependent mechanism, as indicated 
by a significantly reduced expression of NICD1 S3 fragment, and a lack of change in 
dendritic spine densities that persists following novel stimulus exposure. We also 
hypothesize that proper functioning and interaction of these two receptors, given their 
ubiquitous nature, is essential to normal neuronal development and performance 
throughout life. This theory was tested through the experiments listed below. 
 
MATERIALS AND METHODS 
Reagents 
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Except where noted, all materials and reagents were purchased from Sigma (St. 
Louis, MO), or Fisher Scientific (Pittsburgh, PA).  RNA isolation solution was purchased 
from Fluka Chemicals (St. Louis, MO). cDNA synthesis, molecular cloning and PCR 
reagents were purchased from Invitrogen Laboratories (Grand Island, NY).  Equithesin 
was prepared from reagents (40 % propylene glycol, 10 % ETOH, 5 % chloral hydrate, 
1 % pentobarbital). The synthetic cannabinoid agonist WIN and antagonist SR141716A 
were suspended in vehicle from concentrated DMSO stocks (10 mM). Vehicle consisted 
of a suspension of 1:1:18 DMSO:Alkamuls EL-620 (Rhodia, Cranberry, NJ):phosphate-
buffered saline. 
Animals 
As with the Arc protein expression experiments, the subjects to be used in these 
experiments will be adult male zebra finches bred and raised in our aviary.  Before the 
start of behavioral experiments, animals will be singly housed with free access to water, 
grit, mixed seeds (Sunseed VitaFinch) and provided multiple perches.  Animals will be 
maintained on a 14:10 light/dark cycle, and room temperature was maintained at 78° F. 
Cloning of Zebra Finch Notch1 Receptor 
No known reports of sequenced Notch1 gene in zebra finches exist thus far, so 
we attempted to clone a cDNA fragment of Notch1 from whole male zebra finch brain 
RNA using degenerate primers, and reverse transcriptase-polymerase chain reaction 
(RT-PCR). Whole zebra finch brain RNA was lysed and purified using a denaturation 
solution for the isolation of RNA (Fluka Chemicals, St. Louis, MO). Following this, we 
used a SuperScript III First-Strand Synthesis System for RT-PCR to prime isolated RNA 
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with Oligo(dT)20 in an effort to select for mRNA with poly-A 3’ tails; this product was then 
reverse transcribed into cDNA. The mixture was then incubated at 50° C for 50 minutes, 
and then reaction terminated at 85° C for 5 minutes. 1 µl of RNAse H was added to the 
mixture, and allowed to incubate for another 20 minutes at 37° C. The zebra finch 
Notch1 gene was amplified by using a mixture of two sets of degenerate primers to 
conserved regions of the known coding sequences from human, rat, chicken, and 
African Tree frog in the NCBI protein database (accession numbers NP_060087.3, 
NP_001099191.1, XP_415420.2, and NP_001090757 respectively).  The forward   oligo 
DNA primers were named “ZFN15A” (5’-ATGGAATTCATGGAYGAYAAYCAR-3’), 
“ZFN15B” (5’- ATGGAATTCCARTGGACNCARCARCAW-3’), “ZFN13A” (5’-
ACDATRTCSTGSTGCATAAGCTTCAT-3’), and “ZFN13B” (5’-
TTRTTYTGCATRTCYTTAAGCTTCAT-3’).  PCR thermocycling conditions were 
performed in tubes containing 1X PCR buffer as follows: PCR initialization at 95° C for 4 
minutes, and then the following three steps were repeated in sequence for a total of 25 
times: denaturation at 95° C for 45 seconds, annealing at 50° C for 1 minute, and 
extension/elongation at 72° C for 25 seconds. The PCR reaction was then exposed to a 
final elongation at 72° C for 7 minutes, and then held at 4° C until further use. A portion 
of the PCR products were examined on 1.75% agarose-TAE gels to confirm product 
existence and sizes. Following this, PCR products were subcloned into the pCR 2.1 
TOPO plasmid, and transformed into chemically-competent One-Shot TOP10 E.coli 
cells. Plasmid minipreps were performed to isolate DNA, and the inserted cDNA 
sequence was sequenced from the 5’ and 3’ ends by the East Carolina University 
Genome Sequencing Core Laboratory. In order to confirm what had been cloned, 
268 
 
sequences were BLAST searched against other known Notch1 sequences within the 
NCBI Nucleotide database, however little homology was found.  
The following experiments are to be performed once the zebra finch Notch1 receptor 
has been cloned: 
Acute and Chronic Behavioral Experiments 
Three days prior to the start of experiments, birds will be housed singly in visual 
and auditory isolation in soundproof recording chambers. Since it has been shown that 
in cortical neurons, activity-induced Notch1 signaling requires the induction of Arc, the 
method that will be used to promote activity-induced Notch1 receptor activity (cleavage 
of NICD1, S3 fragment) within zebra finch auditory telencephalon will be similar to that 
employed for Arc mRNA induction. In order to explore the kinetics of Notch1 activation, 
animals will be exposed to a tape recording of thirty minutes of novel conspecific song, 
and killed after varying survival intervals. The novel song used consists of a collection of 
five second song bouts from three adult male birds whose song will be unrecognizable 
to experimental animals. Song playbacks will be presented in a fifteen-second medley, 
followed by forty-five seconds of silence, for a total of a one minute block. This 
procedure will be repeated for a total of thirty times. Un-stimulated control groups will be 
exposed to silence, and killed after varying survival intervals that parallel with 
experimental conditions.  
In experiments that involve drug injections, because of the pharmacodynamic properties 
of WIN within the zebra finch, treatments will be administered thirty minutes prior to the 
playback of song stimuli. A similar protocol previously established during experiments 
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involving Arc protein induction will be used here in an effort to determine whether WIN 
treatment would acutely disrupt activity-induced Notch1 receptor activity and molecular 
habituation to repeated presentations of the same song over the course of three days.  
Animals will be scheduled to receive a single intramuscular injection of WIN (3mg/kg), 
SR141716a (6mg/kg), or vehicle via intramuscular injection, thirty minutes before the 
start of song presentation. Silent controls will be exposed to the same drug regimen. On 
the third day, all groups will be given a single intramuscular injection of vehicle. Animals 
will be exposed to the same survival intervals as in the acute experiments above, and 
given an overdose of Equithesin (50 µl), and brains prepared for in-situ hybridization 
experiments.  
Developmental Treatments 
In order to determine whether daily exposure to a cannabinoid agonist during 
sensorimotor learning will enduringly influence Notch1 receptor activity after novel song 
presentation later in adulthood, once daily 50 µl injections of either vehicle or WIN 
(1mg/kg) will be administered into the pectoralis muscle in the morning, thirty minutes 
before lights on for 25 consecutive days, starting at 50 days of age, and ending at 75 
days. We have previously demonstrated that these daily cannabinoid treatments given 
during the zebra finch sensorimotor learning period from 50 to 75 days persistently alter 
vocal development and stereotyped song production (Soderstrom and Johnson, 2003). 
Following the completion of experiments, animals will be allowed to mature to at least 
110 days of age in visual isolation. In order to further validate previous findings of 
persistently altered song in the developmental WIN-treated animals, single birds will be 
isolated in soundproof chambers, and then recorded. Ten complete song bouts from 
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each treatment unit (WIN/50-75 days, vehicle/50-75 days) were randomly selected from 
a collection of recordings taken over the course of seven days. After recordings, 
animals will be killed by Equithesin overdose, and brains prepared for 
immunohistochemistry. After analysis of this developmental experiment, and 
determination of a significant treatment effect, a second experiment will be performed 
using adult animals, in order to assess the developmental dependence of treatment 
effects. The adult experiment will be done employing the same regiment of 25 daily 
treatments given to adult animals that had already learned song.  
In-Situ Hybridizations 
After behavioral treatments, animals will be transcardially perfused with 1x PBS, 
followed by phosphate-buffered 4 % paraformaldehyde [pH = 7.0]. Birds will then be 
decapitated, brains dissected and transferred to an ice-cold solution of phosphate-
buffered 4 % paraformaldehyde overnight. Brains will be blocked down the midline and 
sectioned immediately using a Vibratome. Sections will be collected into an ice-cold 2X 
SCC solution (0.3 M NaCl, and 0.03 M Na3C6H5O7) prepared with DEPC-treated water. 
Sections will then be re-suspended in pre-hybridization buffer (50% formamide, 10% 
Dextran Sulfate, 2X SSC, 1X Denhardt’s Solution, 0.5M DTT, and 0.5mg/ml denatured 
salmon sperm DNA) and incubated for one hour at 48°C.  radiolabeled riboprobes 
synthesized from cloned cDNA fragments will be added to hybridization reactions, and 
reactions incubated overnight at 48C°.  The following morning, sections will be washed 
in decreasing concentrations of 1X SSC.  Negative controls will contain the 
experimental reactions, but will have an additional 100 µg of RNase A added. In order to 
detect signal, slide mounted sections will be coated with a photographic emulsion 
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(Hypercoat LM-1 from Amersham BioSciences), and allowed to incubate at 4° C, for a 
total of three weeks. After developing with Ilford Hypam fixer and Phenisol developer 
(AEH Business Solutions), the autoradiograms are to be counterstained with 0.1% 
thionin and coverslipped with Permount. Mounted tissues will be examined by 
microscopy, as performed in immunohistochemical experiments.   
Optical Density Measurements 
Hybridization reactions are to be examined in various brain regions at 40X, 100X, 
and 1000X using an Olympus BX51 microscope with Nomarski DIC optics. Images will 
be captured using a Spot Insight QE digital camera, and Image-Pro plus 5.0 software 
(MediaCybernetics, Silver Spring, MD). It is important to note that images may not be 
captured under identical, calibrated exposure conditions, due to the fact that with in-situ 
hybridization techniques, not every photon that reaches the camera can be converted 
into measurable output. In order to mitigate this issue, images will be background 
corrected, converted to 8-bit gray scale, an optical density measurements acquired for 
each region of interest. These measurements will then be transformed into percentages 
of the maximal mean optical densities determined across all age groups and brain 
regions examined.  
RESULTS 
Cloning of the Zebra Finch Notch 1 Receptor 
A 963 base-pair fragment of the zebra finch Notch1 receptor was successfully 
amplified via polymerase chain reaction with primers ZFN15A and ZFN13A (see Figure 
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AD1.). We are currently working to subclone this fragment into the PCR 2.1 TOPO 
vector in an effort to verify sequence integrity.   
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Figure AD1. Electrophoretic analysis of PCR products generated in an effort to clone 
ZFN1.  
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APPENDIX E: General Materials and Methods 
In-Silico Cloning 
In an attempt to isolate cDNA sequences contained within genes of interest, 
specific zebra finch ESTs were located within Genbank by accessing the Nucleotide 
database, or for cases where cDNA sequences were unknown, the Protein database 
(http://www.ncbi.nlm.nih.gov/).  Following this, the ESTs were BLASTed against the 
zebra finch genome, and the genomes of other species (specifically human, rat, and 
chicken) in order to determine an adequate level of specific alignment and sequence 
homology (usually between 85 % -100 % sequence homology).   
Following this procedure, NEBcutter V2.0 was used to locate all non-overlapping 
ORFs within the target sequence (http://tools.neb.com/NEBcutter2/).  The program 
included the genetic sequence of E.Coli with our chosen oligonucleotide sequence, and 
used all commercially available type II restriction endonucleases to cut the resulting 
product wherever possible (Vincze et al., 2003).  Only type II restriction endonucleases 
available from New England Biolabs were used by the program to cut oligonucleotide 
sequences, so special care was taken to only use restriction endonucleases from New 
England Biolabs (Beverly, MA) to physically digest DNA products.  Sequences that 
proved interesting after these in-silico procedures were then physically cloned at the 
bench.   
Gene-Specific Primer Design 
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A target segment of DNA was chosen from the zebra finch genome to amplify.  
Primers were designed in an effort to clone into mammalian expression plasmid vectors 
(either PCDNA 3.1+ or p Tracer cmv/bsd), and so the following steps were taken:  Type 
II restriction endonuclease sites were selected from those sites available within the 
multiple cloning site  designed within the vector that were not present in the target cDNA 
coding sequences (i.e., those restriction endonucleases identified as present within the 
cDNA sequence by the NEBcutter V2.0 program were NOT chosen).  When designing 
5’ end cDNA primers, a Kozak consensus sequence was added to the first 19 bases 
chosen from the 5’ end of the target sequence segment. Following this, a spacer and a 
restriction site were added to the beginning of the new 5’ end. To make 3’ end cDNA 
primers, the last 19 or so bases were chosen from the 3’ end of the target sequence 
segment to be cloned. Due to primer ordering requirements, and the fact that all 
sequences are read from 5’ to 3’ end, the corresponding complement of this sequence 
was reverted, and both a restriction site and a spacer were added to the new 5’ end. 
What resulted were to primer sequences that resembled this pattern: 
Forward:     5’-SPACER-RESTRICTION SITE-KOZAK-19 BASE cDNA TARGET SEQUENCE-3’                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Reverse:       5’-SPACER-RESTRICTION SITE-18 BASE REVERTED COMPLEMENT of cDNA TARGET 
SEQUENCE-3’ 
Traditional RACE Cloning 
Total RNA Isolation 
The following methods were adapted from protocols provided by Life 
Technologies (Grand Island, NY), and methods derived by Chomczynski (1993), and 
colleagues (Chomczynski, 1993; Chomczynski and Sacchi, 1987).  All products and 
plasticware used were either cleaned with RNAse Away (Sigma), rinsed with DEPC-
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treated water, or were RNase/DNase-free as purchased.  Zebra finches were 
anesthetized, decapitated, and brains rapidly dissected. Distinct regions of interest were 
quickly isolated on an ice-cold weighing tray, weighed, and added to a polypropylene 
centrifuge tube.  1 ml of denaturation solution for the isolation of RNA, or TRIzol reagent 
per 50 mg of tissue sample. Tissue was then ground on ice to homogeneity using a 
glass and Teflon homogenizer.  Since brain tissues isolated contained a high content of 
fat, additional measures were taken to remove all insoluble material from the samples. 
Following homogenization, the samples were microcentrifuged at 12,000 x g at 4 ° C for 
10 minutes. This results in a separation of the sample into three distinct layers: A pellet 
containing the extracellular matrix, polysaccharides, and high-molecular weight DNA, a 
clear supernatant containing RNA nucleoprotein complexes, and a fatty layer above the 
supernatant. Special care was taken not to disrupt the layers as the middle clear 
supernatant was pipette out, and placed into fresh DNAse/RNAse-free microcentrifuge 
tubes.  In order to commence phase separation, the supernatant was incubated for 5 
minutes at room temperature, in order to permit complete dissociation of the 
nucleoprotein complexes.  0.2 ml of chloroform per 1 ml of denaturation solution for the 
isolation of RNA used for homogenization was added to the mix, and tubes were sealed 
tightly and vortexed for a minimum of 30 seconds.  The mixture was allowed to incubate 
at room temperature for an additional 3 minutes, and then was centrifuged at 12,000 x g 
for 15 minutes at 4° C.  Of the three phases the mixture separated into (a lower reddish 
organic phenol-chloroform phase, an opaque interphase, and a colorless upper 
aqueous phase), the RNA-containing upper aqueous phase was drawn out, all while 
being careful not to disrupt the other phases. The aqueous phase was then placed into 
278 
 
a fresh DNase/RNase free microcentrifuge tube.  An equal volume of 100 % isopropyl 
alcohol was added to the aqueous phase (approximately 0.5 ml of isopropanol per 1ml 
of reagent used for homogenization); this mixture was shaken vigorously, and then 
allowed to incubate at room temperature for 10 minutes. Following this, the mixture was 
again microcentrifuged at 12,000 x g at 4° C for 10 minutes.  At this stage, the RNA 
formed a gel-like pellet inside the bottom of the tube.  Supernatant was discarded and 
the resulting pellet was washed in 1 ml of 75% EtOH/DEPC-treated water per 1ml of 
reagent used for initial homogenization.  The sample was vortexed briefly, 
microcentrifuged at 7500 x g at 4° C for 5 minutes, and wash discarded. This process 
was repeated a total of 3 times. The resulting washed pellet was air dried for 10 minutes 
and either resuspended in a known volume of RNase-free water, or stored as a 100 % 
EtOH precipitate at -80° C.  RNA yield was determined by spectrophotometric analysis 
at an absorbance value of 263 nm. 
First Strand cDNA Synthesis 
The following method was adapted from protocols provided by the Invitrogen 
SuperScript™ III First-Strand Synthesis System for RT-PCR (Cat. No. 18080-051),  and 
molecular cloning handbooks (Sambrook and Russell, 2001). In all cases, isolated total 
RNA preparations were used to synthesize first-strand cDNA. The following reagents 
were mixed, briefly centrifuged, and combined in a 0.5 ml tube:  
Component Amount Per Reaction 
5 µg of total RNA Volume varies with RNA yield 
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50 µM oligo(dT)20 OR  
50 ng/µl random hexamers 
1 µl 
10 mM dNTPs 1 µl 
DEPC-treated water  QS to 10 µl 
Centrifuge tubes were incubated at 65° C for 5 minutes, and then placed on ice for at 
least 1 minute, while the following components were mixed together to create 10µl 
cDNA synthesis mix. Special care was taken to ensure each component was added in 
the following order:  
Component Per Reaction Per 5 
Reactions 
10X RT buffer 2 µl 10 µl 
25 mM MgCl2 4 µl 20 µl 
0.1 M DTT 2 µl 10 µl 
RNaseOUT™ (40 U/ µl) 1 µl 5 µl 
SuperScript™ III Reverse 
Transcriptase (200 U/ µl) 
 
1 µl 5 µl 
Total: 10 µl 50 µl 
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10 µl of cDNA synthesis mix was added to each RNA/primer mixture, mixed gently, and 
collected by brief centrifugation.  Oligo(dT)20-primed mixtures were then incubated at 50 
° C for 50 minutes, and reactions terminated by incubating at 85° C for 5 minutes. 
Random hexamer-primed mixtures were incubated at 25° C for 10 minutes, then at 50° 
C incubation for 50 minutes, followed by reaction termination at 85° C for 5 minutes.  
After reaction termination, tubes were chilled on ice.  After ice-cold, reactions were 
collected by brief centrifugation, and 1 µl of RNase H was added to each tube, and 
incubated for 20 minutes at 37° C.  cDNA synthesis reactions were then either used for 
PCR immediately, or stored at -20° C for later use.  Occasionally, unexpected issues 
arose using this method of cDNA synthesis, so the following steps were taken to 
troubleshoot/correct the problem(s): 
Problem Solution 
No bands after electrophoretic analysis 
of PCR products 
Use positive control RNA to verify the 
efficiency of the  reaction 
 
Inhibitors of reverse transcriptase 
present 
Remove possible inhibitors by 70 % 
EtOH/DEPC-treated water wash, followed 
by 100 % EtOH precipitation of RNA 
preparation. Resuspend in RNase-free 
water.  
 
PCR Amplification of DNA 
PCR reactions were performed in 0.2 ml RNase/DNase-free tubes, in a total 
volume of 50 µl.  Oligonucleotide primers were synthesized by Invitrogen (Grand Island, 
NY).  Primers were reconstituted in sterilized 10mM Tris, pH = 8.0 at a final working 
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concentration of 10 µM.  For every combination of forward and reverse primers run as a 
sample reaction,  a positive control reaction (template cDNA + primers demonstrated to 
amplify target sequence), and a negative control reaction ( forward and reverse primers 
included in the sample reaction, no template cDNA) were included. The following 
components were mixed together to create PCR reactions. Special care was taken to 
ensure each component was added in the following order: 
Reagent Negative Control (-) Positive Control (+) Reaction (R1,2…x) 
Sterile water 40.5 µl 40 µl 40 µl 
10X Polymerase 
Buffer 
5 µl 5 µl 5 µl 
dNTPs 1 µl 1 µl 1 µl 
Forward (5’) primer 0.5 µl 0.5 µl 0.5 µl 
Reverse (3’) primer 0.5 µl 0.5 µl 0.5 µl 
cDNA template ---- 0.5 µl 0.5 µl 
MgCl2* 2 µl 2 µl 2 µl 
Polymerase 
-Taq 
-Vent** 
 
0.5 µl 0.5 µl 0.5 µl 
Total:  50 µl 50 µl 50 µl 
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* The efficiency/success of many of my PCR reactions have been contingent upon the 
concentration of divalent cations (here seen in the form of MgCl2) used in the PCR 
reaction.  I found it advantageous to perform a quick MgCl2 concentration optimization 
in half-log units (from 0.3mM to 3mM). 
**  When sequence fidelity was of the upmost importance, Vent polymerase was 
preferred for use over Taq/Platinum Taq; not only does Vent possess a 5X higher 
fidelity than Taq/Platinum Taq, but these polymerases possess 5’  3’ exonuclease 
activity, whereas Vent possesses 3’  5’ proofreading activity.   
 
Reactions were synthesized on ice, immediately placed into a prewarmed thermocycler 
(set at 94° C), and reactions run for an indicated amount of time dictated by the number 
and length of each cycle.   When using Vent to amplify DNA products for TA subcloning, 
an additional step was added to the PCR procedure.  As amplification with Vent 
produces blunt ended PCR products, 1 µl of Taq was added to each reaction, and 
reactions were allowed to incubate at 72° C for an additional 15 minutes in a final A-
tailing step before returning to the holding temperature of 4° C.  
Occasionally, unexpected issues arose during PCR amplification, so the 
following steps were taken to troubleshoot/correct the problem(s): 
 
Problem Solution 
Annealing Temperature sub-optimal Run a temperature gradient in 2° C 
increments 
dNTP stocks degraded dNTPs are very susceptible to freeze-
thawing. Use fresh aliquots only, and 
discard after one-time use. 
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PCR reaction contamination Always check negative control for bands 
cDNA template degraded Aliquot cDNA to minimize freeze-thawing.  
Run an aliquot on an agarose gel to check 
integrity. 
 
TA cloning of Taq-Amplified PCR Products 
TOPO Cloning Reaction 
Taq-amplified PCR products were subcloned into a linearized vector containing 
single overhanging 3’-deoxythymidine residues covalently bonded to Topoisomerase I.  
This modification allows PCR product inserts with A-tails to efficiently ligate into the 
vector (Puck et al., 1958).  A total of 6 µl of TOPO cloning reaction was set up for 
eventual transformation into chemically-competent DH5-α E. coli cells.  Reagents were 
mixed together in a clean 0.5 ml centrifuge tube at room temperature. 
The reaction was gently mixed, and allowed to incubate for an additional 15 
minutes at room temperature.  The reaction was then placed on ice, until ready to be 
transformed into chemically competent cells. NOTE: reactions were never stored at -20° 
C overnight, for further use.  
Transforming Chemically-Competent DH5-α E. coli Cells 
Vials of One Shot™ Chemically-Competent DH5-α E. Coli Cells were retrieved 
from -80° C, and thawed on ice.  A total of 2 µl of the TOPO cloning reaction (see 
above) was added to a pre-chilled 1.7 ml microcentrifuge tube, and a 25 µl aliquot of 
chemically-competent cells were gently pipetted onto the reaction, while taking special 
care to keep the reaction ice-cold.  Optimal transformation conditions were set up such 
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that the TOPO cloning reaction was ~10 % of the total volume. A 25 µl aliquot of 
chemically-competent cells transformed with pUC 19 DNA served as a positive 
transformation control, and a 25 µl aliquot of chemically-competent cells incubated 
without the TOPO cloning reaction served as a negative transformation control in these 
experiments.  Following reaction setup, the cells were incubated on ice for an additional 
30 minutes.  Next, the reactions were heat shocked in a 42° C water bath for a total of 
30 seconds, then returned to ice for 2 minutes. Then, 200 µl of room temperature S.O.C 
medium was added to reactions, tubes capped tightly, and reactions then shaken 
horizontally at 200 rpm at 37° C for 1 hour. While reactions were shaking, LB/Amp-agar 
plates were pre-warmed in a hybridization oven at 37° C.  Just before reactions were 
finished shaking, pre-warmed plates were spread with 40 µl of X-Gal (40 mg/ml, 
dissolved in N, N-Dimethylformamide) until dry, to allow for blue/white screening.  
Following this, entire ~200 µl reactions were spread evenly with a sterile cell spreader 
onto the pre-warmed selective plates until dry.  Plates were incubated in the pre-
warmed hybridization oven at 37° C overnight (or for a minimum of 12 hours).  Efficient 
TOPO cloning reactions produced several hundred colonies per plate.  The next 
morning, 2-4 well-separated white colonies were picked with sterile pipette tips for 
analysis.   
Isolation of Plasmid DNA from Bacterial Cultures 
The following methods were adapted from Sambrook et al. (2001).   Well-
separated bacterial colonies picked for sequence analysis were cultured overnight at 
37° C, and shaken horizontally at 250 rpm in 1.5 ml of LB broth, containing 50 µg/ml 
ampicillin (Amresco Biochemicals, Solon, OH).  Cultures were decanted into 1.7 ml 
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microcentrifuge tubes, and spun at 15,000 x g for 1 minute.  Following this, 
supernatants were carefully decanted into a sterile beaker containing 10 % bleach, and 
microcentrifuge tubes were inverted onto paper towels to drain and remove drops.  
Next, pellets were resuspended by pipette in 100 µl of Miniprep Solution I. Special care 
was taken to ensure no pellet clumps remained. After this, cells were lysed by adding 
200 µl of Miniprep Solution II.  Microcentrifuge tube caps were closed tightly, and tubes 
inverted several times to thoroughly mix and create a viscous solution.  This solution 
was allowed to incubate at room temperature for 5 minutes.  Next, protein and 
chromosomal DNA was precipitated from solution by adding 150 µl of Miniprep Solution 
III. These mixtures were again inverted several times, and then taped to a horizontal 
shaker and shaken for at least 5 minutes.  The suspensions were microcentrifuged at 
room temperature for 5 minutes at 15,000 x g, and supernatants removed into a clean 
1.7 ml tube, while taking special care to avoid fluffy white precipitate.  Microcentrifuge 
tubes were then placed on ice.  Following this, plasmid DNA was precipitated out of 
solution by adding 2.5 volumes of ice-cold EtOH (approximately 900 µl) to each 
microcentrifuge tube, mixed vigorously, then placed on ice.  Tubes were centrifuged at 
15,000 x g at 4° C, for 10 minutes, and supernatants decanted.  Resulting pellets were 
then washed with two volumes of 70 % EtOH, tubes inverted over a paper towel, and 
pellets allowed to dry.  Pellets were either resuspended in 50 µl of sterile 10 mM Tris, 
pH = 8.0 containing 30 µg/ml of RNase A, or nuclease-free water.  Isolated plasmid 
DNA was then either stored at 4° C for short-term use, or -20° C for later use.  
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Restriction Digestion of DNA 
Restriction digests of DNA were used for plasmid DNA mapping (to confirm that 
isolated DNA plasmids were recombinant) and liberation of cloned insert products from 
vectors in preparation for insert-DNA gel purification.  Firstly, the multiple cloning site of 
the plasmid vector, and specifications used during primer design were used was used to 
determine which restriction enzymes would liberate cDNA inserts. 20 µl restriction 
digest reactions were prepared by placing reagents in 0.5 ml microcentrifuge tubes in 
the following order: 
 
Reagent Uncut Control Plasmid + 
Restriction 
Endonuclease 
A 
Plasmid + 
Restriction 
Endonuclease 
B 
Plasmid + 
Restriction 
Endonuclease 
A and B 
Water 14.5 µ 13.5 µl 13.5 µ 12.5 µl 
10X RE Buffer 2 µl 2 µl 2 µl 2 µl 
BSA* 0.5 µl 0.5 µl 0.5 µl 0.5 µl 
R. 
Endonuclease 
A 
--- 1 µl --- 1 µl 
R. 
Endonuclease 
B 
--- --- 1 µl 1 µl 
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Plasmid Vector 3 µl 3 µl 3 µl 3 µl 
Total: 20 µl 20 µl 20 µl 20 µl 
 
Reagents were incubated in a hybridization oven at 37° C for at least 1 hour. Restriction 
digests mixed with 10 % loading dye were run on a 1.5 % agarose/TAE gel with 
ethidium bromide, and sizes of vector and insert bands were determined by comparison 
to migration of molecular weight markers (either lambda BST EII marker, or 1 KB DNA 
ladder (Invitrogen)). 
Dephosphorylation of Linearized Plasmid  
In instances were the same restriction endonuclease was used to free the DNA 
insert on both ends of the vector, removal of the terminal 5’ phosphate groups on the 
ends of linearized fragments were used to suppress self-ligation and circularization of 
plasmid DNA.  By removing the 5’ phosphate residues from both termini of the plasmid 
with CIAP, recircularization of DNA is substantially minimized (Sambrook and Russell, 
2001).  Therefore, in cases where this technique was needed, 4 µl of CIAP was added 
to every 20 µl of restriction digest reaction, and incubated in the hybridization oven as 
usual. An additional incubation at 85° C was included at the end of incubation time in 
order to deactivate CIAP enzymes. This was followed by phenol/chloroform extraction of 
DNA. 
Phenol/Chloroform Extraction of DNA 
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Occasionally, the DNA isolation methods used would render DNA that was not of 
a level of purity for restriction digestion analysis. To mitigate this issue, we utilized the 
properties of polar solvents (water), and non-polar solvents (phenol, chloroform) to 
separate nucleic acids in solution from protein and cell lysate debris not purified from 
DNA isolation. Equal amounts of a Phenol:Chloroform:Isoamyl alcohol (25:24:1 v/v) 
solution was added to the microcentrifuge tube containing a known volume of DNA in 
water or 10 mM Tris buffer, pH = 8.0.  This mixture was emulsified by vortexing for at 
least 1 minute, followed by a 2 minute centrifugation at room temperature at 14,000 
rpm. The mixture separated into three phases, and the upper aqueous layer (aqueous 
phase) was drawn out, and pipetted into a new tube.  DNA was precipitated out of 
solution by creating a high-salt environment within the aqueous solution in order to 
disrupt the dissolving properties of water.  This was accomplished by adding a volume 
of 3M NaOAC equal to 10 % of the total solution volume to the aqueous phase, shaking 
vigorously, adding an additional 2.5 volumes of ice-cold EtOH to the centrifuge tube, 
then shaking again. This mixture was incubated at -20° C for 1 hour.  Following this, the 
mixture was spun at 4° C for 30 minutes at 14,000 rpm. The resulting pellet was 
decanted of EtOH, and carefully washed 2 times in 70 % EtOH, at room temperature. 
Finally, tubes inverted over a paper towel, and pellets allowed to dry.  Pellets were 
either resuspended in 50 µl of sterile 10 mM Tris, pH = 8.0 containing 30 µg/ml of 
RNase A, or nuclease-free water.  Isolated plasmid DNA was then either stored at 4° C 
for short-term use, or -20° C for later use.  
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DNA Purification from Agarose Gels 
Using an 18 gauge needle, single holes were poked through the lid and base of a 
0.5 ml microcentrifuge tube.  These tubes were then placed into larger 1.7 ml 
microcentrifuge tubes in which lids had been removed, and filled 1/3 of the way with a 
paper slurry filter (made of shredded chromatography paper in sterile 10 mM Tris buffer, 
pH = 8.0).  In order to remove extra buffer, tubes were spun at 14,000 rpm for 3-4 
minutes, and residual buffer collected in the larger tube removed and discarded. DNA 
bands isolated from agarose gel under minimum UV exposure conditions were placed in 
the tubes containing the paper slurry mixture, and spun for 4 minutes at 14,000 rpm. 
The resulting eluted DNA was used to transform chemically-competent E.Coli cells, or 
ligate into linearized plasmid vectors.  
Ligation of Target DNA Inserts into Linearized Vectors 
The ligations were synthesized at 4° C, in 10 µl reactions.  Reagents were added 
to 0.5 ml microcentrifuge tubes in the following order: 
Reagent Positive Control (+) Negative Control (-) Ligation Rxn 
(R1,2…X) 
Water QS to 10 µl QS to 10 µl QS to 10 µl 
5X T4 DNA Ligase 
Buffer 
2 µl 2 µl 2 µl 
Linearized Vector 
Ratio 
1 2 µl 1 
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Insert Ratio 5 --- 5 
T4 DNA Ligase 1 unit (sticky ends) 
5 units (blunt ends) 
1 unit (sticky ends) 
5 units (blunt ends) 
1 unit (sticky ends) 
5 units (blunt ends) 
Total: 10 µl 10 µl 10 µl 
 
Reactions were incubated in a 16° C water bath for 24 hours, then placed on ice the 
following day. Ligated plasmids were then transformed into chemically-competent E.Coli 
cells. 
DNA Sequencing of Results 
 
Plasmid minipreps were performed to isolate DNA, and the inserted cDNA 
sequence was sequenced from the 5’ and 3’ ends by the East Carolina University 
Genome Sequencing Core Laboratory. 
Receptor Protein Analysis 
Cell Culture  
All cell culture dishes/media flasks contained the following components: 
 Culture media- designed to allow cells to maintain their normal function. The type 
of culture media varied depending on the particular cell line. 
 Fetal Bovine Serum- Used as a supplement to cell culture media, as it provided a 
broad spectrum of macromolecules, carrier proteins for lipoid substances and 
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trace elements, attachment and spreading factors, low molecular weight 
nutrients, hormones and growth factors  cells need in order grow and divide.  
 Penicillin/Streptomycin- Used to keep prokaryotic organisms and contamination 
out of cell culture dishes. Special care was taken to used only the specified 
amount, as inappropriate levels may kill or alter cell growth. 
 Amphotericin B- Antimycotic; Special care was taken to used only the specified 
amount, as inappropriate levels are known kill or alter cell growth. 
 Sodium Bicarbonate- Used as a buffer in cell culture media, as it improved the 
pH control of cell culture media (cells were incubated in a CO2 atmosphere that 
sometimes varied between 5 and 10 %).  Sodium bicarbonate was also used as 
a non-toxic means to provide cells with carbonate ions to aid in general metabolic 
functions.  
 Sodium Pyruvate- Added to cell culture media as an additional source of energy, 
and to protect against inappropriately high levels of hydrogen peroxide.  
The PC12 cell line required the following additional component: 
 Coating with either PDL or PLL- Used to enhance cell attachment to plastic and 
glass surfaces. The tissue culture plastic used in these experiments had a net 
negative surface charge produced by plasma treatment of the polystyrene (i.e., 
TC-treated surface). We empirically determined that these cells will grow in 
suspension without this additional step, but overall, PC12 cultures were 
dramatically improved by coating the culture surface with positively-charged 
polymers. In addition to promoting cell adhesion, PLL and PDL is known to 
enhance the adsorption of serum or extracellular matrix proteins to the culture 
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substrate (Barnes et al., 1984; Ham and McKeehan, 1979; Letourneau, 1975; 
McKeehan and Ham, 1976; Poindron et al., 2005; Yavin and Yavin, 1974).  
Preparing Cell Culture Media 
  
All media was prepared and cells cultured according to American Tissue Culture 
Collection guidelines.  The following reagents were used to prepare cell culture media 
for the cell lines used: 
 
Reagent [Conc.] Cho-K1 PC12 PC12-Adh HEK-TN 
Culture Media 1X F-12K, 500 
ml 
RPMI-1640, 
500 ml 
 
F-12K, 500 
ml 
DMEM, 500 
ml 
FBS 1X 50 ml 25 ml 12.5 ml 50 ml 
Horse Serum 1X --- 50 ml --- --- 
HI-Horse 
Serum 
1X --- --- 75 ml --- 
HEPES-
Buffered Saline 
(1 M) 
1x --- 5 ml --- 10 ml 
L-Glutamine 
 (200 mM) 
100X 10 ml 10 ml 10 ml --- 
P/S  100X 5 ml 5 ml 5 ml 5 ml 
Antimycotic 100X 5 ml 5 ml 5 ml 5 ml 
Sodium 
Pyruvate (100 
100X 2.5ml 2.5 ml  --- 
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mM) 
Sodium 
Bicarbonate 
1X --- 0.75 g --- --- 
Total:  572.5 ml 602.5 ml 607.5 ml 570 ml 
 
Media was prepared before subculturing, and stored at 4° C for a maximum of 1 month, 
and immediately discarded upon accidental contamination.  
Preparing for Subculturing Cells 
Thirty minutes prior to the start of subculturing, negative-pressure hoods cell 
culture dishes, and disposable plasticware were exposed to UV radiation.  Cell culture 
media bottles were incubated at 37° C in a hot water bath.  Immediately before 
subculturing, all materials and reagent bottles were disinfected by wiping down with 
ample 70 % 2-propanol, and fresh Kimwipes® , lint-free disposable towelettes, and 
placed under the negative-pressure hood. 
Subculturing Cho-K1 Cells 
Culture medium was removed and discarded by vacuum filtration.  Cell culture 
flasks were briefly rinsed with 2.0 ml of 0.25 % (w/v) Trypsin- 0.53 mM EDTA solution in 
order to remove all traces of serum, which contained trypsin inhibitor.  Following this, 
3.0 ml of Trypsin-EDTA solution was added to the flask, and visualized under an 
inverted microscope for approximately 3 minutes, until cell monolayer became 
detached. Occasionally, when cell detachment seemed difficult to facilitate, flasks were 
placed into a 37° C incubator supplemented with 5 % CO2 for 4 minutes or until 
detachment occurred.  Following this step, flasks were banged against a hard surface 6 
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or 7 times, and cells allowed to collect at the bottom of the flask. A known volume of 
complete growth medium was added to the flask, cells aspirated by gentle pipetting, and 
then counted using a hemacytometer.  Appropriate aliquots of cell suspension were 
added to new culture vessels (usually at a subcultivation ratio of 1:4), and cultures were 
returned to incubate at  37° C, supplemented with 5 % CO2. Medium was renewed 
every 2 days (Puck et al., 1958).  
Subculturing PC12 Cells 
Cell suspension was transferred to a sterile centrifuge tube, and remaining cells 
adhered to the bottom of the plate were removed with 2 ml of Trypsin-EDTA solution. 
These cells were added to the centrifuge tube as well, and cells centrifuged at 225 x g 
for 10 minutes at room temperature.  During this time, fresh plates were prepared by 
adding media to dishes pre-coated with PLL.  Afterwards, cell debris and supernatant 
was discarded by vacuum filtration, and the resulting pellet was resuspended in a 
known volume of fresh medium by rapid aspiration with a sterile 20 gauge needle, and 
counted using a hemacytometer. Aliquots of cell suspension were pipette into coated 
dishes, and swirled carefully to ensure even distribution (usually at a subcultivation ratio 
of 1:2, or 1:3).  Cells were returned to incubate at 37° C, supplemented with 5 % CO2. 
Medium was renewed every 3 days, and cells were subcultured when densities reached 
4 x 106 cells per 1 ml of medium (Greene and Tischler, 1976). 
Subculturing PC12-Adh Cells 
Old culture medium was removed and discarded by vacuum filtration, starting 
from the top edge of the media working down, taking care not to scrape the bottom of 
the flask.  Following this, 10 ml of fresh medium, and 1 ml of Trypsin-EDTA solution was 
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pipetted over the cell sheet, and scraped with a disposable cell scraper.  Next, cells 
were aspirated with a small bore serological pipette to break up clusters and counted 
using a hemacytometer. Appropriate aliquots of cell suspension were added to either 
Corning CellBIND® dishes, or dishes manually coated with a hydrophilic, negatively-
charged amino acid layer. Cells were seeded at a subcultivation ratio of 1:3, twice 
weekly. Cells were returned to incubate at 37° C, supplemented with 5 % CO2.   
Subculturing HEK-293TN Cells 
Medium was removed from cells, and discarded via vacuum filtration. Cells were 
briefly rinsed with Trypsin-EDTA solution, in order to remove traces of serum containing 
trypsin inhibitors. Next, 3.0 ml of Trypsin-EDTA solution was added to the flask, and 
observed under an inverted microscope for 10 minutes, or until cell layer was dispersed.  
Trypsin-EDTA solution was aspirated via vacuum filtration, and 10 ml of complete 
growth medium was added before aspirating cells by gently pipetting. Appropriate 
aliquots were added to new culture vessels; cells were seeded at a subcultivation ratio 
of 1:8, and medium was renewed every 3 days.  
Cryogenic Preservation of Cell Lines 
Media and cell debris were removed from viable cells, either by spinning at 225 x 
g, or trypsinizing (see subculturing methods).  Cells were resuspended in fresh media, 
and DMSO was added to the cell suspension to equal a final concentration of 10 %. 
Cells were counted using a hemacytometer, and suspensions were quickly pipetted into 
2 ml cryogenic tubes, depending on the densities desired.  Cells were initially frozen at -
20° C for 1 hour, then -80° C overnight. The following day, cryogenic vials were 
transferred to liquid nitrogen vapor phase for future use.  
296 
 
General Guidelines for Culturing Cells in Various-Sized Vessels: 
Flask Size Media Volume Trypsin Volume  Suspension 
Volume 
35 mm dish 2-3ml 200ul 40,000 cells 
60 mm dish 4-5ml 500ul 40,000 cells 
100mm dish 10ml 1ml 50-100ul cells 
T75 Flask 20ml 3-5ml 100ul cells 
T150 Flask 30-45ml 10ml 200-400ul cells 
T225 Flask 45ml 10ml 1 ml cells 
  
Transfection of Plasmid DNA into Cultured Cells 
DNA and Lipofectamine optimizations were performed before the start of every 
experiment.  The day before transfections were to occur, cells were removed from 
dishes and counted. Following this, cells were plated at a density of 4 x 104 cells per 
well (24-well plate) in 0.5 ml of complete growth medium, as it was essential that cells 
were transfected during the exponential growth phase.  The next morning, cells were 
observed to be 50-80 % confluent before starting procedures. For each well of cells that 
were transfected, 0.5 µg of DNA was diluted per 100 µl of reduced serum medium 
without serum.  For cell lines more sensitive to transfection reagents, PLUS™ Reagent 
was added in a 1:1 ratio to DNA, directly to the DNA. This mixture was gently incubated 
for 10 minutes at room temperature before being added to the medium.  For each well 
of cells, 0.75-1.75 µl of Lipofectamine LTX was diluted into the DNA/medium solution, 
gently mixed, and incubated for 25 minutes at room temperature, in an effort to allow for 
the formation of DNA-Lipofectamine complexes.  After this, growth medium was 
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removed from cells, and replaced with 0.5 ml of complete growth medium. Exactly 100 
µl of the DNA-Lipofectamine complexes were directly added to each well containing 
cells, and gently mixed by rocking the plate back and forth. Finally, cells were incubated 
at 37° C in a CO2 incubator for 24 hours before being used in other assays for 
transgene expression. 
Scaling Transfections 
Occasionally, cultured cells required transfection in various tissue culture 
formats, and so the amounts of DNA, cells, and transfection reagents were altered 
relative to the surface area of the culture vessel. The following was used as a general 
guideline when scaling transfections: 
Vessel Media 
Volume 
Cells/ 
Well 
DNA Volume 
Dilution 
Media 
 
Lipofectamine PLUS™ 
96-well 100 µl 8 x 103 100 ng 20 µl 0.15 – 0.35 µl 0.1 µl 
48-well 200 µl 2 x 104 200 ng 40 µl 0.3 – 0.7 µl  0.2 µl 
24-well 500 µl 4 x 104 500 ng 100 µl 0.75 – 1.75 µl 0.5 µl 
12-well 1 ml 8 x 104 1 µg 200 µl 1.5 – 3.5 µl 1 µl 
6-well 2 ml 2 x 105 2.5 µg 500 µl 3.75 – 8.75 µl 2.5 µl 
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Pseudoviral Particle Production 
The day before procedure was scheduled to begin, HEK293TN cells were 
cultured in complete medium, supplemented with 10 % FBS and antibiotics. The 
following day, when cells reached 70 % confluence, cells were transfected with an HIV-
based packaging plasmid and DNA construct as described above. After 48 hours of 
incubation, viral supernatant was collected under a BL-3 culture hood into a sterile 50 
ml conical tube, and centrifuged at 3000 rpm for 15 minutes at room temperature, in 
order to pellet cell debris. Following centrifugation, viral supernatant was transferred 
and aliquoted into sterile 1.7 ml microcentrifuge tubes. 
HIV-Based Lentiviral Infections 
Complete culture medium was aspirated from cells that have reached 70% 
confluence. A mixture of complete medium with polybrene was prepared at a final 
concentration of 5 µg/ml. Old culture medium was discarded, and replaced with 10 ml of 
polybrene/media mixture. Cells were infected by adding a 1:1 medium:pseudoviral stock 
mixture to the flasks. Cells were then incubated at 37° C supplemented with 5 % CO2 
overnight. The following day, culture medium was removed, and replaced with 1 ml of 
complete medium.  
Immunocytofluorescence 
Because cells are cultured in a monolayer, immunocytofluorescence was 
performed over a 1 day period. Cells were removed from the incubator, and washed 
three times with 1X PBS. Next, cells were fixed with ice-cold methanol, and incubated at 
-20° C for 10 minutes. Cells were washed again three times with 1X PBS, and blocked 
in 3% BSA in PBS for 30 minutes. Following this, cells were incubated in a 3% 
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BSA/PBS mixture containing primary antibody for 30 minutes, followed by a 0.3% Tri-X 
wash. Then, fluorescent conjugated secondary antibody in a 3% BSA/PBS mixture was 
added to cells (1:100), and washed three times with 0.3% Tri-X, in the dark. Finally, 
cells were mounted on slides with an anti-fade aqueous mounting medium, and allowed 
to dry in the dark at 4° C. 
Receptor Protein Analysis 
Preparation of P2 Membranes 
Zebra finches were overdosed with Equithesin,  and brains were removed and 
placed into a glass and Teflon grinder containing 25 volumes of ice-cold 0.32 M sucrose 
in 5 mM Tris, pH = 7.4. After tissue was ground to homogeneity on ice, homogenate 
was transferred to clean centrifuge tubes, and spun at 1000 X g at 4° C for 15 minutes. 
Pellets were discarded, and supernatant was carefully removed to a separate tube. 
Next, supernatant was centrifuged at 20,000 X g at 4° C, for 60 minutes. Following this, 
resulting pellets were snap-frozen overnight at -80° C, thawed on ice, and resuspended 
in 150 volumes of 50 mM Tris, 10 mM EDTA, pH = 7.4. Membranes were incubated for 
2 hours at 4° C, in order to allow endogenous cation chelating and dissociation of ligand 
from membrane-bound GPCRs. Next, membranes were centrifuged at 20,000 X g for 
60 minutes, re-homogenized, and washed in 150 volumes of 50 mM Tris, 5 mM MgCl2. 
Protein concentrations were determined by the Bradford method.
APPENDIX F: Permission Letters 
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 PT62T@NIH.gov  
Attachments: 
                           ) 
Sent Items 
Thursday, October 11, 2012 11:23 AM 
Hello, 
 
My name is Marcoita Gilbert, a graduating Ph.D student from the department of Pharmacology and 
Toxicology at East Carolina University. I am in the process of writing a general literature review for my 
dissertation, and came across a very helpful figure depicting nationwide drug trends across age groups. 
 
http://www.drugabuse.gov/publications/drugfacts/nationwide-trends 
 
 I would like to ask for permission to use this figure for educational purposes; all material obtain will be 
properly cited. If you should have additional questions, please do not hesitate to contact me. I look 
forward to hearing from you soon.  
 
 
 
Thank you, 
 
Marcoita  
 
 
Marcoita T. Gilbert 
Doctoral Candidate 
Departments of Pharmacology and Toxicology/IDPBS 
East Carolina University 
6S-36 Brody School of Medicine 
Greenville, NC 27834 
Gilbertm02@students.ecu.edu 
Telephone:252-744-2750 
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Dear Marcoita Gilbert, 
  
With reference to your kind email asking for permission to use one of the images on 
CNSforum.com. 
  
Permission is granted to download the image(s) and use them as you wish, including in 
presentations, articles and publications, provided that the copyright notice on the 
images is not hidden nor removed. 
If used on other websites, the images must also link to this website: www.cnsforum.com 
Good luck with your studies! 
  
 
Kind regards 
Gitte Handlos  
From: Gilbertm02@students.ecu.edu [mailto:Gilbertm02@students.ecu.edu]  
Sent: Thursday, October 11, 2012 6:35 PM 
To: cnsforum@cnsforum.com 
Subject: Message sent from Contact Us form on CNSforum 
 
  
A mail has been received from the "Contact Us" form on CNSforum.com 
Name: Marcoita Gilbert 
Email: Gilbertm02@students.ecu.edu 
Subject: Permission to use a figure in dissertation 
Message: 
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Hello,  
My name is Marcoita Gilbert, a graduating Ph.D student in the department of 
Pharmacology at East Carolina University, USA. East Carolina University. I am in the 
process of writing a general literature review for my dissertation, and came across a 
very helpful figure depicting the molecular mechanisms of cannabinoid receptor 
signaling:  
 
http://www.cnsforum.com/imagebank/item/MOA_cannab/default.aspx  
 
I would like to ask for permission to use this figure for educational purposes; all material 
obtain will be properly cited. If you should have additional questions, please do not 
hesitate to contact me. I look forward to hearing from you soon.  
 
Thank you,  
 
Marcoita Gilbert  
 
 
Marcoita T. Gilbert  
Doctoral Candidate  
Departments of Pharmacology and Toxicology/IDPBS  
East Carolina University  
6S-36 Brody School of Medicine  
Greenville, NC 27834  
Gilbertm02@students.ecu.edu  
Telephone:252-744-2750 
 
304 
 
 
Permissions Europe/NL [Permissions.Dordrecht@springer.com] 
 
Inbox 
Wednesday, October 31, 2012 9:56 AM 
Dear Sir, 
  
With reference to your request (copy herewith) to reprint material on which 
Springer Science and Business Media controls the copyright, our permission is 
granted, free of charge, for the use indicated in your enquiry. 
  
This permission 
-     allows you non-exclusive reproduction rights throughout the World. 
-     permission includes use in an electronic form, provided that content 
      * is password protected; 
      * at intranet; 
      * not separately downloadable 
  
- excludes use in any other electronic form. Should you have a specific project 
in mind, please reapply for permission 
  
- requires a full credit (Springer/Kluwer Academic Publishers book/journal title, 
volume, year of publication, page, chapter/article title, name(s) of author(s), 
figure number(s), original copyright notice) to the publication in which the 
material was originally published, by adding: with kind permission of Springer 
Science and Business Media. 
  
The material can only be used for the purpose of defending your dissertation, and 
with a maximum of 100 extra copies in paper. 
  
Permission free of charge on this occasion does not prejudice any rights we might 
have to charge for reproduction of our copyrighted material in the future. 
  
Kind regards, 
  
Nel van der Werf (Ms) 
Rights and Permissions/Springer 
  
Van Godewijckstraat 30 | P.O. Box 17 
3300 AA Dordrecht | The Netherlands 
tel  +31 (0) 78 6576 298    
fax +31 (0)78 65 76-377 
  
Nel.vanderwerf @springer.com 
www.springer.com 
 
 
Gilbert, Marcoita Terreen 
 
Actions 
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To: 
 permissions.dordrecht@springer.com  
Sent Items 
Thursday, October 25, 2012 3:40 PM 
Hello,  
 
I am writing this email in order to request permission from Springer Publishing group to use a figure of 
the molecular structure of the Cannabinoid Receptor 1 from a book source.  
 
This figure (Figure 1) was published in a chapter titled "Cannabinoid Receptors and Signal Transduction", 
by Howlett AC, Shim J-Y. This chapter can be found in the book "Cannabinoids." by V. Di Marzo 
published in 2004 (ISBN 978-0-306-48228-1) and is a part to the Neuroscience Intellegence Unit series.  
 
This figure will be used in the introduction portion of my dissertation, and will be used for academic 
purposes only. My dissertation, titled "CHANGES IN ZEBRA FINCH NEURONAL 
MORPHOLOGY FOLLOWING DEVELOPMENTAL CANNABINOID EXPOSURE" will be 
available in both print and electronic form via ProQuest, the dissertation distributing company.  
 
 
If I can provide further information to you, please let me do not hesitate to contact me. I look forward to 
your reply. 
 
Thanks,  
 
Marcoita T. Gilbert 
Doctoral Candidate 
Departments of Pharmacology and Toxicology/IDPBS 
East Carolina University 
6S-36 Brody School of Medicine 
Greenville, NC 27834 
Gilbertm02@students.ecu.edu 
Telephone: 252-744-2750 
  
 
 
Celeste Carlton [celeste@landesbioscience.com] 
 
Inbox 
Thursday, October 25, 2012 2:24 PM 
Dear Marcoita Gilbert: 
 
We grant you our non-exclusive permission to reproduce Figure 1 in your 
dissertation, provided the following: 
 
1) Since this book is co-published you will also need to obtain permission 
from Springer (who now owns Kluwer). You may use the following websites: 
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http://www.springerlink.com/content/ 
Search for the chapter, then click on "permissions and reprints". 
 
http://www.springer.com/rights?SGWID=0-122-0-0-0 
 
2) Give the following citation in the figure legend: 
 
Reproduced with copyright permission from: Howlett AC, Shim J-Y. 
Cannabinoid receptors and signal transduction. In: Di Marzo V, ed. 
Cannabinoids. Austin/New York: Landes Bioscience/Kluwer Academic / Plenum 
Publishers, 2004:85-98. 
 
Or, if the above citation is given in complete form in a reference list, you may 
instead include the following citation in the figure legend: 
 
Reproduced from reference XX, with copyright permission from Landes 
Bioscience and Kluwer Academic / Plenum Publishers. 
 
This permission includes both print and electronic versions. 
 
Sincerely, 
Celeste Carlton 
 
Production Manager 
Book Department 
Landes Bioscience 
1806 Rio Grande 
Austin, TX 78701 
512.637.6050 Phone 
512.637.6079 FAX 
1.800.736.9948 
celeste@landesbioscience.com 
http://www.LandesBioscience.com  
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Gilbert, Marcoita Terreen 
 
Sent Items 
Thursday, October 25, 2012 1:42 PM 
Hello, I am writing in order to request permission to use a figure in the Landes Bioscience Madame Curie 
Bioscience Database. The figure will be used in the introduction portion of my dissertation, which will be 
electronically available. The figure, of the molecular structure of the Cannabinoid Receptor 1, can be 
found here: 
http://www.landesbioscience.com/curie/chapter/1446/ 
 
and also here in the NIH pubmed database: 
Bookshelf ID: NBK6154, "Cannabinoid Receptors and Signal Transduction", Allyn Howlett (2000) 
 
If I can provide further information to you, please let me do not hesitate to contact me. I look forward to 
your reply. 
 
 
Sincerely, 
 
 
Marcoita T. Gilbert 
 
Doctoral Candidate 
 
Departments of Pharmacology and Toxicology/IDPBS 
 
East Carolina University 
 
6S-36 Brody School of Medicine 
 
Greenville, NC 27834 
 
Gilbertm02@students.ecu.edu 
 
Telephone: 252-744-2750 
 
